date_of_followup,disease_status_at_followup,date_of_relapse,method_of_progression_status,recurrence_tumour_staging_system,recurrence_t_category,recurrence_m_category,recurrence_stage_group,submitter_follow_up_id,submitter_treatment_id,submitter_primary_diagnosis_id,submitter_donor_id,program_id,relapse_type,anatomic_site_progression_or_recurrence,recurrence_n_category
"{'month_interval': 14, 'day_interval': 420}",Relapse or recurrence,"{'month_interval': 42, 'day_interval': 1260}",,St Jude staging system,T1a,M1a,Stage IIAE,FOLLOW_UP_1,,,DONOR_1,SYNTHETIC-1,,,
"{'month_interval': 2, 'day_interval': 60}",Stable,"{'month_interval': 4, 'day_interval': 120}",Tumor marker measurement (procedure),AJCC 6th edition,T2(m),M1b(0),Stage IVA2,FOLLOW_UP_2,,,DONOR_2,SYNTHETIC-1,Local recurrence,,
"{'month_interval': 41, 'day_interval': 1230}",Progression not otherwise specified,"{'month_interval': 3, 'day_interval': 90}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),Ann Arbor staging system,T1a1,M1,Stage IA,FOLLOW_UP_3,,,DONOR_3,SYNTHETIC-1,Biochemical progression,,N0(i+)
"{'month_interval': 45, 'day_interval': 1350}",Partial remission,,Physical examination procedure (procedure)|Histopathology test (procedure),Lugano staging system,T3a,M1d,Occult Carcinoma,FOLLOW_UP_4,,,DONOR_4,SYNTHETIC-1,,C14,NX
"{'month_interval': 17, 'day_interval': 510}",Partial remission,"{'month_interval': 42, 'day_interval': 1260}",Physical examination procedure (procedure),,T2(s),M1c,,FOLLOW_UP_5,,,DONOR_5,SYNTHETIC-1,Distant recurrence/metastasis,,N1c
"{'month_interval': 1, 'day_interval': 30}",Relapse or recurrence,"{'month_interval': 25, 'day_interval': 750}",Histopathology test (procedure),Ann Arbor staging system,,MX,Stage IIIBES,FOLLOW_UP_6,,,DONOR_6,SYNTHETIC-1,Distant recurrence/metastasis,C13|C02,N0b (no biopsy)
,Partial remission,"{'month_interval': 48, 'day_interval': 1440}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),Revised International staging system (RISS),T1b,M1b(1),Stage IIES,FOLLOW_UP_7,,,DONOR_7,SYNTHETIC-1,Local recurrence and distant metastasis,,N0
"{'month_interval': 8, 'day_interval': 240}",,"{'month_interval': 3, 'day_interval': 90}",Physical examination procedure (procedure)|Tumor marker measurement (procedure),AJCC 6th edition,T1a(s),M1a(1),Stage I,FOLLOW_UP_8,,,DONOR_8,SYNTHETIC-1,Local recurrence and distant metastasis,,N3a
"{'month_interval': 46, 'day_interval': 1380}",Partial remission,"{'month_interval': 15, 'day_interval': 450}",,AJCC 8th edition,T3,M1d,,FOLLOW_UP_9,,,DONOR_9,SYNTHETIC-1,Progression (liquid tumours),,
"{'month_interval': 39, 'day_interval': 1170}",,"{'month_interval': 1, 'day_interval': 30}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),International Neuroblastoma Staging System,,M0,In situ,FOLLOW_UP_10,,,DONOR_10,SYNTHETIC-1,Local recurrence,C10,N0(i+)
"{'month_interval': 42, 'day_interval': 1260}",Progression not otherwise specified,"{'month_interval': 16, 'day_interval': 480}",,Lugano staging system,T3c,M1b(0),Stage IIIAE,FOLLOW_UP_11,,,DONOR_11,SYNTHETIC-1,Biochemical progression,C05|C10,N2c
"{'month_interval': 48, 'day_interval': 1440}",Complete remission,"{'month_interval': 14, 'day_interval': 420}",,AJCC 6th edition,,M1a,Stage IIC,FOLLOW_UP_12,,,DONOR_12,SYNTHETIC-1,Distant recurrence/metastasis,,N3b
"{'month_interval': 39, 'day_interval': 1170}",Distant progression,,,,Ta,,Stage IVE,FOLLOW_UP_13,,,DONOR_13,SYNTHETIC-1,Biochemical progression,,N3b
"{'month_interval': 4, 'day_interval': 120}",Partial remission,"{'month_interval': 17, 'day_interval': 510}",Imaging (procedure),Durie-Salmon staging system,T1b2,M1b,Stage IBE,FOLLOW_UP_14,,,DONOR_14,SYNTHETIC-1,,C04|C09,N2b
,Complete remission,"{'month_interval': 2, 'day_interval': 60}",Physical examination procedure (procedure),Ann Arbor staging system,T1b,M1a,Stage II bulky,FOLLOW_UP_15,,,DONOR_15,SYNTHETIC-1,,C16,N0a (biopsy)
"{'month_interval': 37, 'day_interval': 1110}",,"{'month_interval': 28, 'day_interval': 840}",Tumor marker measurement (procedure)|Histopathology test (procedure),International Neuroblastoma Staging System,T4b(s),M0,Stage IVBE,FOLLOW_UP_16,,,DONOR_16,SYNTHETIC-1,Progression (liquid tumours),,N1a(sn)
"{'month_interval': 39, 'day_interval': 1170}",Complete remission,"{'month_interval': 15, 'day_interval': 450}",,SEER staging system,Tis pu,M1d(0),Stage IIEA,FOLLOW_UP_17,,,DONOR_17,SYNTHETIC-1,Biochemical progression,,N4
"{'month_interval': 1, 'day_interval': 30}",No evidence of disease,,,Binet staging system,,M1d(1),Stage L1,FOLLOW_UP_18,,,DONOR_18,SYNTHETIC-1,,C17|C07,N0(mol+)
,Distant progression,"{'month_interval': 33, 'day_interval': 990}",Tumor marker measurement (procedure)|Imaging (procedure),,T3(s),M1e,Stage IIIA,FOLLOW_UP_19,,,DONOR_19,SYNTHETIC-1,Progression (liquid tumours),C04,
"{'month_interval': 4, 'day_interval': 120}",Distant progression,"{'month_interval': 46, 'day_interval': 1380}",,St Jude staging system,T1b1,M1a(0),,FOLLOW_UP_20,,,DONOR_20,SYNTHETIC-1,Biochemical progression,,N0(mol-)
"{'month_interval': 16, 'day_interval': 480}",No evidence of disease,"{'month_interval': 26, 'day_interval': 780}",,St Jude staging system,,,Stage B,FOLLOW_UP_21,,,DONOR_21,SYNTHETIC-1,Progression (liquid tumours),,N4
"{'month_interval': 7, 'day_interval': 210}",,"{'month_interval': 1, 'day_interval': 30}",,FIGO staging system,T3b,M1b,Stage IBS,FOLLOW_UP_22,,,DONOR_22,SYNTHETIC-1,,,N3c
,Relapse or recurrence,"{'month_interval': 25, 'day_interval': 750}",,,T2a1,M1d,Stage IIA1,FOLLOW_UP_23,,,DONOR_23,SYNTHETIC-1,,C16|C03,
"{'month_interval': 6, 'day_interval': 180}",No evidence of disease,"{'month_interval': 48, 'day_interval': 1440}",,FIGO staging system,Tis(LAMN),M1a,,FOLLOW_UP_24,,,DONOR_24,SYNTHETIC-1,Biochemical progression,C20,N4
"{'month_interval': 38, 'day_interval': 1140}",Relapse or recurrence,"{'month_interval': 11, 'day_interval': 330}",,FIGO staging system,,M1e,Stage IVA1,FOLLOW_UP_25,,,DONOR_25,SYNTHETIC-1,Progression (liquid tumours),,
"{'month_interval': 6, 'day_interval': 180}",Progression not otherwise specified,"{'month_interval': 31, 'day_interval': 930}",,AJCC 7th edition,T4b(s),M1d(1),Stage 0is,FOLLOW_UP_26,,,DONOR_26,SYNTHETIC-1,,,N0b (no biopsy)
"{'month_interval': 8, 'day_interval': 240}",Partial remission,"{'month_interval': 41, 'day_interval': 1230}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),FIGO staging system,T4a(s),,,FOLLOW_UP_27,,,DONOR_27,SYNTHETIC-1,Progression (liquid tumours),C11|C05,N3b
"{'month_interval': 42, 'day_interval': 1260}",,"{'month_interval': 44, 'day_interval': 1320}",Histopathology test (procedure),Durie-Salmon staging system,Tis(DCIS),M1c(0),,FOLLOW_UP_28,,,DONOR_28,SYNTHETIC-1,Distant recurrence/metastasis,C13,N1b
"{'month_interval': 17, 'day_interval': 510}",,"{'month_interval': 24, 'day_interval': 720}",Physical examination procedure (procedure)|Histopathology test (procedure),Binet staging system,T3(m),M1a(0),,FOLLOW_UP_29,,,DONOR_29,SYNTHETIC-1,Local recurrence,,
"{'month_interval': 4, 'day_interval': 120}",Complete remission,"{'month_interval': 15, 'day_interval': 450}",,Lugano staging system,,M1c,Stage M,FOLLOW_UP_30,,,DONOR_30,SYNTHETIC-1,Progression (liquid tumours),,N1a
"{'month_interval': 33, 'day_interval': 990}",,"{'month_interval': 5, 'day_interval': 150}",Histopathology test (procedure)|Imaging (procedure),Rai staging system,T2b,MX,Stage IA,FOLLOW_UP_31,,,DONOR_31,SYNTHETIC-1,Local recurrence and distant metastasis,C06,N0(i+)
"{'month_interval': 35, 'day_interval': 1050}",No evidence of disease,"{'month_interval': 42, 'day_interval': 1260}",Tumor marker measurement (procedure),International Neuroblastoma Staging System,T1d,M1d(1),Stage 0,FOLLOW_UP_32,,PRIMARY_DIAGNOSIS_32,DONOR_32,SYNTHETIC-1,Biochemical progression,,
"{'month_interval': 40, 'day_interval': 1200}",Stable,"{'month_interval': 13, 'day_interval': 390}",,SEER staging system,T2a,M1c(0),Stage IIBES,FOLLOW_UP_33,,PRIMARY_DIAGNOSIS_33,DONOR_33,SYNTHETIC-1,,C18|C10,
"{'month_interval': 11, 'day_interval': 330}",Complete remission,,,International Neuroblastoma Staging System,Tis pd,M1d(1),Regionalized,FOLLOW_UP_34,,PRIMARY_DIAGNOSIS_34,DONOR_34,SYNTHETIC-1,Progression (liquid tumours),,N0(mol-)
"{'month_interval': 6, 'day_interval': 180}",Loco-regional progression,"{'month_interval': 3, 'day_interval': 90}",Assessment of symptom control (procedure),International Neuroblastoma Staging System,T1d,,Stage IES,FOLLOW_UP_35,,PRIMARY_DIAGNOSIS_35,DONOR_35,SYNTHETIC-1,,C01,N2
,,"{'month_interval': 12, 'day_interval': 360}",,International Neuroblastoma Staging System,T4e,M0(i+),,FOLLOW_UP_36,,PRIMARY_DIAGNOSIS_36,DONOR_36,SYNTHETIC-1,Biochemical progression,C19|C04,N0(mol-)
,Relapse or recurrence,"{'month_interval': 14, 'day_interval': 420}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),SEER staging system,Tis(Paget's),M1d(0),Stage 1B,FOLLOW_UP_37,,PRIMARY_DIAGNOSIS_37,DONOR_37,SYNTHETIC-1,Biochemical progression,C02,N0a
"{'month_interval': 39, 'day_interval': 1170}",Stable,,,St Jude staging system,Tis pd,,Stage 0a,FOLLOW_UP_38,,PRIMARY_DIAGNOSIS_38,DONOR_38,SYNTHETIC-1,Progression (liquid tumours),C15|C08,N2
"{'month_interval': 29, 'day_interval': 870}",Relapse or recurrence,"{'month_interval': 50, 'day_interval': 1500}",Imaging (procedure)|Tumor marker measurement (procedure),Binet staging system,T2a1,M1c(0),Stage IIIC1,FOLLOW_UP_39,,PRIMARY_DIAGNOSIS_39,DONOR_39,SYNTHETIC-1,Local recurrence and distant metastasis,C18|C08,N0a (biopsy)
,Distant progression,,,Binet staging system,,M1c(1),Stage 1B,FOLLOW_UP_40,,PRIMARY_DIAGNOSIS_40,DONOR_40,SYNTHETIC-1,Local recurrence,,N2
"{'month_interval': 44, 'day_interval': 1320}",,,Imaging (procedure),Lugano staging system,T1b(s),,,FOLLOW_UP_41,,PRIMARY_DIAGNOSIS_41,DONOR_1,SYNTHETIC-1,Distant recurrence/metastasis,,N2c
"{'month_interval': 32, 'day_interval': 960}",Progression not otherwise specified,,,FIGO staging system,Tis pu,,Stage I,FOLLOW_UP_42,,PRIMARY_DIAGNOSIS_42,DONOR_2,SYNTHETIC-1,,C17,N1a(sn)
,Partial remission,,,FIGO staging system,T1a1,M1b,,FOLLOW_UP_43,,PRIMARY_DIAGNOSIS_43,DONOR_3,SYNTHETIC-1,Progression (liquid tumours),,N1c
"{'month_interval': 21, 'day_interval': 630}",Loco-regional progression,"{'month_interval': 50, 'day_interval': 1500}",Tumor marker measurement (procedure),AJCC 8th edition,,,Stage IA1,FOLLOW_UP_44,,PRIMARY_DIAGNOSIS_44,DONOR_4,SYNTHETIC-1,Progression (liquid tumours),C14|C13,N2c
,Stable,"{'month_interval': 19, 'day_interval': 570}",,SEER staging system,T1b1,M1b(0),,FOLLOW_UP_45,,PRIMARY_DIAGNOSIS_45,DONOR_5,SYNTHETIC-1,Local recurrence and distant metastasis,C18,
"{'month_interval': 4, 'day_interval': 120}",,,Histopathology test (procedure),,T3d,M1b(0),Stage IBES,FOLLOW_UP_46,,PRIMARY_DIAGNOSIS_46,DONOR_6,SYNTHETIC-1,,,
,Stable,,,AJCC 8th edition,T0,,Stage B,FOLLOW_UP_47,,PRIMARY_DIAGNOSIS_47,DONOR_7,SYNTHETIC-1,Local recurrence and distant metastasis,,N3c
"{'month_interval': 43, 'day_interval': 1290}",No evidence of disease,,,AJCC 8th edition,T4d,M1b,,FOLLOW_UP_48,,PRIMARY_DIAGNOSIS_48,DONOR_8,SYNTHETIC-1,Local recurrence,,N2b
,Relapse or recurrence,"{'month_interval': 19, 'day_interval': 570}",,Binet staging system,T1b1,,Stage IIBS,FOLLOW_UP_49,,PRIMARY_DIAGNOSIS_49,DONOR_9,SYNTHETIC-1,Biochemical progression,C11,N0b (no biopsy)
"{'month_interval': 45, 'day_interval': 1350}",Stable,"{'month_interval': 49, 'day_interval': 1470}",Tumor marker measurement (procedure),Revised International staging system (RISS),T2a,M1c(0),Stage IIIAES,FOLLOW_UP_50,,PRIMARY_DIAGNOSIS_50,DONOR_10,SYNTHETIC-1,Local recurrence,C09,
"{'month_interval': 42, 'day_interval': 1260}",Relapse or recurrence,,,Ann Arbor staging system,T1b,M1d,Stage IIA1,FOLLOW_UP_51,,PRIMARY_DIAGNOSIS_51,DONOR_11,SYNTHETIC-1,Biochemical progression,,N2a
,Distant progression,"{'month_interval': 6, 'day_interval': 180}",Physical examination procedure (procedure),Ann Arbor staging system,T4b(s),M1a(0),Stage IVS,FOLLOW_UP_52,,PRIMARY_DIAGNOSIS_52,DONOR_12,SYNTHETIC-1,Biochemical progression,C13,
"{'month_interval': 45, 'day_interval': 1350}",,"{'month_interval': 26, 'day_interval': 780}",Laboratory data interpretation (procedure)|Tumor marker measurement (procedure),,T2a2,M1a(0),Stage IB,FOLLOW_UP_53,,PRIMARY_DIAGNOSIS_53,DONOR_13,SYNTHETIC-1,Local recurrence,,N0(mol+)
"{'month_interval': 41, 'day_interval': 1230}",,"{'month_interval': 6, 'day_interval': 180}",Imaging (procedure)|Assessment of symptom control (procedure),SEER staging system,T0,M1b(1),Stage IVBS,FOLLOW_UP_54,,PRIMARY_DIAGNOSIS_54,DONOR_14,SYNTHETIC-1,Biochemical progression,C02|C08,NX
"{'month_interval': 17, 'day_interval': 510}",No evidence of disease,"{'month_interval': 46, 'day_interval': 1380}",,St Jude staging system,Tis,,Stage IAE,FOLLOW_UP_55,,PRIMARY_DIAGNOSIS_55,DONOR_15,SYNTHETIC-1,Local recurrence,C17|C10,N0(i+)
"{'month_interval': 13, 'day_interval': 390}",Relapse or recurrence,,Imaging (procedure),SEER staging system,T4b(s),,Stage IVAE,FOLLOW_UP_56,,PRIMARY_DIAGNOSIS_56,DONOR_16,SYNTHETIC-1,Distant recurrence/metastasis,,N1
"{'month_interval': 41, 'day_interval': 1230}",Complete remission,"{'month_interval': 32, 'day_interval': 960}",Tumor marker measurement (procedure)|Histopathology test (procedure),Lugano staging system,T2(m),M1a(0),,FOLLOW_UP_57,,PRIMARY_DIAGNOSIS_57,DONOR_17,SYNTHETIC-1,Biochemical progression,C18,NX
"{'month_interval': 8, 'day_interval': 240}",Complete remission,"{'month_interval': 50, 'day_interval': 1500}",,Lugano staging system,,,Stage IAB,FOLLOW_UP_58,,PRIMARY_DIAGNOSIS_58,DONOR_18,SYNTHETIC-1,Biochemical progression,C09,
"{'month_interval': 20, 'day_interval': 600}",Loco-regional progression,,,AJCC 6th edition,T2a,M1,Stage IVAES,FOLLOW_UP_59,,PRIMARY_DIAGNOSIS_59,DONOR_19,SYNTHETIC-1,Progression (liquid tumours),C05,
"{'month_interval': 13, 'day_interval': 390}",,"{'month_interval': 37, 'day_interval': 1110}",Imaging (procedure),Durie-Salmon staging system,T4c,M0(i+),Stage IVE,FOLLOW_UP_60,,PRIMARY_DIAGNOSIS_60,DONOR_20,SYNTHETIC-1,Progression (liquid tumours),,N0(i-)
"{'month_interval': 24, 'day_interval': 720}",Distant progression,"{'month_interval': 4, 'day_interval': 120}",Imaging (procedure)|Histopathology test (procedure),Revised International staging system (RISS),T3,M1c(1),Stage IIIAES,FOLLOW_UP_61,,PRIMARY_DIAGNOSIS_61,DONOR_21,SYNTHETIC-1,Local recurrence,C03,N1mi
"{'month_interval': 29, 'day_interval': 870}",Partial remission,,,Ann Arbor staging system,T1c,M1c(1),,FOLLOW_UP_62,,PRIMARY_DIAGNOSIS_62,DONOR_22,SYNTHETIC-1,Local recurrence,C12|C03,N0a (biopsy)
"{'month_interval': 19, 'day_interval': 570}",Loco-regional progression,,Physical examination procedure (procedure)|Histopathology test (procedure),Rai staging system,T4b(s),M1d(0),Stage IB1,FOLLOW_UP_63,,PRIMARY_DIAGNOSIS_63,DONOR_23,SYNTHETIC-1,Distant recurrence/metastasis,C07|C03,N2c
,Stable,"{'month_interval': 1, 'day_interval': 30}",,Revised International staging system (RISS),,M1b(0),,FOLLOW_UP_64,,PRIMARY_DIAGNOSIS_64,DONOR_24,SYNTHETIC-1,Biochemical progression,C10,N1a(sn)
"{'month_interval': 32, 'day_interval': 960}",Complete remission,"{'month_interval': 16, 'day_interval': 480}",Physical examination procedure (procedure)|Histopathology test (procedure),Binet staging system,TX,M1a(0),,FOLLOW_UP_65,,PRIMARY_DIAGNOSIS_65,DONOR_25,SYNTHETIC-1,Distant recurrence/metastasis,,N3c
"{'month_interval': 17, 'day_interval': 510}",Partial remission,"{'month_interval': 13, 'day_interval': 390}",Physical examination procedure (procedure),International Neuroblastoma Staging System,T3(s),M1e,Stage IAB,FOLLOW_UP_66,,PRIMARY_DIAGNOSIS_66,DONOR_26,SYNTHETIC-1,Progression (liquid tumours),,N0b (no biopsy)
"{'month_interval': 18, 'day_interval': 540}",Distant progression,"{'month_interval': 43, 'day_interval': 1290}",,Rai staging system,T4e,M1,Stage 0a,FOLLOW_UP_67,,PRIMARY_DIAGNOSIS_67,DONOR_27,SYNTHETIC-1,Distant recurrence/metastasis,C11|C10,N1b
"{'month_interval': 31, 'day_interval': 930}",Loco-regional progression,,Imaging (procedure),,T1a,M1b(0),Stage IIIA2,FOLLOW_UP_68,,PRIMARY_DIAGNOSIS_68,DONOR_28,SYNTHETIC-1,,,
"{'month_interval': 49, 'day_interval': 1470}",Progression not otherwise specified,"{'month_interval': 39, 'day_interval': 1170}",Laboratory data interpretation (procedure)|Imaging (procedure),AJCC 8th edition,T0,M1a(1),Stage IIIA,FOLLOW_UP_69,,PRIMARY_DIAGNOSIS_69,DONOR_29,SYNTHETIC-1,Local recurrence,,N0
"{'month_interval': 40, 'day_interval': 1200}",No evidence of disease,"{'month_interval': 27, 'day_interval': 810}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),SEER staging system,T3,M1c(0),Stage 1,FOLLOW_UP_70,,PRIMARY_DIAGNOSIS_70,DONOR_30,SYNTHETIC-1,Biochemical progression,C03|C14,N0
"{'month_interval': 22, 'day_interval': 660}",Stable,"{'month_interval': 37, 'day_interval': 1110}",Imaging (procedure)|Laboratory data interpretation (procedure),Binet staging system,Tis(DCIS),M1c,Regionalized,FOLLOW_UP_71,,PRIMARY_DIAGNOSIS_71,DONOR_31,SYNTHETIC-1,Local recurrence and distant metastasis,C05,N3c
"{'month_interval': 11, 'day_interval': 330}",Partial remission,,Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,T1a2,M1d(1),Stage 1A,FOLLOW_UP_72,,PRIMARY_DIAGNOSIS_72,DONOR_32,SYNTHETIC-1,Local recurrence and distant metastasis,,N0a (biopsy)
"{'month_interval': 49, 'day_interval': 1470}",No evidence of disease,,Physical examination procedure (procedure),FIGO staging system,,M1a(1),,FOLLOW_UP_73,,PRIMARY_DIAGNOSIS_73,DONOR_33,SYNTHETIC-1,Progression (liquid tumours),C18,N0(i-)
"{'month_interval': 42, 'day_interval': 1260}",Stable,"{'month_interval': 1, 'day_interval': 30}",Laboratory data interpretation (procedure),AJCC 6th edition,T4b(s),M0,Stage IIIE,FOLLOW_UP_74,,PRIMARY_DIAGNOSIS_74,DONOR_34,SYNTHETIC-1,,,N4
"{'month_interval': 9, 'day_interval': 270}",No evidence of disease,"{'month_interval': 42, 'day_interval': 1260}",,,T2,M1c(1),Stage L2,FOLLOW_UP_75,,PRIMARY_DIAGNOSIS_75,DONOR_35,SYNTHETIC-1,Biochemical progression,,N1
"{'month_interval': 26, 'day_interval': 780}",Partial remission,"{'month_interval': 14, 'day_interval': 420}",,Rai staging system,T4d,M1d(0),Stage IVAES,FOLLOW_UP_76,,PRIMARY_DIAGNOSIS_76,DONOR_36,SYNTHETIC-1,,,N3
"{'month_interval': 48, 'day_interval': 1440}",Relapse or recurrence,"{'month_interval': 49, 'day_interval': 1470}",Imaging (procedure)|Histopathology test (procedure),AJCC 6th edition,T4b,MX,Stage IIEB,FOLLOW_UP_77,,PRIMARY_DIAGNOSIS_77,DONOR_37,SYNTHETIC-1,Local recurrence,,NX
"{'month_interval': 45, 'day_interval': 1350}",Progression not otherwise specified,"{'month_interval': 8, 'day_interval': 240}",,St Jude staging system,T3,,Stage Ms,FOLLOW_UP_78,,PRIMARY_DIAGNOSIS_78,DONOR_38,SYNTHETIC-1,,C02,N3b
"{'month_interval': 27, 'day_interval': 810}",Partial remission,"{'month_interval': 19, 'day_interval': 570}",,,T1,,Stage IIS,FOLLOW_UP_79,,PRIMARY_DIAGNOSIS_79,DONOR_39,SYNTHETIC-1,Progression (liquid tumours),,N1mi
"{'month_interval': 37, 'day_interval': 1110}",Loco-regional progression,"{'month_interval': 19, 'day_interval': 570}",,,,M1b,Stage IIID,FOLLOW_UP_80,,PRIMARY_DIAGNOSIS_80,DONOR_40,SYNTHETIC-1,Progression (liquid tumours),C19|C12,
"{'month_interval': 38, 'day_interval': 1140}",Complete remission,"{'month_interval': 14, 'day_interval': 420}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),AJCC 8th edition,,,Stage IIIBS,FOLLOW_UP_81,,PRIMARY_DIAGNOSIS_81,DONOR_1,SYNTHETIC-1,Local recurrence,C12,N0(mol+)
"{'month_interval': 16, 'day_interval': 480}",Relapse or recurrence,"{'month_interval': 14, 'day_interval': 420}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),SEER staging system,T2a,,Stage IIEA,FOLLOW_UP_82,,PRIMARY_DIAGNOSIS_82,DONOR_2,SYNTHETIC-1,Local recurrence and distant metastasis,C12|C06,N3c
"{'month_interval': 18, 'day_interval': 540}",,"{'month_interval': 46, 'day_interval': 1380}",Laboratory data interpretation (procedure),FIGO staging system,,M1d,Stage IIIS,FOLLOW_UP_83,,PRIMARY_DIAGNOSIS_83,DONOR_3,SYNTHETIC-1,Local recurrence and distant metastasis,,
"{'month_interval': 20, 'day_interval': 600}",Distant progression,"{'month_interval': 30, 'day_interval': 900}",,SEER staging system,T4,M0,,FOLLOW_UP_84,,PRIMARY_DIAGNOSIS_84,DONOR_4,SYNTHETIC-1,,,N1a(sn)
"{'month_interval': 42, 'day_interval': 1260}",,"{'month_interval': 18, 'day_interval': 540}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),Binet staging system,T1d,M0,Stage 2B,FOLLOW_UP_85,,PRIMARY_DIAGNOSIS_85,DONOR_5,SYNTHETIC-1,Distant recurrence/metastasis,C10|C04,N0
"{'month_interval': 46, 'day_interval': 1380}",Progression not otherwise specified,"{'month_interval': 38, 'day_interval': 1140}",,,T3a,M1d,Stage IIBS,FOLLOW_UP_86,,PRIMARY_DIAGNOSIS_86,DONOR_6,SYNTHETIC-1,,C18,N0(mol+)
"{'month_interval': 41, 'day_interval': 1230}",Loco-regional progression,"{'month_interval': 47, 'day_interval': 1410}",,International Neuroblastoma Staging System,T4e,,Stage IVA1,FOLLOW_UP_87,,PRIMARY_DIAGNOSIS_87,DONOR_7,SYNTHETIC-1,Biochemical progression,,N3
"{'month_interval': 14, 'day_interval': 420}",Relapse or recurrence,"{'month_interval': 27, 'day_interval': 810}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Durie-Salmon staging system,Tis(Paget),M0,Stage IS,FOLLOW_UP_88,,PRIMARY_DIAGNOSIS_88,DONOR_8,SYNTHETIC-1,Progression (liquid tumours),C15,N3
"{'month_interval': 40, 'day_interval': 1200}",Distant progression,"{'month_interval': 17, 'day_interval': 510}",,St Jude staging system,T1b2,,Stage C,FOLLOW_UP_89,,PRIMARY_DIAGNOSIS_89,DONOR_9,SYNTHETIC-1,Biochemical progression,C03|C12,NX
"{'month_interval': 19, 'day_interval': 570}",Partial remission,"{'month_interval': 34, 'day_interval': 1020}",Tumor marker measurement (procedure)|Imaging (procedure),Binet staging system,T1a2,,Stage IVB,FOLLOW_UP_90,,PRIMARY_DIAGNOSIS_90,DONOR_10,SYNTHETIC-1,Biochemical progression,C18,
"{'month_interval': 30, 'day_interval': 900}",Complete remission,"{'month_interval': 39, 'day_interval': 1170}",Laboratory data interpretation (procedure),St Jude staging system,T4d,M1d,Stage IAES,FOLLOW_UP_91,,PRIMARY_DIAGNOSIS_91,DONOR_11,SYNTHETIC-1,Local recurrence,C15|C01,N1a
"{'month_interval': 7, 'day_interval': 210}",,"{'month_interval': 48, 'day_interval': 1440}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),Ann Arbor staging system,Tis pu,,Stage IVC,FOLLOW_UP_92,,PRIMARY_DIAGNOSIS_92,DONOR_12,SYNTHETIC-1,Distant recurrence/metastasis,,N2b
"{'month_interval': 29, 'day_interval': 870}",Loco-regional progression,"{'month_interval': 8, 'day_interval': 240}",Assessment of symptom control (procedure),International Neuroblastoma Staging System,,M1a(1),Stage IEB,FOLLOW_UP_93,,PRIMARY_DIAGNOSIS_93,DONOR_13,SYNTHETIC-1,Biochemical progression,C12|C17,N2
"{'month_interval': 46, 'day_interval': 1380}",Partial remission,"{'month_interval': 32, 'day_interval': 960}",Physical examination procedure (procedure),AJCC 6th edition,T2c,M1b,,FOLLOW_UP_94,,PRIMARY_DIAGNOSIS_94,DONOR_14,SYNTHETIC-1,Biochemical progression,,N0a (biopsy)
"{'month_interval': 29, 'day_interval': 870}",Relapse or recurrence,"{'month_interval': 43, 'day_interval': 1290}",Physical examination procedure (procedure),AJCC 6th edition,T1a(m),M1b,Stage IBES,FOLLOW_UP_95,,PRIMARY_DIAGNOSIS_95,DONOR_15,SYNTHETIC-1,Biochemical progression,C13,N4
"{'month_interval': 3, 'day_interval': 90}",Loco-regional progression,,Tumor marker measurement (procedure)|Assessment of symptom control (procedure),Rai staging system,,MX,Stage 0,FOLLOW_UP_96,,PRIMARY_DIAGNOSIS_96,DONOR_16,SYNTHETIC-1,Distant recurrence/metastasis,,N0a
"{'month_interval': 1, 'day_interval': 30}",,"{'month_interval': 25, 'day_interval': 750}",Imaging (procedure),Lugano staging system,T3d,M1e,Stage Ms,FOLLOW_UP_97,,PRIMARY_DIAGNOSIS_97,DONOR_17,SYNTHETIC-1,Biochemical progression,,N1
"{'month_interval': 9, 'day_interval': 270}",Complete remission,,,Durie-Salmon staging system,T2a1,M0,Stage IIIA,FOLLOW_UP_98,,PRIMARY_DIAGNOSIS_98,DONOR_18,SYNTHETIC-1,Local recurrence,,N1c
"{'month_interval': 38, 'day_interval': 1140}",Loco-regional progression,"{'month_interval': 48, 'day_interval': 1440}",,,Tis(LAMN),M1e,Stage IS,FOLLOW_UP_99,,PRIMARY_DIAGNOSIS_99,DONOR_19,SYNTHETIC-1,Distant recurrence/metastasis,C12|C05,
,Stable,"{'month_interval': 45, 'day_interval': 1350}",Histopathology test (procedure)|Imaging (procedure),International Neuroblastoma Risk Group Staging System,Tis,M1d(0),Stage IVA1,FOLLOW_UP_100,,PRIMARY_DIAGNOSIS_100,DONOR_20,SYNTHETIC-1,Biochemical progression,C18,N0(i+)
"{'month_interval': 36, 'day_interval': 1080}",Relapse or recurrence,"{'month_interval': 42, 'day_interval': 1260}",,AJCC 8th edition,,M1b(0),Stage IVBES,FOLLOW_UP_101,,PRIMARY_DIAGNOSIS_101,DONOR_21,SYNTHETIC-1,Distant recurrence/metastasis,C17,N2
"{'month_interval': 10, 'day_interval': 300}",Relapse or recurrence,"{'month_interval': 3, 'day_interval': 90}",Laboratory data interpretation (procedure),Durie-Salmon staging system,T1b(s),M1d,Stage IA2,FOLLOW_UP_102,,PRIMARY_DIAGNOSIS_102,DONOR_22,SYNTHETIC-1,Distant recurrence/metastasis,C16,N0
"{'month_interval': 29, 'day_interval': 870}",Distant progression,"{'month_interval': 18, 'day_interval': 540}",Histopathology test (procedure),AJCC 6th edition,T1a(m),M1a,Stage IA,FOLLOW_UP_103,,PRIMARY_DIAGNOSIS_103,DONOR_23,SYNTHETIC-1,,C17|C11,N1a(sn)
"{'month_interval': 31, 'day_interval': 930}",Distant progression,"{'month_interval': 45, 'day_interval': 1350}",Laboratory data interpretation (procedure),FIGO staging system,,M0(i+),Stage IEB,FOLLOW_UP_104,,PRIMARY_DIAGNOSIS_104,DONOR_24,SYNTHETIC-1,Local recurrence,,NX
"{'month_interval': 34, 'day_interval': 1020}",Partial remission,"{'month_interval': 44, 'day_interval': 1320}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),International Neuroblastoma Staging System,T2a2,M0,,FOLLOW_UP_105,,PRIMARY_DIAGNOSIS_105,DONOR_25,SYNTHETIC-1,Progression (liquid tumours),C19,NX
"{'month_interval': 40, 'day_interval': 1200}",Complete remission,"{'month_interval': 13, 'day_interval': 390}",Histopathology test (procedure)|Tumor marker measurement (procedure),,,M1a,Stage A,FOLLOW_UP_106,,PRIMARY_DIAGNOSIS_106,DONOR_26,SYNTHETIC-1,Progression (liquid tumours),,N0a
"{'month_interval': 31, 'day_interval': 930}",Complete remission,"{'month_interval': 8, 'day_interval': 240}",Histopathology test (procedure),,Ta,M1,Stage IIIBE,FOLLOW_UP_107,,PRIMARY_DIAGNOSIS_107,DONOR_27,SYNTHETIC-1,Local recurrence,,N1a
"{'month_interval': 44, 'day_interval': 1320}",Stable,"{'month_interval': 1, 'day_interval': 30}",,International Neuroblastoma Staging System,T3d,M1b,Stage IIA1,FOLLOW_UP_108,,PRIMARY_DIAGNOSIS_108,DONOR_28,SYNTHETIC-1,Local recurrence,,N3c
"{'month_interval': 11, 'day_interval': 330}",,,Laboratory data interpretation (procedure),SEER staging system,T2a,M1a(0),Stage IB2,FOLLOW_UP_109,,PRIMARY_DIAGNOSIS_109,DONOR_29,SYNTHETIC-1,,C09,N3b
"{'month_interval': 27, 'day_interval': 810}",Distant progression,"{'month_interval': 45, 'day_interval': 1350}",Laboratory data interpretation (procedure),,T1d,,Stage 4S,FOLLOW_UP_110,,PRIMARY_DIAGNOSIS_110,DONOR_30,SYNTHETIC-1,,,
,No evidence of disease,"{'month_interval': 24, 'day_interval': 720}",Imaging (procedure)|Physical examination procedure (procedure),SEER staging system,T4b,M1c(0),Stage IIAS,FOLLOW_UP_111,,PRIMARY_DIAGNOSIS_111,DONOR_31,SYNTHETIC-1,Biochemical progression,C17,N0(mol+)
"{'month_interval': 13, 'day_interval': 390}",Relapse or recurrence,"{'month_interval': 26, 'day_interval': 780}",Histopathology test (procedure)|Laboratory data interpretation (procedure),St Jude staging system,T2(m),M1d,,FOLLOW_UP_112,,PRIMARY_DIAGNOSIS_112,DONOR_32,SYNTHETIC-1,Local recurrence,C15,N3
"{'month_interval': 49, 'day_interval': 1470}",Distant progression,"{'month_interval': 7, 'day_interval': 210}",,FIGO staging system,T3(s),M0,Stage IIAES,FOLLOW_UP_113,,PRIMARY_DIAGNOSIS_113,DONOR_33,SYNTHETIC-1,,,N1
"{'month_interval': 27, 'day_interval': 810}",Distant progression,"{'month_interval': 42, 'day_interval': 1260}",Laboratory data interpretation (procedure),Revised International staging system (RISS),T1d,M1e,Stage 1A,FOLLOW_UP_114,,PRIMARY_DIAGNOSIS_114,DONOR_34,SYNTHETIC-1,Biochemical progression,C05|C12,
"{'month_interval': 45, 'day_interval': 1350}",Relapse or recurrence,"{'month_interval': 23, 'day_interval': 690}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),AJCC 7th edition,T4b(s),M1c(1),,FOLLOW_UP_115,,PRIMARY_DIAGNOSIS_115,DONOR_35,SYNTHETIC-1,Local recurrence,,N2c
,Partial remission,"{'month_interval': 35, 'day_interval': 1050}",Tumor marker measurement (procedure),AJCC 8th edition,,M1b(0),Stage IIAE,FOLLOW_UP_116,,PRIMARY_DIAGNOSIS_116,DONOR_36,SYNTHETIC-1,Local recurrence,C08,N1c
"{'month_interval': 49, 'day_interval': 1470}",Complete remission,"{'month_interval': 41, 'day_interval': 1230}",,Binet staging system,,MX,Stage IIBE,FOLLOW_UP_117,,PRIMARY_DIAGNOSIS_117,DONOR_37,SYNTHETIC-1,Distant recurrence/metastasis,C12,
"{'month_interval': 21, 'day_interval': 630}",Progression not otherwise specified,"{'month_interval': 19, 'day_interval': 570}",,,T3(m),,,FOLLOW_UP_118,,PRIMARY_DIAGNOSIS_118,DONOR_38,SYNTHETIC-1,Progression (liquid tumours),C16,N1c
"{'month_interval': 30, 'day_interval': 900}",Complete remission,"{'month_interval': 30, 'day_interval': 900}",Histopathology test (procedure)|Imaging (procedure),,T1b2,M1a,Stage IVES,FOLLOW_UP_119,,PRIMARY_DIAGNOSIS_119,DONOR_39,SYNTHETIC-1,Local recurrence and distant metastasis,C04,
"{'month_interval': 18, 'day_interval': 540}",Partial remission,,Imaging (procedure),Binet staging system,Tis pu,M1c,Stage IIID,FOLLOW_UP_120,,PRIMARY_DIAGNOSIS_120,DONOR_40,SYNTHETIC-1,Local recurrence and distant metastasis,C19|C04,N2mi
"{'month_interval': 41, 'day_interval': 1230}",Progression not otherwise specified,,,Rai staging system,T2b,,,FOLLOW_UP_121,,PRIMARY_DIAGNOSIS_121,DONOR_1,SYNTHETIC-1,Local recurrence and distant metastasis,,N1mi
"{'month_interval': 43, 'day_interval': 1290}",Stable,"{'month_interval': 30, 'day_interval': 900}",Histopathology test (procedure)|Physical examination procedure (procedure),International Neuroblastoma Risk Group Staging System,T1mi,M1a(0),Stage Ms,FOLLOW_UP_122,,PRIMARY_DIAGNOSIS_122,DONOR_2,SYNTHETIC-1,Biochemical progression,,N0(i+)
"{'month_interval': 22, 'day_interval': 660}",Partial remission,"{'month_interval': 47, 'day_interval': 1410}",Histopathology test (procedure),Rai staging system,T4b(s),,Stage IIAE,FOLLOW_UP_123,,PRIMARY_DIAGNOSIS_123,DONOR_3,SYNTHETIC-1,Distant recurrence/metastasis,C12,NX
"{'month_interval': 8, 'day_interval': 240}",Progression not otherwise specified,"{'month_interval': 19, 'day_interval': 570}",,Lugano staging system,T2,,Stage 3,FOLLOW_UP_124,,PRIMARY_DIAGNOSIS_124,DONOR_4,SYNTHETIC-1,Local recurrence and distant metastasis,,
"{'month_interval': 38, 'day_interval': 1140}",Partial remission,"{'month_interval': 48, 'day_interval': 1440}",,Lugano staging system,Tis(Paget),M0,Stage IVB,FOLLOW_UP_125,,PRIMARY_DIAGNOSIS_125,DONOR_5,SYNTHETIC-1,Biochemical progression,C03,N2
"{'month_interval': 41, 'day_interval': 1230}",Stable,"{'month_interval': 27, 'day_interval': 810}",Physical examination procedure (procedure),Lugano staging system,Tis(LCIS),M0(i+),Stage L1,FOLLOW_UP_126,,PRIMARY_DIAGNOSIS_126,DONOR_6,SYNTHETIC-1,Local recurrence and distant metastasis,C19|C05,N2c
"{'month_interval': 9, 'day_interval': 270}",No evidence of disease,"{'month_interval': 20, 'day_interval': 600}",Histopathology test (procedure)|Tumor marker measurement (procedure),AJCC 7th edition,T1b(m),M1d(1),Stage IBES,FOLLOW_UP_127,,PRIMARY_DIAGNOSIS_127,DONOR_7,SYNTHETIC-1,Biochemical progression,C02,
"{'month_interval': 16, 'day_interval': 480}",Progression not otherwise specified,"{'month_interval': 8, 'day_interval': 240}",,St Jude staging system,,M0,Stage IBES,FOLLOW_UP_128,,PRIMARY_DIAGNOSIS_128,DONOR_8,SYNTHETIC-1,Local recurrence and distant metastasis,,N0a (biopsy)
"{'month_interval': 25, 'day_interval': 750}",Partial remission,,,Binet staging system,T1b(m),,Stage 4,FOLLOW_UP_129,,PRIMARY_DIAGNOSIS_129,DONOR_9,SYNTHETIC-1,Local recurrence and distant metastasis,C05|C17,
"{'month_interval': 9, 'day_interval': 270}",Loco-regional progression,"{'month_interval': 28, 'day_interval': 840}",Tumor marker measurement (procedure),SEER staging system,Tis(Paget's),M1d(1),Stage IIAE,FOLLOW_UP_130,,PRIMARY_DIAGNOSIS_130,DONOR_10,SYNTHETIC-1,Progression (liquid tumours),,
"{'month_interval': 42, 'day_interval': 1260}",Complete remission,"{'month_interval': 31, 'day_interval': 930}",Laboratory data interpretation (procedure),Lugano staging system,T3(m),M0,Stage IBES,FOLLOW_UP_131,,PRIMARY_DIAGNOSIS_131,DONOR_11,SYNTHETIC-1,Biochemical progression,,N0b
"{'month_interval': 34, 'day_interval': 1020}",Complete remission,"{'month_interval': 32, 'day_interval': 960}",,,,M1d(1),Stage IIIBE,FOLLOW_UP_132,,PRIMARY_DIAGNOSIS_132,DONOR_12,SYNTHETIC-1,Distant recurrence/metastasis,,N3c
,Complete remission,"{'month_interval': 36, 'day_interval': 1080}",Assessment of symptom control (procedure),Durie-Salmon staging system,Ta,,Stage IIBES,FOLLOW_UP_133,,PRIMARY_DIAGNOSIS_133,DONOR_13,SYNTHETIC-1,Biochemical progression,,N0(i+)
"{'month_interval': 10, 'day_interval': 300}",No evidence of disease,"{'month_interval': 42, 'day_interval': 1260}",,SEER staging system,,M1c(1),Stage 0is,FOLLOW_UP_134,,PRIMARY_DIAGNOSIS_134,DONOR_14,SYNTHETIC-1,Local recurrence and distant metastasis,,N2a
"{'month_interval': 41, 'day_interval': 1230}",,"{'month_interval': 32, 'day_interval': 960}",Tumor marker measurement (procedure)|Histopathology test (procedure),Binet staging system,T4,M1d(1),Stage IAB,FOLLOW_UP_135,,PRIMARY_DIAGNOSIS_135,DONOR_15,SYNTHETIC-1,Distant recurrence/metastasis,,N0(i-)
"{'month_interval': 26, 'day_interval': 780}",,,Tumor marker measurement (procedure)|Imaging (procedure),Binet staging system,T2b,,,FOLLOW_UP_136,,PRIMARY_DIAGNOSIS_136,DONOR_16,SYNTHETIC-1,Biochemical progression,C10,N0(mol-)
"{'month_interval': 20, 'day_interval': 600}",Distant progression,"{'month_interval': 6, 'day_interval': 180}",,,T1,M1a,Stage IIIES,FOLLOW_UP_137,,PRIMARY_DIAGNOSIS_137,DONOR_17,SYNTHETIC-1,Progression (liquid tumours),,
"{'month_interval': 41, 'day_interval': 1230}",Stable,"{'month_interval': 25, 'day_interval': 750}",Histopathology test (procedure),SEER staging system,Tis pd,M1d(0),Stage IIIB,FOLLOW_UP_138,,PRIMARY_DIAGNOSIS_138,DONOR_18,SYNTHETIC-1,,C03,N0(i+)
,Partial remission,"{'month_interval': 23, 'day_interval': 690}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),,T1a1,M1d(0),Stage IEB,FOLLOW_UP_139,,PRIMARY_DIAGNOSIS_139,DONOR_19,SYNTHETIC-1,Distant recurrence/metastasis,,N0(i-)
"{'month_interval': 30, 'day_interval': 900}",,"{'month_interval': 7, 'day_interval': 210}",Tumor marker measurement (procedure),Revised International staging system (RISS),T2a1,M1b(1),Stage IVBS,FOLLOW_UP_140,,PRIMARY_DIAGNOSIS_140,DONOR_20,SYNTHETIC-1,Local recurrence and distant metastasis,C15,N3
"{'month_interval': 17, 'day_interval': 510}",Complete remission,"{'month_interval': 34, 'day_interval': 1020}",Physical examination procedure (procedure),,T4b,M1,Stage 1B,FOLLOW_UP_141,,PRIMARY_DIAGNOSIS_141,DONOR_21,SYNTHETIC-1,Biochemical progression,,N3a
"{'month_interval': 36, 'day_interval': 1080}",No evidence of disease,"{'month_interval': 4, 'day_interval': 120}",,,Tis pu,M1c(0),Stage IIE,FOLLOW_UP_142,,PRIMARY_DIAGNOSIS_142,DONOR_22,SYNTHETIC-1,Biochemical progression,,
"{'month_interval': 50, 'day_interval': 1500}",,"{'month_interval': 35, 'day_interval': 1050}",Histopathology test (procedure),,Tis(Paget's),MX,,FOLLOW_UP_143,,PRIMARY_DIAGNOSIS_143,DONOR_23,SYNTHETIC-1,Local recurrence,,N2
"{'month_interval': 9, 'day_interval': 270}",No evidence of disease,"{'month_interval': 31, 'day_interval': 930}",,St Jude staging system,T3a,M1d(0),,FOLLOW_UP_144,,PRIMARY_DIAGNOSIS_144,DONOR_24,SYNTHETIC-1,,,N2
"{'month_interval': 12, 'day_interval': 360}",Distant progression,"{'month_interval': 2, 'day_interval': 60}",Tumor marker measurement (procedure),SEER staging system,Tis(LAMN),M1a(1),Stage IS,FOLLOW_UP_145,,PRIMARY_DIAGNOSIS_145,DONOR_25,SYNTHETIC-1,Distant recurrence/metastasis,C03,N2c
"{'month_interval': 32, 'day_interval': 960}",Progression not otherwise specified,"{'month_interval': 33, 'day_interval': 990}",,St Jude staging system,T4e,M1d,Stage IES,FOLLOW_UP_146,,PRIMARY_DIAGNOSIS_146,DONOR_26,SYNTHETIC-1,,,N1
"{'month_interval': 23, 'day_interval': 690}",Partial remission,"{'month_interval': 46, 'day_interval': 1380}",,,T3c,,Stage IA,FOLLOW_UP_147,,PRIMARY_DIAGNOSIS_147,DONOR_27,SYNTHETIC-1,Biochemical progression,,N3b
"{'month_interval': 44, 'day_interval': 1320}",Complete remission,"{'month_interval': 34, 'day_interval': 1020}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),AJCC 6th edition,T2c,M1,Stage IAS,FOLLOW_UP_148,,PRIMARY_DIAGNOSIS_148,DONOR_28,SYNTHETIC-1,Progression (liquid tumours),C06|C02,N1a(sn)
"{'month_interval': 23, 'day_interval': 690}",Partial remission,"{'month_interval': 47, 'day_interval': 1410}",,Durie-Salmon staging system,Tis pu,M1b(1),,FOLLOW_UP_149,,PRIMARY_DIAGNOSIS_149,DONOR_29,SYNTHETIC-1,Progression (liquid tumours),,N4
"{'month_interval': 38, 'day_interval': 1140}",Progression not otherwise specified,"{'month_interval': 31, 'day_interval': 930}",Tumor marker measurement (procedure),AJCC 7th edition,Tis(Paget's),M1b(0),,FOLLOW_UP_150,,PRIMARY_DIAGNOSIS_150,DONOR_30,SYNTHETIC-1,Progression (liquid tumours),C02,
"{'month_interval': 27, 'day_interval': 810}",Complete remission,"{'month_interval': 5, 'day_interval': 150}",Tumor marker measurement (procedure),FIGO staging system,T3(m),MX,Stage IVAS,FOLLOW_UP_151,,PRIMARY_DIAGNOSIS_151,DONOR_31,SYNTHETIC-1,Local recurrence and distant metastasis,C18,N1b
"{'month_interval': 26, 'day_interval': 780}",No evidence of disease,,,AJCC 7th edition,,M0,Stage IIBE,FOLLOW_UP_152,,PRIMARY_DIAGNOSIS_152,DONOR_32,SYNTHETIC-1,Local recurrence,C18,N1a
"{'month_interval': 43, 'day_interval': 1290}",No evidence of disease,"{'month_interval': 22, 'day_interval': 660}",Physical examination procedure (procedure),FIGO staging system,T3e,M1a(0),,FOLLOW_UP_153,,PRIMARY_DIAGNOSIS_153,DONOR_33,SYNTHETIC-1,Distant recurrence/metastasis,,N0a
"{'month_interval': 30, 'day_interval': 900}",Complete remission,"{'month_interval': 45, 'day_interval': 1350}",Physical examination procedure (procedure),AJCC 6th edition,,MX,,FOLLOW_UP_154,,PRIMARY_DIAGNOSIS_154,DONOR_34,SYNTHETIC-1,Local recurrence,,N3
"{'month_interval': 44, 'day_interval': 1320}",Partial remission,"{'month_interval': 23, 'day_interval': 690}",Imaging (procedure)|Histopathology test (procedure),SEER staging system,T1b2,M1c,Stage IVBES,FOLLOW_UP_155,,PRIMARY_DIAGNOSIS_155,DONOR_35,SYNTHETIC-1,Local recurrence and distant metastasis,,N2
"{'month_interval': 13, 'day_interval': 390}",No evidence of disease,"{'month_interval': 3, 'day_interval': 90}",,International Neuroblastoma Risk Group Staging System,T2a1,,Stage IIA1,FOLLOW_UP_156,,PRIMARY_DIAGNOSIS_156,DONOR_36,SYNTHETIC-1,Local recurrence and distant metastasis,C06|C15,N0(i+)
"{'month_interval': 16, 'day_interval': 480}",Complete remission,"{'month_interval': 8, 'day_interval': 240}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Revised International staging system (RISS),T2d,M1c(1),Stage IVA1,FOLLOW_UP_157,,PRIMARY_DIAGNOSIS_157,DONOR_37,SYNTHETIC-1,,,N1b
,Progression not otherwise specified,"{'month_interval': 50, 'day_interval': 1500}",,FIGO staging system,T0,M1d,Stage IIE,FOLLOW_UP_158,,PRIMARY_DIAGNOSIS_158,DONOR_38,SYNTHETIC-1,Distant recurrence/metastasis,C08,N1
"{'month_interval': 34, 'day_interval': 1020}",Stable,"{'month_interval': 37, 'day_interval': 1110}",Laboratory data interpretation (procedure)|Histopathology test (procedure),Rai staging system,Ta,M1a(0),Stage IVES,FOLLOW_UP_159,,PRIMARY_DIAGNOSIS_159,DONOR_39,SYNTHETIC-1,Local recurrence and distant metastasis,C16|C13,N0(mol-)
"{'month_interval': 9, 'day_interval': 270}",Loco-regional progression,"{'month_interval': 35, 'day_interval': 1050}",,Ann Arbor staging system,T4b(s),M1c,Stage 1B,FOLLOW_UP_160,,PRIMARY_DIAGNOSIS_160,DONOR_40,SYNTHETIC-1,Local recurrence and distant metastasis,,N0b (no biopsy)
"{'month_interval': 22, 'day_interval': 660}",Distant progression,,,AJCC 7th edition,Tis(Paget's),M1a,Stage 1B,FOLLOW_UP_161,,PRIMARY_DIAGNOSIS_1,DONOR_1,SYNTHETIC-1,,C03|C16,
"{'month_interval': 32, 'day_interval': 960}",Progression not otherwise specified,"{'month_interval': 42, 'day_interval': 1260}",Assessment of symptom control (procedure)|Histopathology test (procedure),Rai staging system,T4c,M1c,Stage IIBES,FOLLOW_UP_162,,PRIMARY_DIAGNOSIS_2,DONOR_2,SYNTHETIC-1,,,N1c
"{'month_interval': 20, 'day_interval': 600}",Distant progression,"{'month_interval': 49, 'day_interval': 1470}",Imaging (procedure)|Physical examination procedure (procedure),FIGO staging system,T3a,M1d(0),,FOLLOW_UP_163,,PRIMARY_DIAGNOSIS_3,DONOR_3,SYNTHETIC-1,Biochemical progression,C09|C13,N0a
"{'month_interval': 18, 'day_interval': 540}",,"{'month_interval': 12, 'day_interval': 360}",Tumor marker measurement (procedure),International Neuroblastoma Staging System,T3,M1d(0),Stage IIB,FOLLOW_UP_164,,PRIMARY_DIAGNOSIS_4,DONOR_4,SYNTHETIC-1,,C17,N1
"{'month_interval': 47, 'day_interval': 1410}",,"{'month_interval': 9, 'day_interval': 270}",Tumor marker measurement (procedure),,T4e,,Stage IIIAS,FOLLOW_UP_165,,PRIMARY_DIAGNOSIS_5,DONOR_5,SYNTHETIC-1,Biochemical progression,C16|C04,N1a
"{'month_interval': 19, 'day_interval': 570}",No evidence of disease,"{'month_interval': 13, 'day_interval': 390}",,AJCC 7th edition,T4b,M1c,Stage IVA,FOLLOW_UP_166,,PRIMARY_DIAGNOSIS_6,DONOR_6,SYNTHETIC-1,Progression (liquid tumours),C01,N0b
"{'month_interval': 5, 'day_interval': 150}",Distant progression,"{'month_interval': 11, 'day_interval': 330}",Tumor marker measurement (procedure),Rai staging system,,M1c(0),Stage IAE,FOLLOW_UP_167,,PRIMARY_DIAGNOSIS_7,DONOR_7,SYNTHETIC-1,Progression (liquid tumours),,N2mi
"{'month_interval': 31, 'day_interval': 930}",Distant progression,"{'month_interval': 35, 'day_interval': 1050}",Physical examination procedure (procedure),International Neuroblastoma Risk Group Staging System,T1c,M1a(0),Stage B,FOLLOW_UP_168,,PRIMARY_DIAGNOSIS_8,DONOR_8,SYNTHETIC-1,Local recurrence,C14,N0a (biopsy)
,Relapse or recurrence,"{'month_interval': 16, 'day_interval': 480}",,Revised International staging system (RISS),T1,M1a(0),Stage 4,FOLLOW_UP_169,,PRIMARY_DIAGNOSIS_9,DONOR_9,SYNTHETIC-1,Biochemical progression,C01|C13,
"{'month_interval': 40, 'day_interval': 1200}",,"{'month_interval': 38, 'day_interval': 1140}",Histopathology test (procedure),SEER staging system,Tis(Paget's),M1d(1),Stage C,FOLLOW_UP_170,,PRIMARY_DIAGNOSIS_10,DONOR_10,SYNTHETIC-1,Biochemical progression,C17|C19,
"{'month_interval': 47, 'day_interval': 1410}",Complete remission,"{'month_interval': 1, 'day_interval': 30}",Laboratory data interpretation (procedure),AJCC 6th edition,T4a(s),M1a,,FOLLOW_UP_171,,PRIMARY_DIAGNOSIS_11,DONOR_11,SYNTHETIC-1,Progression (liquid tumours),,N3a
"{'month_interval': 5, 'day_interval': 150}",Partial remission,"{'month_interval': 28, 'day_interval': 840}",Histopathology test (procedure),,T3,M1b(0),,FOLLOW_UP_172,,PRIMARY_DIAGNOSIS_12,DONOR_12,SYNTHETIC-1,,,N0(mol+)
"{'month_interval': 10, 'day_interval': 300}",Stable,"{'month_interval': 33, 'day_interval': 990}",,Ann Arbor staging system,,M1d(1),Stage IIBS,FOLLOW_UP_173,,PRIMARY_DIAGNOSIS_13,DONOR_13,SYNTHETIC-1,Local recurrence and distant metastasis,,
"{'month_interval': 44, 'day_interval': 1320}",Relapse or recurrence,"{'month_interval': 47, 'day_interval': 1410}",Histopathology test (procedure),Rai staging system,T4d,M1a(1),Stage IVBS,FOLLOW_UP_174,,PRIMARY_DIAGNOSIS_14,DONOR_14,SYNTHETIC-1,Local recurrence and distant metastasis,,N2a
,No evidence of disease,"{'month_interval': 33, 'day_interval': 990}",Imaging (procedure)|Tumor marker measurement (procedure),International Neuroblastoma Risk Group Staging System,T2b,M1b,Stage IVBES,FOLLOW_UP_175,,PRIMARY_DIAGNOSIS_15,DONOR_15,SYNTHETIC-1,Local recurrence,C11|C20,N0(i-)
"{'month_interval': 26, 'day_interval': 780}",Progression not otherwise specified,"{'month_interval': 40, 'day_interval': 1200}",,,,M1c(1),Stage IVA2,FOLLOW_UP_176,,PRIMARY_DIAGNOSIS_16,DONOR_16,SYNTHETIC-1,Biochemical progression,,N0(mol+)
"{'month_interval': 46, 'day_interval': 1380}",No evidence of disease,"{'month_interval': 22, 'day_interval': 660}",Tumor marker measurement (procedure),International Neuroblastoma Risk Group Staging System,T2,,Stage IVC,FOLLOW_UP_177,,PRIMARY_DIAGNOSIS_17,DONOR_17,SYNTHETIC-1,Biochemical progression,C16,N0b (no biopsy)
"{'month_interval': 23, 'day_interval': 690}",No evidence of disease,"{'month_interval': 39, 'day_interval': 1170}",,Revised International staging system (RISS),Tis(LAMN),M1a(1),,FOLLOW_UP_178,,PRIMARY_DIAGNOSIS_18,DONOR_18,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(i+)
"{'month_interval': 19, 'day_interval': 570}",Relapse or recurrence,"{'month_interval': 38, 'day_interval': 1140}",Imaging (procedure),International Neuroblastoma Risk Group Staging System,T2,M1d,,FOLLOW_UP_179,,PRIMARY_DIAGNOSIS_19,DONOR_19,SYNTHETIC-1,Progression (liquid tumours),C04,N0(i-)
"{'month_interval': 38, 'day_interval': 1140}",Progression not otherwise specified,"{'month_interval': 12, 'day_interval': 360}",,AJCC 8th edition,T2(m),M1a(0),Stage L2,FOLLOW_UP_180,,PRIMARY_DIAGNOSIS_20,DONOR_20,SYNTHETIC-1,Distant recurrence/metastasis,,N0a (biopsy)
"{'month_interval': 3, 'day_interval': 90}",Stable,"{'month_interval': 22, 'day_interval': 660}",Laboratory data interpretation (procedure),,TX,M1b(0),Stage IV,FOLLOW_UP_181,,PRIMARY_DIAGNOSIS_21,DONOR_21,SYNTHETIC-1,Biochemical progression,,N1b
"{'month_interval': 40, 'day_interval': 1200}",Loco-regional progression,"{'month_interval': 22, 'day_interval': 660}",Histopathology test (procedure),International Neuroblastoma Staging System,Ta,M1c(0),Stage IVBE,FOLLOW_UP_182,,PRIMARY_DIAGNOSIS_22,DONOR_22,SYNTHETIC-1,Distant recurrence/metastasis,,N1
"{'month_interval': 3, 'day_interval': 90}",,"{'month_interval': 16, 'day_interval': 480}",Assessment of symptom control (procedure),Durie-Salmon staging system,,M1d(0),Stage II,FOLLOW_UP_183,,PRIMARY_DIAGNOSIS_23,DONOR_23,SYNTHETIC-1,Biochemical progression,,N2a
,Progression not otherwise specified,,Physical examination procedure (procedure),Rai staging system,T2,,Stage IBS,FOLLOW_UP_184,,PRIMARY_DIAGNOSIS_24,DONOR_24,SYNTHETIC-1,,,N0a (biopsy)
,Stable,,Assessment of symptom control (procedure)|Physical examination procedure (procedure),Rai staging system,T1d,M1d(1),Stage IA2,FOLLOW_UP_185,,PRIMARY_DIAGNOSIS_25,DONOR_25,SYNTHETIC-1,Local recurrence,C10,
"{'month_interval': 1, 'day_interval': 30}",Loco-regional progression,"{'month_interval': 31, 'day_interval': 930}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Ann Arbor staging system,Tis(LAMN),M1c,Stage IIIES,FOLLOW_UP_186,,PRIMARY_DIAGNOSIS_26,DONOR_26,SYNTHETIC-1,,,N2mi
"{'month_interval': 31, 'day_interval': 930}",Complete remission,"{'month_interval': 45, 'day_interval': 1350}",Physical examination procedure (procedure)|Histopathology test (procedure),Rai staging system,T2c,M1a,Stage IEB,FOLLOW_UP_187,,PRIMARY_DIAGNOSIS_27,DONOR_27,SYNTHETIC-1,Biochemical progression,,N3
,Distant progression,"{'month_interval': 39, 'day_interval': 1170}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),AJCC 7th edition,,M1d,Stage IIID,FOLLOW_UP_188,,PRIMARY_DIAGNOSIS_28,DONOR_28,SYNTHETIC-1,,,N0b
"{'month_interval': 15, 'day_interval': 450}",Loco-regional progression,"{'month_interval': 21, 'day_interval': 630}",Imaging (procedure),AJCC 8th edition,TX,M1c(0),,FOLLOW_UP_189,,PRIMARY_DIAGNOSIS_29,DONOR_29,SYNTHETIC-1,Progression (liquid tumours),,N1
,No evidence of disease,"{'month_interval': 18, 'day_interval': 540}",,,T4,MX,Stage I,FOLLOW_UP_190,,PRIMARY_DIAGNOSIS_30,DONOR_30,SYNTHETIC-1,Biochemical progression,,
"{'month_interval': 27, 'day_interval': 810}",,"{'month_interval': 17, 'day_interval': 510}",Tumor marker measurement (procedure),,T4a(s),M1b(0),Stage IIIS,FOLLOW_UP_191,,PRIMARY_DIAGNOSIS_31,DONOR_31,SYNTHETIC-1,Progression (liquid tumours),,N0b
"{'month_interval': 41, 'day_interval': 1230}",Complete remission,"{'month_interval': 50, 'day_interval': 1500}",Tumor marker measurement (procedure),Revised International staging system (RISS),,MX,Stage IIIAS,FOLLOW_UP_192,,PRIMARY_DIAGNOSIS_32,DONOR_32,SYNTHETIC-1,Biochemical progression,C04,N2b
"{'month_interval': 5, 'day_interval': 150}",Distant progression,"{'month_interval': 12, 'day_interval': 360}",Imaging (procedure)|Histopathology test (procedure),,Tis(LCIS),M1d(0),Stage IVA,FOLLOW_UP_193,,PRIMARY_DIAGNOSIS_33,DONOR_33,SYNTHETIC-1,Biochemical progression,,
"{'month_interval': 16, 'day_interval': 480}",Complete remission,"{'month_interval': 16, 'day_interval': 480}",Histopathology test (procedure),Rai staging system,T3b,,Stage IIIC2,FOLLOW_UP_194,,PRIMARY_DIAGNOSIS_34,DONOR_34,SYNTHETIC-1,Progression (liquid tumours),C05|C15,N0(i+)
"{'month_interval': 14, 'day_interval': 420}",Loco-regional progression,"{'month_interval': 7, 'day_interval': 210}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),SEER staging system,T3(m),M1a,Stage IIEA,FOLLOW_UP_195,,PRIMARY_DIAGNOSIS_35,DONOR_35,SYNTHETIC-1,Local recurrence,C12,
"{'month_interval': 8, 'day_interval': 240}",Stable,,Assessment of symptom control (procedure),Durie-Salmon staging system,,MX,,FOLLOW_UP_196,,PRIMARY_DIAGNOSIS_36,DONOR_36,SYNTHETIC-1,Local recurrence and distant metastasis,C15|C16,N2b
,Distant progression,"{'month_interval': 26, 'day_interval': 780}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),SEER staging system,T3c,M1,Stage IIS,FOLLOW_UP_197,,PRIMARY_DIAGNOSIS_37,DONOR_37,SYNTHETIC-1,Distant recurrence/metastasis,C10|C04,
"{'month_interval': 30, 'day_interval': 900}",Loco-regional progression,"{'month_interval': 6, 'day_interval': 180}",Histopathology test (procedure),AJCC 7th edition,T3b,,Stage 4S,FOLLOW_UP_198,,PRIMARY_DIAGNOSIS_38,DONOR_38,SYNTHETIC-1,Biochemical progression,C19,N4
"{'month_interval': 48, 'day_interval': 1440}",Progression not otherwise specified,"{'month_interval': 34, 'day_interval': 1020}",Laboratory data interpretation (procedure),,T3b,M1d(1),In situ,FOLLOW_UP_199,,PRIMARY_DIAGNOSIS_39,DONOR_39,SYNTHETIC-1,Distant recurrence/metastasis,C18,N0
"{'month_interval': 7, 'day_interval': 210}",Relapse or recurrence,"{'month_interval': 7, 'day_interval': 210}",,Revised International staging system (RISS),Tis pd,M1c,Stage IVS,FOLLOW_UP_200,,PRIMARY_DIAGNOSIS_40,DONOR_40,SYNTHETIC-1,Biochemical progression,C02|C17,N2c
"{'month_interval': 19, 'day_interval': 570}",,"{'month_interval': 37, 'day_interval': 1110}",Histopathology test (procedure)|Assessment of symptom control (procedure),AJCC 8th edition,T2,M1d(1),Stage IVAE,FOLLOW_UP_201,,PRIMARY_DIAGNOSIS_41,DONOR_1,SYNTHETIC-1,Local recurrence,,N0(i-)
"{'month_interval': 29, 'day_interval': 870}",Relapse or recurrence,"{'month_interval': 5, 'day_interval': 150}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),Durie-Salmon staging system,T4e,M1d(1),Stage IIIC1,FOLLOW_UP_202,,PRIMARY_DIAGNOSIS_42,DONOR_2,SYNTHETIC-1,Biochemical progression,,N1b
"{'month_interval': 6, 'day_interval': 180}",Loco-regional progression,"{'month_interval': 34, 'day_interval': 1020}",,Ann Arbor staging system,T2d,M1c(0),Stage IEA,FOLLOW_UP_203,,PRIMARY_DIAGNOSIS_43,DONOR_3,SYNTHETIC-1,Local recurrence,C13|C05,N0a (biopsy)
"{'month_interval': 20, 'day_interval': 600}",Relapse or recurrence,"{'month_interval': 16, 'day_interval': 480}",Laboratory data interpretation (procedure),St Jude staging system,T1b(s),,Stage IIIBS,FOLLOW_UP_204,,PRIMARY_DIAGNOSIS_44,DONOR_4,SYNTHETIC-1,Local recurrence,,
,Partial remission,"{'month_interval': 9, 'day_interval': 270}",Tumor marker measurement (procedure),International Neuroblastoma Risk Group Staging System,T0,M0(i+),Stage 3,FOLLOW_UP_205,,PRIMARY_DIAGNOSIS_45,DONOR_5,SYNTHETIC-1,Biochemical progression,C01,N3a
,Distant progression,"{'month_interval': 47, 'day_interval': 1410}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),Revised International staging system (RISS),T3a,M1d(0),Stage IVE,FOLLOW_UP_206,,PRIMARY_DIAGNOSIS_46,DONOR_6,SYNTHETIC-1,Local recurrence and distant metastasis,C16|C04,N3c
,,"{'month_interval': 23, 'day_interval': 690}",Imaging (procedure),,Tis(LCIS),M0,Stage IIBS,FOLLOW_UP_207,,PRIMARY_DIAGNOSIS_47,DONOR_7,SYNTHETIC-1,Local recurrence,C06|C03,N0(mol-)
"{'month_interval': 24, 'day_interval': 720}",,"{'month_interval': 20, 'day_interval': 600}",Assessment of symptom control (procedure),Lugano staging system,Tis(Paget's),M1d(1),Stage IA2,FOLLOW_UP_208,,PRIMARY_DIAGNOSIS_48,DONOR_8,SYNTHETIC-1,Distant recurrence/metastasis,,N3b
"{'month_interval': 7, 'day_interval': 210}",Relapse or recurrence,"{'month_interval': 40, 'day_interval': 1200}",,International Neuroblastoma Staging System,T1b,M1e,Stage IVBS,FOLLOW_UP_209,,PRIMARY_DIAGNOSIS_49,DONOR_9,SYNTHETIC-1,Progression (liquid tumours),C04|C17,N0(i-)
"{'month_interval': 50, 'day_interval': 1500}",No evidence of disease,"{'month_interval': 20, 'day_interval': 600}",,AJCC 6th edition,T3,M1d(1),Stage IIIE,FOLLOW_UP_210,,PRIMARY_DIAGNOSIS_50,DONOR_10,SYNTHETIC-1,,C09,N1mi
"{'month_interval': 32, 'day_interval': 960}",Stable,"{'month_interval': 33, 'day_interval': 990}",Assessment of symptom control (procedure)|Physical examination procedure (procedure),AJCC 7th edition,,M1c(1),,FOLLOW_UP_211,,PRIMARY_DIAGNOSIS_51,DONOR_11,SYNTHETIC-1,Local recurrence,,
"{'month_interval': 11, 'day_interval': 330}",,"{'month_interval': 14, 'day_interval': 420}",Histopathology test (procedure),FIGO staging system,T2b,MX,Stage IAE,FOLLOW_UP_212,,PRIMARY_DIAGNOSIS_52,DONOR_12,SYNTHETIC-1,Progression (liquid tumours),C03,N1mi
"{'month_interval': 46, 'day_interval': 1380}",,"{'month_interval': 24, 'day_interval': 720}",Tumor marker measurement (procedure)|Histopathology test (procedure),International Neuroblastoma Staging System,T4b(s),M1,Stage IVE,FOLLOW_UP_213,,PRIMARY_DIAGNOSIS_53,DONOR_13,SYNTHETIC-1,Biochemical progression,C20|C11,N1
"{'month_interval': 28, 'day_interval': 840}",Relapse or recurrence,"{'month_interval': 13, 'day_interval': 390}",Physical examination procedure (procedure),AJCC 7th edition,T2c,M1c(0),Stage Ms,FOLLOW_UP_214,,PRIMARY_DIAGNOSIS_54,DONOR_14,SYNTHETIC-1,Local recurrence and distant metastasis,C08,N3b
"{'month_interval': 39, 'day_interval': 1170}",Distant progression,"{'month_interval': 48, 'day_interval': 1440}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),,T1a,M0,Stage 4,FOLLOW_UP_215,,PRIMARY_DIAGNOSIS_55,DONOR_15,SYNTHETIC-1,Biochemical progression,C18,
"{'month_interval': 28, 'day_interval': 840}",Stable,"{'month_interval': 33, 'day_interval': 990}",,Durie-Salmon staging system,Tis(LCIS),,,FOLLOW_UP_216,,PRIMARY_DIAGNOSIS_56,DONOR_16,SYNTHETIC-1,Local recurrence,,N2mi
,Partial remission,"{'month_interval': 18, 'day_interval': 540}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),,T3a,M1c,Localized,FOLLOW_UP_217,,PRIMARY_DIAGNOSIS_57,DONOR_17,SYNTHETIC-1,Local recurrence and distant metastasis,C04|C10,N0a
"{'month_interval': 20, 'day_interval': 600}",Complete remission,"{'month_interval': 44, 'day_interval': 1320}",Histopathology test (procedure)|Laboratory data interpretation (procedure),AJCC 6th edition,T1a2,,,FOLLOW_UP_218,,PRIMARY_DIAGNOSIS_58,DONOR_18,SYNTHETIC-1,Local recurrence,,N1c
"{'month_interval': 17, 'day_interval': 510}",Loco-regional progression,"{'month_interval': 37, 'day_interval': 1110}",Assessment of symptom control (procedure)|Histopathology test (procedure),St Jude staging system,T1,M1b,Stage 1A,FOLLOW_UP_219,,PRIMARY_DIAGNOSIS_59,DONOR_19,SYNTHETIC-1,Local recurrence,C20,N1b
"{'month_interval': 19, 'day_interval': 570}",Loco-regional progression,"{'month_interval': 31, 'day_interval': 930}",Tumor marker measurement (procedure)|Histopathology test (procedure),,,M1b,Stage IIB,FOLLOW_UP_220,,PRIMARY_DIAGNOSIS_60,DONOR_20,SYNTHETIC-1,Distant recurrence/metastasis,,N0b
"{'month_interval': 25, 'day_interval': 750}",Stable,"{'month_interval': 35, 'day_interval': 1050}",Tumor marker measurement (procedure)|Histopathology test (procedure),Rai staging system,T2a1,M1a,Stage II,FOLLOW_UP_221,,PRIMARY_DIAGNOSIS_61,DONOR_21,SYNTHETIC-1,,C19|C11,
"{'month_interval': 33, 'day_interval': 990}",Relapse or recurrence,"{'month_interval': 18, 'day_interval': 540}",Physical examination procedure (procedure),International Neuroblastoma Risk Group Staging System,T2(s),M1d,Stage IIES,FOLLOW_UP_222,,PRIMARY_DIAGNOSIS_62,DONOR_22,SYNTHETIC-1,Distant recurrence/metastasis,,N1a
"{'month_interval': 7, 'day_interval': 210}",No evidence of disease,"{'month_interval': 42, 'day_interval': 1260}",Assessment of symptom control (procedure),,T2(m),M1e,Stage IVA,FOLLOW_UP_223,,PRIMARY_DIAGNOSIS_63,DONOR_23,SYNTHETIC-1,Biochemical progression,,N1a(sn)
"{'month_interval': 48, 'day_interval': 1440}",Progression not otherwise specified,"{'month_interval': 14, 'day_interval': 420}",Histopathology test (procedure)|Physical examination procedure (procedure),FIGO staging system,T4,M0(i+),Stage IIIA,FOLLOW_UP_224,,PRIMARY_DIAGNOSIS_64,DONOR_24,SYNTHETIC-1,Local recurrence,C04,N1
"{'month_interval': 3, 'day_interval': 90}",Distant progression,"{'month_interval': 1, 'day_interval': 30}",,International Neuroblastoma Staging System,T4b,M0,Stage IIA2,FOLLOW_UP_225,,PRIMARY_DIAGNOSIS_65,DONOR_25,SYNTHETIC-1,Biochemical progression,,N0(mol-)
"{'month_interval': 17, 'day_interval': 510}",Partial remission,,,Binet staging system,T4b,M1b,Stage B,FOLLOW_UP_226,,PRIMARY_DIAGNOSIS_66,DONOR_26,SYNTHETIC-1,Distant recurrence/metastasis,,N2c
"{'month_interval': 28, 'day_interval': 840}",,,Imaging (procedure)|Tumor marker measurement (procedure),Ann Arbor staging system,T3a,M1c(0),Stage IIIBS,FOLLOW_UP_227,,PRIMARY_DIAGNOSIS_67,DONOR_27,SYNTHETIC-1,Progression (liquid tumours),C07|C08,N2a
"{'month_interval': 36, 'day_interval': 1080}",Relapse or recurrence,"{'month_interval': 19, 'day_interval': 570}",,SEER staging system,Tis(LAMN),M1c(0),,FOLLOW_UP_228,,PRIMARY_DIAGNOSIS_68,DONOR_28,SYNTHETIC-1,Progression (liquid tumours),,N0a (biopsy)
"{'month_interval': 25, 'day_interval': 750}",Progression not otherwise specified,"{'month_interval': 31, 'day_interval': 930}",Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,T1b1,M1b(1),Stage IIIAE,FOLLOW_UP_229,,PRIMARY_DIAGNOSIS_69,DONOR_29,SYNTHETIC-1,Distant recurrence/metastasis,,N1b
,Progression not otherwise specified,"{'month_interval': 49, 'day_interval': 1470}",Assessment of symptom control (procedure),Binet staging system,T1b1,,Stage IVAS,FOLLOW_UP_230,,PRIMARY_DIAGNOSIS_70,DONOR_30,SYNTHETIC-1,Local recurrence and distant metastasis,C07|C14,N0
,Relapse or recurrence,"{'month_interval': 34, 'day_interval': 1020}",Physical examination procedure (procedure),SEER staging system,T4a(m),M1b,Stage IEB,FOLLOW_UP_231,,PRIMARY_DIAGNOSIS_71,DONOR_31,SYNTHETIC-1,Biochemical progression,C03,N1a
"{'month_interval': 21, 'day_interval': 630}",Progression not otherwise specified,"{'month_interval': 12, 'day_interval': 360}",,Lugano staging system,,,Stage IIIAE,FOLLOW_UP_232,,PRIMARY_DIAGNOSIS_72,DONOR_32,SYNTHETIC-1,Local recurrence,C01|C10,N0b
"{'month_interval': 40, 'day_interval': 1200}",Complete remission,,Assessment of symptom control (procedure)|Tumor marker measurement (procedure),Ann Arbor staging system,T1b,M0(i+),Stage 0is,FOLLOW_UP_233,,PRIMARY_DIAGNOSIS_73,DONOR_33,SYNTHETIC-1,,C02|C10,N4
"{'month_interval': 19, 'day_interval': 570}",Progression not otherwise specified,"{'month_interval': 44, 'day_interval': 1320}",,Ann Arbor staging system,T1a,M1e,Stage 2B,FOLLOW_UP_234,,PRIMARY_DIAGNOSIS_74,DONOR_34,SYNTHETIC-1,Local recurrence,C01|C14,N2a
"{'month_interval': 34, 'day_interval': 1020}",Partial remission,"{'month_interval': 33, 'day_interval': 990}",,AJCC 8th edition,T1mi,,Stage IIBE,FOLLOW_UP_235,,PRIMARY_DIAGNOSIS_75,DONOR_35,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(mol+)
"{'month_interval': 20, 'day_interval': 600}",Loco-regional progression,"{'month_interval': 23, 'day_interval': 690}",Laboratory data interpretation (procedure),AJCC 6th edition,Tis(Paget's),M1a,Occult Carcinoma,FOLLOW_UP_236,,PRIMARY_DIAGNOSIS_76,DONOR_36,SYNTHETIC-1,Distant recurrence/metastasis,,N2b
,Stable,"{'month_interval': 16, 'day_interval': 480}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Rai staging system,,M0(i+),Stage IVB,FOLLOW_UP_237,,PRIMARY_DIAGNOSIS_77,DONOR_37,SYNTHETIC-1,,C17|C06,N2c
"{'month_interval': 4, 'day_interval': 120}",Stable,"{'month_interval': 15, 'day_interval': 450}",Laboratory data interpretation (procedure)|Histopathology test (procedure),AJCC 8th edition,,M1c(0),Stage IVA2,FOLLOW_UP_238,,PRIMARY_DIAGNOSIS_78,DONOR_38,SYNTHETIC-1,,C02,N3a
"{'month_interval': 42, 'day_interval': 1260}",Relapse or recurrence,"{'month_interval': 4, 'day_interval': 120}",,AJCC 7th edition,T3(m),M0,Stage IEB,FOLLOW_UP_239,,PRIMARY_DIAGNOSIS_79,DONOR_39,SYNTHETIC-1,Local recurrence,,N0(mol+)
"{'month_interval': 40, 'day_interval': 1200}",Distant progression,"{'month_interval': 31, 'day_interval': 930}",Histopathology test (procedure),International Neuroblastoma Staging System,T1a1,,,FOLLOW_UP_240,,PRIMARY_DIAGNOSIS_80,DONOR_40,SYNTHETIC-1,,,
"{'month_interval': 32, 'day_interval': 960}",,"{'month_interval': 13, 'day_interval': 390}",,SEER staging system,T1b,M1c,Stage IIBS,FOLLOW_UP_241,,PRIMARY_DIAGNOSIS_81,DONOR_1,SYNTHETIC-1,Distant recurrence/metastasis,,N1a(sn)
"{'month_interval': 44, 'day_interval': 1320}",Partial remission,"{'month_interval': 8, 'day_interval': 240}",,Revised International staging system (RISS),T4a(m),M1d(0),,FOLLOW_UP_242,,PRIMARY_DIAGNOSIS_82,DONOR_2,SYNTHETIC-1,Local recurrence and distant metastasis,C18|C14,N1mi
"{'month_interval': 24, 'day_interval': 720}",No evidence of disease,"{'month_interval': 41, 'day_interval': 1230}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Binet staging system,T1a(s),M1c(0),Stage IC,FOLLOW_UP_243,,PRIMARY_DIAGNOSIS_83,DONOR_3,SYNTHETIC-1,Distant recurrence/metastasis,C17|C16,N0(i+)
,Complete remission,"{'month_interval': 39, 'day_interval': 1170}",Imaging (procedure),,Tis(Paget's),M1b,Stage IB1,FOLLOW_UP_244,,PRIMARY_DIAGNOSIS_84,DONOR_4,SYNTHETIC-1,Biochemical progression,C13,N0a (biopsy)
"{'month_interval': 29, 'day_interval': 870}",Partial remission,,,Rai staging system,T4d,M1d(0),Stage IB,FOLLOW_UP_245,,PRIMARY_DIAGNOSIS_85,DONOR_5,SYNTHETIC-1,Progression (liquid tumours),C11|C19,N1b
"{'month_interval': 32, 'day_interval': 960}",Stable,"{'month_interval': 48, 'day_interval': 1440}",Physical examination procedure (procedure)|Imaging (procedure),,T1mi,M1a(0),Stage IIEB,FOLLOW_UP_246,,PRIMARY_DIAGNOSIS_86,DONOR_6,SYNTHETIC-1,Progression (liquid tumours),,N1b
"{'month_interval': 38, 'day_interval': 1140}",Distant progression,,Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),Binet staging system,T4a,M1e,Stage IAB,FOLLOW_UP_247,,PRIMARY_DIAGNOSIS_87,DONOR_7,SYNTHETIC-1,Local recurrence and distant metastasis,C09|C11,NX
"{'month_interval': 3, 'day_interval': 90}",,"{'month_interval': 18, 'day_interval': 540}",,,T4,M1a,Stage IC,FOLLOW_UP_248,,PRIMARY_DIAGNOSIS_88,DONOR_8,SYNTHETIC-1,Local recurrence and distant metastasis,C10|C08,N3a
"{'month_interval': 32, 'day_interval': 960}",Complete remission,"{'month_interval': 31, 'day_interval': 930}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),Lugano staging system,T2,M1a,Stage IEB,FOLLOW_UP_249,,PRIMARY_DIAGNOSIS_89,DONOR_9,SYNTHETIC-1,Progression (liquid tumours),C11|C01,N2c
"{'month_interval': 34, 'day_interval': 1020}",,"{'month_interval': 44, 'day_interval': 1320}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),International Neuroblastoma Staging System,T4b(s),M1b,Stage IBES,FOLLOW_UP_250,,PRIMARY_DIAGNOSIS_90,DONOR_10,SYNTHETIC-1,,,N3c
"{'month_interval': 14, 'day_interval': 420}",Loco-regional progression,"{'month_interval': 18, 'day_interval': 540}",,Rai staging system,,M1d(1),Occult Carcinoma,FOLLOW_UP_251,,PRIMARY_DIAGNOSIS_91,DONOR_11,SYNTHETIC-1,Biochemical progression,,
"{'month_interval': 46, 'day_interval': 1380}",Complete remission,"{'month_interval': 28, 'day_interval': 840}",Imaging (procedure)|Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,,M1b(1),,FOLLOW_UP_252,,PRIMARY_DIAGNOSIS_92,DONOR_12,SYNTHETIC-1,Progression (liquid tumours),,N2mi
"{'month_interval': 15, 'day_interval': 450}",Stable,,Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,T3d,M1e,Stage IIBES,FOLLOW_UP_253,,PRIMARY_DIAGNOSIS_93,DONOR_13,SYNTHETIC-1,Local recurrence and distant metastasis,C16,N3a
"{'month_interval': 33, 'day_interval': 990}",Progression not otherwise specified,"{'month_interval': 35, 'day_interval': 1050}",Tumor marker measurement (procedure),St Jude staging system,T3(m),M1a(1),,FOLLOW_UP_254,,PRIMARY_DIAGNOSIS_94,DONOR_14,SYNTHETIC-1,Distant recurrence/metastasis,C16|C07,
"{'month_interval': 18, 'day_interval': 540}",,"{'month_interval': 28, 'day_interval': 840}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Ann Arbor staging system,T1d,,Stage IIIA,FOLLOW_UP_255,,PRIMARY_DIAGNOSIS_95,DONOR_15,SYNTHETIC-1,Progression (liquid tumours),,N4
"{'month_interval': 10, 'day_interval': 300}",Progression not otherwise specified,"{'month_interval': 40, 'day_interval': 1200}",Physical examination procedure (procedure),International Neuroblastoma Staging System,T2a2,M1e,Stage L1,FOLLOW_UP_256,,PRIMARY_DIAGNOSIS_96,DONOR_16,SYNTHETIC-1,Distant recurrence/metastasis,,N1
"{'month_interval': 34, 'day_interval': 1020}",Relapse or recurrence,"{'month_interval': 29, 'day_interval': 870}",Imaging (procedure),,Ta,M1b(1),Stage IIIC2,FOLLOW_UP_257,,PRIMARY_DIAGNOSIS_97,DONOR_17,SYNTHETIC-1,Local recurrence,,
"{'month_interval': 50, 'day_interval': 1500}",No evidence of disease,"{'month_interval': 25, 'day_interval': 750}",Laboratory data interpretation (procedure),FIGO staging system,T4b,M1a(1),Stage IEA,FOLLOW_UP_258,,PRIMARY_DIAGNOSIS_98,DONOR_18,SYNTHETIC-1,Local recurrence,C14|C16,N1mi
"{'month_interval': 24, 'day_interval': 720}",Stable,"{'month_interval': 24, 'day_interval': 720}",,International Neuroblastoma Risk Group Staging System,Tis pd,,Stage IIS,FOLLOW_UP_259,,PRIMARY_DIAGNOSIS_99,DONOR_19,SYNTHETIC-1,Progression (liquid tumours),C17,N2b
"{'month_interval': 41, 'day_interval': 1230}",Relapse or recurrence,"{'month_interval': 9, 'day_interval': 270}",,St Jude staging system,T4e,M0,Stage IVAE,FOLLOW_UP_260,,PRIMARY_DIAGNOSIS_100,DONOR_20,SYNTHETIC-1,Progression (liquid tumours),C09,
"{'month_interval': 41, 'day_interval': 1230}",Partial remission,"{'month_interval': 42, 'day_interval': 1260}",,AJCC 8th edition,T1a(s),MX,Stage IVA,FOLLOW_UP_261,,PRIMARY_DIAGNOSIS_101,DONOR_21,SYNTHETIC-1,Distant recurrence/metastasis,,N0(mol+)
"{'month_interval': 30, 'day_interval': 900}",,"{'month_interval': 24, 'day_interval': 720}",Laboratory data interpretation (procedure),International Neuroblastoma Staging System,,,Stage IB2,FOLLOW_UP_262,,PRIMARY_DIAGNOSIS_102,DONOR_22,SYNTHETIC-1,Progression (liquid tumours),C16|C06,N3b
"{'month_interval': 17, 'day_interval': 510}",Loco-regional progression,"{'month_interval': 31, 'day_interval': 930}",Assessment of symptom control (procedure)|Physical examination procedure (procedure),International Neuroblastoma Staging System,T1a(m),M1a(1),,FOLLOW_UP_263,,PRIMARY_DIAGNOSIS_103,DONOR_23,SYNTHETIC-1,Biochemical progression,C14,
"{'month_interval': 47, 'day_interval': 1410}",,"{'month_interval': 13, 'day_interval': 390}",Imaging (procedure),St Jude staging system,,M1b(1),Stage IIIB,FOLLOW_UP_264,,PRIMARY_DIAGNOSIS_104,DONOR_24,SYNTHETIC-1,Local recurrence,,
"{'month_interval': 42, 'day_interval': 1260}",Stable,,Imaging (procedure),,T4b(s),M1b,Stage IVAS,FOLLOW_UP_265,,PRIMARY_DIAGNOSIS_105,DONOR_25,SYNTHETIC-1,Distant recurrence/metastasis,C05,N1a
"{'month_interval': 13, 'day_interval': 390}",Stable,"{'month_interval': 20, 'day_interval': 600}",Histopathology test (procedure),,,M1b,Stage II,FOLLOW_UP_266,,PRIMARY_DIAGNOSIS_106,DONOR_26,SYNTHETIC-1,Biochemical progression,C10|C12,
"{'month_interval': 1, 'day_interval': 30}",Loco-regional progression,"{'month_interval': 45, 'day_interval': 1350}",Physical examination procedure (procedure),International Neuroblastoma Staging System,,M0,Stage IIIBES,FOLLOW_UP_267,,PRIMARY_DIAGNOSIS_107,DONOR_27,SYNTHETIC-1,Biochemical progression,C14,N1mi
"{'month_interval': 12, 'day_interval': 360}",Progression not otherwise specified,"{'month_interval': 16, 'day_interval': 480}",Laboratory data interpretation (procedure),,T1a(m),,Stage IVE,FOLLOW_UP_268,,PRIMARY_DIAGNOSIS_108,DONOR_28,SYNTHETIC-1,Distant recurrence/metastasis,C07|C10,NX
"{'month_interval': 40, 'day_interval': 1200}",No evidence of disease,"{'month_interval': 47, 'day_interval': 1410}",Histopathology test (procedure),International Neuroblastoma Staging System,T1d,,Stage IC,FOLLOW_UP_269,,PRIMARY_DIAGNOSIS_109,DONOR_29,SYNTHETIC-1,Biochemical progression,,N0(i+)
,Distant progression,"{'month_interval': 10, 'day_interval': 300}",,,T4a(s),M1b,,FOLLOW_UP_270,,PRIMARY_DIAGNOSIS_110,DONOR_30,SYNTHETIC-1,Local recurrence and distant metastasis,C16,N0a (biopsy)
"{'month_interval': 45, 'day_interval': 1350}",,"{'month_interval': 11, 'day_interval': 330}",Laboratory data interpretation (procedure),Binet staging system,T4b(s),M1d,,FOLLOW_UP_271,,PRIMARY_DIAGNOSIS_111,DONOR_31,SYNTHETIC-1,Biochemical progression,,N2b
"{'month_interval': 25, 'day_interval': 750}",,"{'month_interval': 12, 'day_interval': 360}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),AJCC 8th edition,T2c,,,FOLLOW_UP_272,,PRIMARY_DIAGNOSIS_112,DONOR_32,SYNTHETIC-1,,C05|C11,
"{'month_interval': 2, 'day_interval': 60}",Relapse or recurrence,"{'month_interval': 49, 'day_interval': 1470}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),Lugano staging system,T4b(s),M1b(1),Stage IIIE,FOLLOW_UP_273,,PRIMARY_DIAGNOSIS_113,DONOR_33,SYNTHETIC-1,Distant recurrence/metastasis,C20|C09,N1mi
"{'month_interval': 6, 'day_interval': 180}",Relapse or recurrence,"{'month_interval': 30, 'day_interval': 900}",,Ann Arbor staging system,T2d,M0,Stage IIIC,FOLLOW_UP_274,,PRIMARY_DIAGNOSIS_114,DONOR_34,SYNTHETIC-1,Progression (liquid tumours),C02|C10,N0(mol+)
"{'month_interval': 48, 'day_interval': 1440}",Loco-regional progression,"{'month_interval': 4, 'day_interval': 120}",,AJCC 6th edition,,M1d,Stage IAE,FOLLOW_UP_275,,PRIMARY_DIAGNOSIS_115,DONOR_35,SYNTHETIC-1,Biochemical progression,C13,N4
"{'month_interval': 25, 'day_interval': 750}",Distant progression,,Physical examination procedure (procedure),Revised International staging system (RISS),T1b,M1c(0),,FOLLOW_UP_276,,PRIMARY_DIAGNOSIS_116,DONOR_36,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(i-)
"{'month_interval': 40, 'day_interval': 1200}",,"{'month_interval': 8, 'day_interval': 240}",Imaging (procedure)|Physical examination procedure (procedure),International Neuroblastoma Staging System,Tis(LCIS),M1a(1),Stage IIBE,FOLLOW_UP_277,,PRIMARY_DIAGNOSIS_117,DONOR_37,SYNTHETIC-1,Biochemical progression,C20|C15,
"{'month_interval': 32, 'day_interval': 960}",Relapse or recurrence,"{'month_interval': 15, 'day_interval': 450}",,,T1b2,M1d(1),Stage IBES,FOLLOW_UP_278,,PRIMARY_DIAGNOSIS_118,DONOR_38,SYNTHETIC-1,Progression (liquid tumours),,N1
"{'month_interval': 13, 'day_interval': 390}",No evidence of disease,"{'month_interval': 19, 'day_interval': 570}",,AJCC 7th edition,T2(s),M1,Stage A,FOLLOW_UP_279,,PRIMARY_DIAGNOSIS_119,DONOR_39,SYNTHETIC-1,,C07,N0a
"{'month_interval': 2, 'day_interval': 60}",Stable,"{'month_interval': 9, 'day_interval': 270}",,AJCC 6th edition,,,Stage IIIAS,FOLLOW_UP_280,,PRIMARY_DIAGNOSIS_120,DONOR_40,SYNTHETIC-1,Local recurrence,C18|C10,N0
"{'month_interval': 29, 'day_interval': 870}",Distant progression,"{'month_interval': 3, 'day_interval': 90}",Histopathology test (procedure)|Assessment of symptom control (procedure),AJCC 6th edition,Tis(LAMN),M1d(0),Stage IVAES,FOLLOW_UP_281,,PRIMARY_DIAGNOSIS_121,DONOR_1,SYNTHETIC-1,Local recurrence,,N0
"{'month_interval': 10, 'day_interval': 300}",,"{'month_interval': 32, 'day_interval': 960}",Histopathology test (procedure)|Physical examination procedure (procedure),International Neuroblastoma Staging System,T2,M1b(1),Stage II,FOLLOW_UP_282,,PRIMARY_DIAGNOSIS_122,DONOR_2,SYNTHETIC-1,Distant recurrence/metastasis,,NX
"{'month_interval': 3, 'day_interval': 90}",Partial remission,"{'month_interval': 47, 'day_interval': 1410}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),Binet staging system,,M1,Stage IAB,FOLLOW_UP_283,,PRIMARY_DIAGNOSIS_123,DONOR_3,SYNTHETIC-1,Distant recurrence/metastasis,C17|C02,N0b
"{'month_interval': 43, 'day_interval': 1290}",Partial remission,"{'month_interval': 3, 'day_interval': 90}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),Ann Arbor staging system,,M1b,Stage II bulky,FOLLOW_UP_284,,PRIMARY_DIAGNOSIS_124,DONOR_4,SYNTHETIC-1,Biochemical progression,C05|C18,N1a(sn)
"{'month_interval': 24, 'day_interval': 720}",,"{'month_interval': 33, 'day_interval': 990}",Imaging (procedure),AJCC 6th edition,T2d,M1c(1),,FOLLOW_UP_285,,PRIMARY_DIAGNOSIS_125,DONOR_5,SYNTHETIC-1,Local recurrence,C20,N3
"{'month_interval': 47, 'day_interval': 1410}",Distant progression,"{'month_interval': 37, 'day_interval': 1110}",Histopathology test (procedure)|Imaging (procedure),Rai staging system,T4a,M1a(0),Stage IIIBES,FOLLOW_UP_286,,PRIMARY_DIAGNOSIS_126,DONOR_6,SYNTHETIC-1,Local recurrence,C09|C03,N0
,Loco-regional progression,"{'month_interval': 39, 'day_interval': 1170}",,FIGO staging system,TX,M1d(0),Stage IIEA,FOLLOW_UP_287,,PRIMARY_DIAGNOSIS_127,DONOR_7,SYNTHETIC-1,,,
"{'month_interval': 5, 'day_interval': 150}",No evidence of disease,"{'month_interval': 26, 'day_interval': 780}",Histopathology test (procedure)|Physical examination procedure (procedure),International Neuroblastoma Staging System,T3(s),,Stage IA1,FOLLOW_UP_288,,PRIMARY_DIAGNOSIS_128,DONOR_8,SYNTHETIC-1,Local recurrence,,N0b
,,"{'month_interval': 34, 'day_interval': 1020}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),Rai staging system,T1b(s),,,FOLLOW_UP_289,,PRIMARY_DIAGNOSIS_129,DONOR_9,SYNTHETIC-1,Progression (liquid tumours),C17,N3b
"{'month_interval': 19, 'day_interval': 570}",Loco-regional progression,"{'month_interval': 36, 'day_interval': 1080}",Physical examination procedure (procedure),International Neuroblastoma Risk Group Staging System,T1b,M1c(1),Stage 2B,FOLLOW_UP_290,,PRIMARY_DIAGNOSIS_130,DONOR_10,SYNTHETIC-1,Progression (liquid tumours),C11,N3b
"{'month_interval': 6, 'day_interval': 180}",Partial remission,"{'month_interval': 20, 'day_interval': 600}",Assessment of symptom control (procedure)|Imaging (procedure),International Neuroblastoma Staging System,T1b,M1c,Stage IIIC1,FOLLOW_UP_291,,PRIMARY_DIAGNOSIS_131,DONOR_11,SYNTHETIC-1,Local recurrence,C17,N0
"{'month_interval': 31, 'day_interval': 930}",Stable,"{'month_interval': 12, 'day_interval': 360}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),Lugano staging system,T0,M1d,,FOLLOW_UP_292,,PRIMARY_DIAGNOSIS_132,DONOR_12,SYNTHETIC-1,Local recurrence and distant metastasis,,NX
"{'month_interval': 17, 'day_interval': 510}",,"{'month_interval': 34, 'day_interval': 1020}",,AJCC 8th edition,T2(m),M1d,Stage IIIC2,FOLLOW_UP_293,,PRIMARY_DIAGNOSIS_133,DONOR_13,SYNTHETIC-1,Local recurrence and distant metastasis,,N0b
"{'month_interval': 21, 'day_interval': 630}",No evidence of disease,"{'month_interval': 19, 'day_interval': 570}",Laboratory data interpretation (procedure)|Tumor marker measurement (procedure),AJCC 7th edition,T2c,M1d,Stage IVA1,FOLLOW_UP_294,,PRIMARY_DIAGNOSIS_134,DONOR_14,SYNTHETIC-1,Progression (liquid tumours),,N2
"{'month_interval': 3, 'day_interval': 90}",Stable,"{'month_interval': 10, 'day_interval': 300}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),Durie-Salmon staging system,Ta,M1a(0),Stage IIB,FOLLOW_UP_295,,PRIMARY_DIAGNOSIS_135,DONOR_15,SYNTHETIC-1,Distant recurrence/metastasis,,N3b
"{'month_interval': 46, 'day_interval': 1380}",Distant progression,"{'month_interval': 21, 'day_interval': 630}",,FIGO staging system,T2d,,,FOLLOW_UP_296,,PRIMARY_DIAGNOSIS_136,DONOR_16,SYNTHETIC-1,Distant recurrence/metastasis,,N2
,Loco-regional progression,"{'month_interval': 35, 'day_interval': 1050}",,International Neuroblastoma Staging System,Tis pd,M1b(0),Distant,FOLLOW_UP_297,,PRIMARY_DIAGNOSIS_137,DONOR_17,SYNTHETIC-1,Progression (liquid tumours),C11|C06,N1mi
"{'month_interval': 9, 'day_interval': 270}",Progression not otherwise specified,"{'month_interval': 22, 'day_interval': 660}",Assessment of symptom control (procedure),Rai staging system,T4a(m),M1b(0),Stage IIIAE,FOLLOW_UP_298,,PRIMARY_DIAGNOSIS_138,DONOR_18,SYNTHETIC-1,Local recurrence and distant metastasis,C15|C07,N2
"{'month_interval': 4, 'day_interval': 120}",Relapse or recurrence,"{'month_interval': 32, 'day_interval': 960}",Histopathology test (procedure)|Laboratory data interpretation (procedure),AJCC 7th edition,T1a2,M1d(1),,FOLLOW_UP_299,,PRIMARY_DIAGNOSIS_139,DONOR_19,SYNTHETIC-1,Biochemical progression,C16,
"{'month_interval': 1, 'day_interval': 30}",Relapse or recurrence,"{'month_interval': 47, 'day_interval': 1410}",Histopathology test (procedure),St Jude staging system,T1a(s),M1d(0),Stage II bulky,FOLLOW_UP_300,,PRIMARY_DIAGNOSIS_140,DONOR_20,SYNTHETIC-1,Distant recurrence/metastasis,,N3c
"{'month_interval': 31, 'day_interval': 930}",,"{'month_interval': 19, 'day_interval': 570}",Imaging (procedure),,Tis pd,M1c,Stage IVBE,FOLLOW_UP_301,,PRIMARY_DIAGNOSIS_141,DONOR_21,SYNTHETIC-1,Progression (liquid tumours),C10|C20,N0(mol-)
"{'month_interval': 16, 'day_interval': 480}",No evidence of disease,"{'month_interval': 28, 'day_interval': 840}",,Ann Arbor staging system,T1b1,M1a(0),Stage IES,FOLLOW_UP_302,,PRIMARY_DIAGNOSIS_142,DONOR_22,SYNTHETIC-1,Distant recurrence/metastasis,,N2mi
"{'month_interval': 24, 'day_interval': 720}",Loco-regional progression,"{'month_interval': 26, 'day_interval': 780}",,Durie-Salmon staging system,T2,M1d(1),Stage IE,FOLLOW_UP_303,,PRIMARY_DIAGNOSIS_143,DONOR_23,SYNTHETIC-1,Local recurrence and distant metastasis,C12,N0(mol-)
"{'month_interval': 13, 'day_interval': 390}",Stable,"{'month_interval': 3, 'day_interval': 90}",,AJCC 7th edition,Tis(Paget's),M1a(0),,FOLLOW_UP_304,,PRIMARY_DIAGNOSIS_144,DONOR_24,SYNTHETIC-1,,C04,
"{'month_interval': 8, 'day_interval': 240}",Progression not otherwise specified,,Assessment of symptom control (procedure),,T1,M1e,Stage IVAES,FOLLOW_UP_305,,PRIMARY_DIAGNOSIS_145,DONOR_25,SYNTHETIC-1,Local recurrence,C03|C13,N4
"{'month_interval': 49, 'day_interval': 1470}",No evidence of disease,"{'month_interval': 11, 'day_interval': 330}",Assessment of symptom control (procedure),Revised International staging system (RISS),,M0,Stage IAB,FOLLOW_UP_306,,PRIMARY_DIAGNOSIS_146,DONOR_26,SYNTHETIC-1,,C09|C20,N1
"{'month_interval': 9, 'day_interval': 270}",Progression not otherwise specified,"{'month_interval': 29, 'day_interval': 870}",Physical examination procedure (procedure)|Imaging (procedure),Ann Arbor staging system,,M1b,,FOLLOW_UP_307,,PRIMARY_DIAGNOSIS_147,DONOR_27,SYNTHETIC-1,Biochemical progression,C05|C07,N4
"{'month_interval': 22, 'day_interval': 660}",Loco-regional progression,"{'month_interval': 37, 'day_interval': 1110}",Histopathology test (procedure),International Neuroblastoma Staging System,T4a,,Stage IIIS,FOLLOW_UP_308,,PRIMARY_DIAGNOSIS_148,DONOR_28,SYNTHETIC-1,Progression (liquid tumours),,N3
"{'month_interval': 25, 'day_interval': 750}",,"{'month_interval': 4, 'day_interval': 120}",,AJCC 7th edition,T3(s),M1b(1),Stage 0a,FOLLOW_UP_309,,PRIMARY_DIAGNOSIS_149,DONOR_29,SYNTHETIC-1,Progression (liquid tumours),,NX
"{'month_interval': 15, 'day_interval': 450}",Relapse or recurrence,"{'month_interval': 6, 'day_interval': 180}",,International Neuroblastoma Risk Group Staging System,T2b,M1c,,FOLLOW_UP_310,,PRIMARY_DIAGNOSIS_150,DONOR_30,SYNTHETIC-1,Progression (liquid tumours),C03,N0(i-)
"{'month_interval': 38, 'day_interval': 1140}",,"{'month_interval': 26, 'day_interval': 780}",Imaging (procedure)|Tumor marker measurement (procedure),,,M1d(0),Stage IB2,FOLLOW_UP_311,,PRIMARY_DIAGNOSIS_151,DONOR_31,SYNTHETIC-1,Local recurrence,C18|C12,N0(i+)
"{'month_interval': 22, 'day_interval': 660}",Progression not otherwise specified,,Imaging (procedure),Binet staging system,T2a2,M1c(0),Stage IIEA,FOLLOW_UP_312,,PRIMARY_DIAGNOSIS_152,DONOR_32,SYNTHETIC-1,Local recurrence and distant metastasis,C20|C01,N1a(sn)
"{'month_interval': 46, 'day_interval': 1380}",No evidence of disease,"{'month_interval': 9, 'day_interval': 270}",,AJCC 6th edition,T1,M1d(0),Stage IIA1,FOLLOW_UP_313,,PRIMARY_DIAGNOSIS_153,DONOR_33,SYNTHETIC-1,Local recurrence,C05|C16,N0(mol-)
"{'month_interval': 2, 'day_interval': 60}",No evidence of disease,"{'month_interval': 5, 'day_interval': 150}",Laboratory data interpretation (procedure)|Imaging (procedure),Durie-Salmon staging system,Tis(DCIS),M1b,Stage IIIE,FOLLOW_UP_314,,PRIMARY_DIAGNOSIS_154,DONOR_34,SYNTHETIC-1,Progression (liquid tumours),C19,N2
"{'month_interval': 43, 'day_interval': 1290}",Distant progression,"{'month_interval': 26, 'day_interval': 780}",Physical examination procedure (procedure),Durie-Salmon staging system,,M1c(1),Stage IIIB,FOLLOW_UP_315,,PRIMARY_DIAGNOSIS_155,DONOR_35,SYNTHETIC-1,Distant recurrence/metastasis,C01,N2a
"{'month_interval': 28, 'day_interval': 840}",Distant progression,"{'month_interval': 44, 'day_interval': 1320}",Tumor marker measurement (procedure),Rai staging system,T2,M1c(0),Stage IIIAES,FOLLOW_UP_316,,PRIMARY_DIAGNOSIS_156,DONOR_36,SYNTHETIC-1,Progression (liquid tumours),C12,N1
"{'month_interval': 16, 'day_interval': 480}",Loco-regional progression,"{'month_interval': 29, 'day_interval': 870}",,International Neuroblastoma Staging System,T4a(m),M1b(1),Stage IIID,FOLLOW_UP_317,,PRIMARY_DIAGNOSIS_157,DONOR_37,SYNTHETIC-1,Biochemical progression,C14|C08,N3
,Complete remission,"{'month_interval': 12, 'day_interval': 360}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),Rai staging system,T1d,M1b,Stage IVBES,FOLLOW_UP_318,,PRIMARY_DIAGNOSIS_158,DONOR_38,SYNTHETIC-1,Distant recurrence/metastasis,,N2a
"{'month_interval': 23, 'day_interval': 690}",Distant progression,,Imaging (procedure),International Neuroblastoma Risk Group Staging System,T4e,M1c(0),Stage IIBS,FOLLOW_UP_319,,PRIMARY_DIAGNOSIS_159,DONOR_39,SYNTHETIC-1,Progression (liquid tumours),C17,N2c
"{'month_interval': 9, 'day_interval': 270}",Progression not otherwise specified,"{'month_interval': 20, 'day_interval': 600}",Physical examination procedure (procedure),AJCC 8th edition,T1b1,M1b(0),Stage IIIBS,FOLLOW_UP_320,,PRIMARY_DIAGNOSIS_160,DONOR_40,SYNTHETIC-1,Local recurrence and distant metastasis,C08,N1
,No evidence of disease,"{'month_interval': 44, 'day_interval': 1320}",,Revised International staging system (RISS),,M1c(1),Stage IAES,FOLLOW_UP_321,,PRIMARY_DIAGNOSIS_1,DONOR_1,SYNTHETIC-1,Local recurrence,,N0(i-)
"{'month_interval': 7, 'day_interval': 210}",,"{'month_interval': 31, 'day_interval': 930}",Assessment of symptom control (procedure),FIGO staging system,T3c,,Stage IIEB,FOLLOW_UP_322,,PRIMARY_DIAGNOSIS_2,DONOR_2,SYNTHETIC-1,Local recurrence and distant metastasis,,NX
"{'month_interval': 47, 'day_interval': 1410}",Partial remission,"{'month_interval': 9, 'day_interval': 270}",Physical examination procedure (procedure),Revised International staging system (RISS),,,,FOLLOW_UP_323,,PRIMARY_DIAGNOSIS_3,DONOR_3,SYNTHETIC-1,Progression (liquid tumours),C06|C20,N1
"{'month_interval': 38, 'day_interval': 1140}",No evidence of disease,"{'month_interval': 18, 'day_interval': 540}",,St Jude staging system,Tis(LCIS),M1d,Stage IVA,FOLLOW_UP_324,,PRIMARY_DIAGNOSIS_4,DONOR_4,SYNTHETIC-1,Biochemical progression,,N0
"{'month_interval': 18, 'day_interval': 540}",,"{'month_interval': 8, 'day_interval': 240}",Laboratory data interpretation (procedure),Durie-Salmon staging system,T4e,,Stage L2,FOLLOW_UP_325,,PRIMARY_DIAGNOSIS_5,DONOR_5,SYNTHETIC-1,,C11,NX
"{'month_interval': 22, 'day_interval': 660}",,"{'month_interval': 32, 'day_interval': 960}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),,Tis(Paget),M1d(1),,FOLLOW_UP_326,,PRIMARY_DIAGNOSIS_6,DONOR_6,SYNTHETIC-1,Local recurrence,C05|C12,N2b
"{'month_interval': 35, 'day_interval': 1050}",,,Histopathology test (procedure)|Physical examination procedure (procedure),,T4b,M1b(0),Stage IVBE,FOLLOW_UP_327,,PRIMARY_DIAGNOSIS_7,DONOR_7,SYNTHETIC-1,Progression (liquid tumours),,N2b
"{'month_interval': 10, 'day_interval': 300}",Relapse or recurrence,"{'month_interval': 40, 'day_interval': 1200}",Physical examination procedure (procedure),AJCC 7th edition,Tis pd,M1c(0),Stage C,FOLLOW_UP_328,,PRIMARY_DIAGNOSIS_8,DONOR_8,SYNTHETIC-1,Progression (liquid tumours),,
,Relapse or recurrence,"{'month_interval': 16, 'day_interval': 480}",Imaging (procedure)|Laboratory data interpretation (procedure),SEER staging system,Tis(Paget),M1b(0),,FOLLOW_UP_329,,PRIMARY_DIAGNOSIS_9,DONOR_9,SYNTHETIC-1,Local recurrence,C19,
"{'month_interval': 33, 'day_interval': 990}",Complete remission,,Assessment of symptom control (procedure)|Tumor marker measurement (procedure),Binet staging system,T1a(s),M1a(1),Stage IIES,FOLLOW_UP_330,,PRIMARY_DIAGNOSIS_10,DONOR_10,SYNTHETIC-1,Biochemical progression,,N3
"{'month_interval': 14, 'day_interval': 420}",Relapse or recurrence,"{'month_interval': 39, 'day_interval': 1170}",Imaging (procedure),Ann Arbor staging system,,M1a,,FOLLOW_UP_331,,PRIMARY_DIAGNOSIS_11,DONOR_11,SYNTHETIC-1,Distant recurrence/metastasis,C11|C03,N3a
"{'month_interval': 12, 'day_interval': 360}",,,,St Jude staging system,T1c,,,FOLLOW_UP_332,,PRIMARY_DIAGNOSIS_12,DONOR_12,SYNTHETIC-1,Progression (liquid tumours),,N0(i+)
"{'month_interval': 45, 'day_interval': 1350}",Stable,"{'month_interval': 22, 'day_interval': 660}",Tumor marker measurement (procedure),Ann Arbor staging system,T1a,M0,Stage IBE,FOLLOW_UP_333,,PRIMARY_DIAGNOSIS_13,DONOR_13,SYNTHETIC-1,Local recurrence and distant metastasis,,NX
"{'month_interval': 9, 'day_interval': 270}",Stable,"{'month_interval': 36, 'day_interval': 1080}",,Durie-Salmon staging system,Tis(LAMN),,Stage 1,FOLLOW_UP_334,,PRIMARY_DIAGNOSIS_14,DONOR_14,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(i-)
"{'month_interval': 31, 'day_interval': 930}",Partial remission,"{'month_interval': 8, 'day_interval': 240}",Physical examination procedure (procedure),Durie-Salmon staging system,T1a1,,,FOLLOW_UP_335,,PRIMARY_DIAGNOSIS_15,DONOR_15,SYNTHETIC-1,Local recurrence and distant metastasis,,
"{'month_interval': 34, 'day_interval': 1020}",Relapse or recurrence,"{'month_interval': 38, 'day_interval': 1140}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),Binet staging system,,M1a(0),Stage IIIAE,FOLLOW_UP_336,,PRIMARY_DIAGNOSIS_16,DONOR_16,SYNTHETIC-1,Biochemical progression,C10|C17,N2mi
"{'month_interval': 48, 'day_interval': 1440}",Loco-regional progression,"{'month_interval': 42, 'day_interval': 1260}",Tumor marker measurement (procedure)|Imaging (procedure),St Jude staging system,Tis(LCIS),,Stage IB,FOLLOW_UP_337,,PRIMARY_DIAGNOSIS_17,DONOR_17,SYNTHETIC-1,Biochemical progression,C12|C16,N1b
"{'month_interval': 34, 'day_interval': 1020}",Partial remission,"{'month_interval': 14, 'day_interval': 420}",Laboratory data interpretation (procedure),International Neuroblastoma Staging System,T4e,,Stage IIIBS,FOLLOW_UP_338,,PRIMARY_DIAGNOSIS_18,DONOR_18,SYNTHETIC-1,Local recurrence,,
,Distant progression,,Laboratory data interpretation (procedure)|Histopathology test (procedure),Rai staging system,T1a1,,Stage IS,FOLLOW_UP_339,,PRIMARY_DIAGNOSIS_19,DONOR_19,SYNTHETIC-1,Local recurrence,,N0(mol+)
"{'month_interval': 3, 'day_interval': 90}",Progression not otherwise specified,"{'month_interval': 15, 'day_interval': 450}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),SEER staging system,Tis(Paget's),MX,Stage IVA1,FOLLOW_UP_340,,PRIMARY_DIAGNOSIS_20,DONOR_20,SYNTHETIC-1,Progression (liquid tumours),,N0b
,No evidence of disease,"{'month_interval': 22, 'day_interval': 660}",,Ann Arbor staging system,T1b(s),M1a(0),Stage IEB,FOLLOW_UP_341,,PRIMARY_DIAGNOSIS_21,DONOR_21,SYNTHETIC-1,Distant recurrence/metastasis,C05,N0b (no biopsy)
"{'month_interval': 48, 'day_interval': 1440}",Complete remission,"{'month_interval': 21, 'day_interval': 630}",Laboratory data interpretation (procedure),Lugano staging system,T4b(s),MX,,FOLLOW_UP_342,,PRIMARY_DIAGNOSIS_22,DONOR_22,SYNTHETIC-1,,C08|C09,
"{'month_interval': 35, 'day_interval': 1050}",Relapse or recurrence,"{'month_interval': 40, 'day_interval': 1200}",Laboratory data interpretation (procedure)|Histopathology test (procedure),Revised International staging system (RISS),T3(m),M0,Distant,FOLLOW_UP_343,,PRIMARY_DIAGNOSIS_23,DONOR_23,SYNTHETIC-1,Biochemical progression,C17,
"{'month_interval': 16, 'day_interval': 480}",,"{'month_interval': 11, 'day_interval': 330}",,Durie-Salmon staging system,T1b2,M1c,Stage IIIE,FOLLOW_UP_344,,PRIMARY_DIAGNOSIS_24,DONOR_24,SYNTHETIC-1,Local recurrence and distant metastasis,C09|C13,N2
"{'month_interval': 24, 'day_interval': 720}",,"{'month_interval': 14, 'day_interval': 420}",,Rai staging system,T1a2,M1b(1),Stage IIA2,FOLLOW_UP_345,,PRIMARY_DIAGNOSIS_25,DONOR_25,SYNTHETIC-1,,,N3b
"{'month_interval': 9, 'day_interval': 270}",Complete remission,,,Binet staging system,Tis(DCIS),M1a,Stage IIBES,FOLLOW_UP_346,,PRIMARY_DIAGNOSIS_26,DONOR_26,SYNTHETIC-1,,,N0
"{'month_interval': 16, 'day_interval': 480}",Partial remission,"{'month_interval': 34, 'day_interval': 1020}",Imaging (procedure),International Neuroblastoma Staging System,T4a(s),M1d,Stage 1A,FOLLOW_UP_347,,PRIMARY_DIAGNOSIS_27,DONOR_27,SYNTHETIC-1,Local recurrence and distant metastasis,,N0
"{'month_interval': 45, 'day_interval': 1350}",No evidence of disease,"{'month_interval': 46, 'day_interval': 1380}",,,Tis(Paget's),M1,Stage IIID,FOLLOW_UP_348,,PRIMARY_DIAGNOSIS_28,DONOR_28,SYNTHETIC-1,Distant recurrence/metastasis,,
,Stable,"{'month_interval': 27, 'day_interval': 810}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),St Jude staging system,Tis pd,,Localized,FOLLOW_UP_349,,PRIMARY_DIAGNOSIS_29,DONOR_29,SYNTHETIC-1,Local recurrence,C02|C08,N4
"{'month_interval': 7, 'day_interval': 210}",No evidence of disease,"{'month_interval': 19, 'day_interval': 570}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),AJCC 7th edition,,M1c,Regionalized,FOLLOW_UP_350,,PRIMARY_DIAGNOSIS_30,DONOR_30,SYNTHETIC-1,Biochemical progression,C17,
,Loco-regional progression,"{'month_interval': 37, 'day_interval': 1110}",Imaging (procedure)|Histopathology test (procedure),SEER staging system,T2a1,M1e,Stage IVC,FOLLOW_UP_351,,PRIMARY_DIAGNOSIS_31,DONOR_31,SYNTHETIC-1,Local recurrence and distant metastasis,C06,
"{'month_interval': 27, 'day_interval': 810}",Relapse or recurrence,"{'month_interval': 9, 'day_interval': 270}",Assessment of symptom control (procedure),AJCC 7th edition,T4b,,Stage IAES,FOLLOW_UP_352,,PRIMARY_DIAGNOSIS_32,DONOR_32,SYNTHETIC-1,Distant recurrence/metastasis,C09|C20,N2a
"{'month_interval': 32, 'day_interval': 960}",Complete remission,"{'month_interval': 17, 'day_interval': 510}",Histopathology test (procedure),Durie-Salmon staging system,T2,M1c(1),Stage IVES,FOLLOW_UP_353,,PRIMARY_DIAGNOSIS_33,DONOR_33,SYNTHETIC-1,Local recurrence,,N0
"{'month_interval': 18, 'day_interval': 540}",Complete remission,"{'month_interval': 26, 'day_interval': 780}",Physical examination procedure (procedure)|Imaging (procedure),FIGO staging system,T4a(s),M1a(1),Stage 4S,FOLLOW_UP_354,,PRIMARY_DIAGNOSIS_34,DONOR_34,SYNTHETIC-1,Biochemical progression,C13,N0a (biopsy)
"{'month_interval': 29, 'day_interval': 870}",Stable,,,International Neuroblastoma Staging System,T1b1,M1b(0),Stage IIIA,FOLLOW_UP_355,,PRIMARY_DIAGNOSIS_35,DONOR_35,SYNTHETIC-1,Progression (liquid tumours),,N1a
"{'month_interval': 11, 'day_interval': 330}",No evidence of disease,"{'month_interval': 26, 'day_interval': 780}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),St Jude staging system,T4b,M1b,Localized,FOLLOW_UP_356,,PRIMARY_DIAGNOSIS_36,DONOR_36,SYNTHETIC-1,Local recurrence,C15,N0a
"{'month_interval': 40, 'day_interval': 1200}",Stable,,Histopathology test (procedure),Lugano staging system,T2(m),MX,,FOLLOW_UP_357,,PRIMARY_DIAGNOSIS_37,DONOR_37,SYNTHETIC-1,Progression (liquid tumours),C14|C12,
,,"{'month_interval': 8, 'day_interval': 240}",,St Jude staging system,T2a2,M1a(0),Distant,FOLLOW_UP_358,,PRIMARY_DIAGNOSIS_38,DONOR_38,SYNTHETIC-1,Biochemical progression,,N1a
,Stable,"{'month_interval': 47, 'day_interval': 1410}",Physical examination procedure (procedure),Revised International staging system (RISS),Tis(Paget),,Stage IVA1,FOLLOW_UP_359,,PRIMARY_DIAGNOSIS_39,DONOR_39,SYNTHETIC-1,Local recurrence,,N0b
"{'month_interval': 22, 'day_interval': 660}",Distant progression,,,FIGO staging system,Tis,M1d,Stage IIIE,FOLLOW_UP_360,,PRIMARY_DIAGNOSIS_40,DONOR_40,SYNTHETIC-1,Local recurrence,C20|C13,
"{'month_interval': 1, 'day_interval': 30}",No evidence of disease,"{'month_interval': 32, 'day_interval': 960}",Imaging (procedure)|Assessment of symptom control (procedure),Durie-Salmon staging system,T1b2,,Stage 1,FOLLOW_UP_361,,PRIMARY_DIAGNOSIS_41,DONOR_1,SYNTHETIC-1,,,N0
"{'month_interval': 19, 'day_interval': 570}",Distant progression,"{'month_interval': 22, 'day_interval': 660}",Assessment of symptom control (procedure),FIGO staging system,,M1d(1),,FOLLOW_UP_362,,PRIMARY_DIAGNOSIS_42,DONOR_2,SYNTHETIC-1,Progression (liquid tumours),,N0a (biopsy)
"{'month_interval': 48, 'day_interval': 1440}",Stable,"{'month_interval': 18, 'day_interval': 540}",Tumor marker measurement (procedure),Rai staging system,,M1a,Stage A,FOLLOW_UP_363,,PRIMARY_DIAGNOSIS_43,DONOR_3,SYNTHETIC-1,,,
"{'month_interval': 5, 'day_interval': 150}",Complete remission,"{'month_interval': 12, 'day_interval': 360}",,Rai staging system,T2(s),M1d(0),Stage IVAE,FOLLOW_UP_364,,PRIMARY_DIAGNOSIS_44,DONOR_4,SYNTHETIC-1,Distant recurrence/metastasis,C15,
,Stable,"{'month_interval': 16, 'day_interval': 480}",,Durie-Salmon staging system,Tis(Paget's),M1c(0),Stage IB,FOLLOW_UP_365,,PRIMARY_DIAGNOSIS_45,DONOR_5,SYNTHETIC-1,Progression (liquid tumours),C05,N2mi
,,,,Ann Arbor staging system,T1b1,M1c(0),Stage IIIA,FOLLOW_UP_366,,PRIMARY_DIAGNOSIS_46,DONOR_6,SYNTHETIC-1,Biochemical progression,C13,N0b
"{'month_interval': 20, 'day_interval': 600}",Progression not otherwise specified,"{'month_interval': 43, 'day_interval': 1290}",Imaging (procedure)|Tumor marker measurement (procedure),AJCC 6th edition,T3a,MX,Stage 0,FOLLOW_UP_367,,PRIMARY_DIAGNOSIS_47,DONOR_7,SYNTHETIC-1,Local recurrence and distant metastasis,C09|C11,N0(i-)
"{'month_interval': 43, 'day_interval': 1290}",Partial remission,"{'month_interval': 32, 'day_interval': 960}",,AJCC 8th edition,Tis,M1c(0),Stage 1,FOLLOW_UP_368,,PRIMARY_DIAGNOSIS_48,DONOR_8,SYNTHETIC-1,Biochemical progression,C05,N2a
"{'month_interval': 31, 'day_interval': 930}",Loco-regional progression,,,AJCC 7th edition,T1a,M1e,,FOLLOW_UP_369,,PRIMARY_DIAGNOSIS_49,DONOR_9,SYNTHETIC-1,Local recurrence and distant metastasis,,N4
"{'month_interval': 49, 'day_interval': 1470}",Stable,"{'month_interval': 28, 'day_interval': 840}",,International Neuroblastoma Staging System,,M0,Stage 2A,FOLLOW_UP_370,,PRIMARY_DIAGNOSIS_50,DONOR_10,SYNTHETIC-1,,C18,
"{'month_interval': 33, 'day_interval': 990}",,"{'month_interval': 7, 'day_interval': 210}",Laboratory data interpretation (procedure)|Histopathology test (procedure),International Neuroblastoma Risk Group Staging System,Tis(LCIS),M1e,,FOLLOW_UP_371,,PRIMARY_DIAGNOSIS_51,DONOR_11,SYNTHETIC-1,,C08,N1c
"{'month_interval': 37, 'day_interval': 1110}",No evidence of disease,,Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),AJCC 8th edition,T1a1,M1b(0),Stage IIBES,FOLLOW_UP_372,,PRIMARY_DIAGNOSIS_52,DONOR_12,SYNTHETIC-1,Biochemical progression,C12|C16,N1c
,No evidence of disease,,Imaging (procedure)|Assessment of symptom control (procedure),AJCC 6th edition,,M1e,Stage IVA1,FOLLOW_UP_373,,PRIMARY_DIAGNOSIS_53,DONOR_13,SYNTHETIC-1,Local recurrence,C14|C11,N0a (biopsy)
"{'month_interval': 12, 'day_interval': 360}",Relapse or recurrence,"{'month_interval': 24, 'day_interval': 720}",Physical examination procedure (procedure),SEER staging system,T3c,,,FOLLOW_UP_374,,PRIMARY_DIAGNOSIS_54,DONOR_14,SYNTHETIC-1,Biochemical progression,,N0(i-)
"{'month_interval': 36, 'day_interval': 1080}",Progression not otherwise specified,"{'month_interval': 8, 'day_interval': 240}",,,T3(s),MX,Stage IBS,FOLLOW_UP_375,,PRIMARY_DIAGNOSIS_55,DONOR_15,SYNTHETIC-1,Distant recurrence/metastasis,,N3
"{'month_interval': 6, 'day_interval': 180}",Partial remission,"{'month_interval': 23, 'day_interval': 690}",,Lugano staging system,Ta,M1a,Stage II,FOLLOW_UP_376,,PRIMARY_DIAGNOSIS_56,DONOR_16,SYNTHETIC-1,Progression (liquid tumours),C07|C20,N2mi
"{'month_interval': 5, 'day_interval': 150}",Loco-regional progression,,,,T4a(m),,Stage IIB,FOLLOW_UP_377,,PRIMARY_DIAGNOSIS_57,DONOR_17,SYNTHETIC-1,Local recurrence and distant metastasis,,NX
"{'month_interval': 23, 'day_interval': 690}",Loco-regional progression,"{'month_interval': 4, 'day_interval': 120}",,AJCC 7th edition,Tis(LAMN),M1b(0),,FOLLOW_UP_378,,PRIMARY_DIAGNOSIS_58,DONOR_18,SYNTHETIC-1,,C15,N0a
"{'month_interval': 36, 'day_interval': 1080}",Complete remission,"{'month_interval': 20, 'day_interval': 600}",Imaging (procedure),Lugano staging system,Tis pd,M1c,Stage IIES,FOLLOW_UP_379,,PRIMARY_DIAGNOSIS_59,DONOR_19,SYNTHETIC-1,Biochemical progression,C07|C20,N0
"{'month_interval': 43, 'day_interval': 1290}",Complete remission,"{'month_interval': 3, 'day_interval': 90}",Histopathology test (procedure)|Laboratory data interpretation (procedure),SEER staging system,Tis(LCIS),M1c(1),Stage IB,FOLLOW_UP_380,,PRIMARY_DIAGNOSIS_60,DONOR_20,SYNTHETIC-1,Local recurrence and distant metastasis,,
"{'month_interval': 23, 'day_interval': 690}",No evidence of disease,"{'month_interval': 45, 'day_interval': 1350}",,Ann Arbor staging system,T3b,M1c(0),,FOLLOW_UP_381,,PRIMARY_DIAGNOSIS_61,DONOR_21,SYNTHETIC-1,Progression (liquid tumours),C06,N2b
"{'month_interval': 32, 'day_interval': 960}",Loco-regional progression,,Physical examination procedure (procedure),Rai staging system,,M1b(0),Stage I,FOLLOW_UP_382,,PRIMARY_DIAGNOSIS_62,DONOR_22,SYNTHETIC-1,Local recurrence and distant metastasis,C05|C02,N0b (no biopsy)
,Complete remission,"{'month_interval': 7, 'day_interval': 210}",,International Neuroblastoma Staging System,T2d,M1a(1),Stage IIA2,FOLLOW_UP_383,,PRIMARY_DIAGNOSIS_63,DONOR_23,SYNTHETIC-1,Distant recurrence/metastasis,,N1b
"{'month_interval': 50, 'day_interval': 1500}",Stable,"{'month_interval': 34, 'day_interval': 1020}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Staging System,,,Stage 2B,FOLLOW_UP_384,,PRIMARY_DIAGNOSIS_64,DONOR_24,SYNTHETIC-1,Biochemical progression,,N3b
"{'month_interval': 16, 'day_interval': 480}",Complete remission,"{'month_interval': 17, 'day_interval': 510}",Physical examination procedure (procedure)|Histopathology test (procedure),Rai staging system,T3d,M1a,Stage IIA2,FOLLOW_UP_385,,PRIMARY_DIAGNOSIS_65,DONOR_25,SYNTHETIC-1,Local recurrence and distant metastasis,C11|C04,N0(mol-)
"{'month_interval': 42, 'day_interval': 1260}",Complete remission,"{'month_interval': 5, 'day_interval': 150}",Assessment of symptom control (procedure),,T4b,M1c(1),Stage 2B,FOLLOW_UP_386,,PRIMARY_DIAGNOSIS_66,DONOR_26,SYNTHETIC-1,Biochemical progression,C03|C14,N3a
"{'month_interval': 18, 'day_interval': 540}",Distant progression,"{'month_interval': 4, 'day_interval': 120}",,International Neuroblastoma Staging System,T4,M1c,Stage 0a,FOLLOW_UP_387,,PRIMARY_DIAGNOSIS_67,DONOR_27,SYNTHETIC-1,Progression (liquid tumours),C02|C14,N0(i+)
"{'month_interval': 47, 'day_interval': 1410}",Partial remission,"{'month_interval': 25, 'day_interval': 750}",,,,M1b,Stage IVA,FOLLOW_UP_388,,PRIMARY_DIAGNOSIS_68,DONOR_28,SYNTHETIC-1,Local recurrence,C16,N0a (biopsy)
"{'month_interval': 26, 'day_interval': 780}",Loco-regional progression,"{'month_interval': 44, 'day_interval': 1320}",Laboratory data interpretation (procedure),Durie-Salmon staging system,,,Stage IIIC2,FOLLOW_UP_389,,PRIMARY_DIAGNOSIS_69,DONOR_29,SYNTHETIC-1,Distant recurrence/metastasis,C20,N1a
"{'month_interval': 22, 'day_interval': 660}",Loco-regional progression,"{'month_interval': 27, 'day_interval': 810}",,Lugano staging system,,M0(i+),Stage IEA,FOLLOW_UP_390,,PRIMARY_DIAGNOSIS_70,DONOR_30,SYNTHETIC-1,,C18|C06,N3b
"{'month_interval': 35, 'day_interval': 1050}",Partial remission,"{'month_interval': 6, 'day_interval': 180}",Assessment of symptom control (procedure),Rai staging system,,M1e,Stage C,FOLLOW_UP_391,,PRIMARY_DIAGNOSIS_71,DONOR_31,SYNTHETIC-1,Local recurrence,,N0
"{'month_interval': 36, 'day_interval': 1080}",,"{'month_interval': 14, 'day_interval': 420}",Tumor marker measurement (procedure),Rai staging system,T3b,M1e,Stage B,FOLLOW_UP_392,,PRIMARY_DIAGNOSIS_72,DONOR_32,SYNTHETIC-1,Biochemical progression,C08,N0
,No evidence of disease,"{'month_interval': 39, 'day_interval': 1170}",Assessment of symptom control (procedure)|Imaging (procedure),AJCC 6th edition,,M1a(1),Stage IS,FOLLOW_UP_393,,PRIMARY_DIAGNOSIS_73,DONOR_33,SYNTHETIC-1,Distant recurrence/metastasis,,N3a
"{'month_interval': 49, 'day_interval': 1470}",,"{'month_interval': 10, 'day_interval': 300}",Histopathology test (procedure)|Imaging (procedure),AJCC 8th edition,T1b(m),,Stage II,FOLLOW_UP_394,,PRIMARY_DIAGNOSIS_74,DONOR_34,SYNTHETIC-1,Local recurrence,C07,N1b
,Complete remission,,Assessment of symptom control (procedure)|Tumor marker measurement (procedure),SEER staging system,T3(s),,Stage 1B,FOLLOW_UP_395,,PRIMARY_DIAGNOSIS_75,DONOR_35,SYNTHETIC-1,Biochemical progression,C09,N0b
"{'month_interval': 46, 'day_interval': 1380}",,"{'month_interval': 33, 'day_interval': 990}",,Binet staging system,T4b,M0,Stage IIIES,FOLLOW_UP_396,,PRIMARY_DIAGNOSIS_76,DONOR_36,SYNTHETIC-1,Local recurrence,,N0b (no biopsy)
"{'month_interval': 19, 'day_interval': 570}",Progression not otherwise specified,"{'month_interval': 34, 'day_interval': 1020}",Histopathology test (procedure)|Physical examination procedure (procedure),AJCC 6th edition,T1b,M1d(0),Stage 0,FOLLOW_UP_397,,PRIMARY_DIAGNOSIS_77,DONOR_37,SYNTHETIC-1,Distant recurrence/metastasis,C02,NX
"{'month_interval': 7, 'day_interval': 210}",Progression not otherwise specified,"{'month_interval': 2, 'day_interval': 60}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),,Ta,,,FOLLOW_UP_398,,PRIMARY_DIAGNOSIS_78,DONOR_38,SYNTHETIC-1,Biochemical progression,,
"{'month_interval': 27, 'day_interval': 810}",Complete remission,"{'month_interval': 32, 'day_interval': 960}",,FIGO staging system,T4a(m),,Stage II,FOLLOW_UP_399,,PRIMARY_DIAGNOSIS_79,DONOR_39,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(mol+)
"{'month_interval': 50, 'day_interval': 1500}",Stable,"{'month_interval': 33, 'day_interval': 990}",Histopathology test (procedure)|Imaging (procedure),International Neuroblastoma Staging System,T2d,M0(i+),Stage IIIBS,FOLLOW_UP_400,,PRIMARY_DIAGNOSIS_80,DONOR_40,SYNTHETIC-1,Progression (liquid tumours),,N0a
"{'month_interval': 36, 'day_interval': 1080}",Distant progression,"{'month_interval': 15, 'day_interval': 450}",Assessment of symptom control (procedure)|Histopathology test (procedure),St Jude staging system,T1b,M1c(1),Stage IBES,FOLLOW_UP_401,,PRIMARY_DIAGNOSIS_81,DONOR_1,SYNTHETIC-1,Distant recurrence/metastasis,C18|C14,N0(i+)
"{'month_interval': 31, 'day_interval': 930}",Stable,"{'month_interval': 44, 'day_interval': 1320}",,,T4b(s),M1a(0),Stage IBE,FOLLOW_UP_402,,PRIMARY_DIAGNOSIS_82,DONOR_2,SYNTHETIC-1,Progression (liquid tumours),C09,N0
"{'month_interval': 44, 'day_interval': 1320}",Progression not otherwise specified,"{'month_interval': 17, 'day_interval': 510}",Imaging (procedure)|Laboratory data interpretation (procedure),Rai staging system,T2d,,,FOLLOW_UP_403,,PRIMARY_DIAGNOSIS_83,DONOR_3,SYNTHETIC-1,,,N2b
"{'month_interval': 50, 'day_interval': 1500}",Distant progression,"{'month_interval': 22, 'day_interval': 660}",,International Neuroblastoma Staging System,T4,M1,In situ,FOLLOW_UP_404,TREATMENT_404,,DONOR_4,SYNTHETIC-1,Local recurrence and distant metastasis,,N2a
,No evidence of disease,,,SEER staging system,T1c,M0(i+),,FOLLOW_UP_405,TREATMENT_405,,DONOR_5,SYNTHETIC-1,Biochemical progression,C10|C16,N1mi
"{'month_interval': 20, 'day_interval': 600}",No evidence of disease,,,,T3,M1c,Stage IIIAS,FOLLOW_UP_406,TREATMENT_406,,DONOR_6,SYNTHETIC-1,Distant recurrence/metastasis,,N0(i+)
"{'month_interval': 3, 'day_interval': 90}",No evidence of disease,,Physical examination procedure (procedure),International Neuroblastoma Staging System,Tis(LAMN),,Stage IIA2,FOLLOW_UP_407,TREATMENT_407,,DONOR_7,SYNTHETIC-1,Local recurrence and distant metastasis,C20|C08,N0a (biopsy)
"{'month_interval': 22, 'day_interval': 660}",Distant progression,"{'month_interval': 22, 'day_interval': 660}",Imaging (procedure)|Laboratory data interpretation (procedure),,T1b1,M1c,Stage L1,FOLLOW_UP_408,TREATMENT_408,,DONOR_8,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(mol-)
"{'month_interval': 9, 'day_interval': 270}",Progression not otherwise specified,"{'month_interval': 42, 'day_interval': 1260}",Histopathology test (procedure)|Tumor marker measurement (procedure),AJCC 8th edition,T1mi,M1c(0),,FOLLOW_UP_409,TREATMENT_409,,DONOR_9,SYNTHETIC-1,Local recurrence,C10,N1b
"{'month_interval': 14, 'day_interval': 420}",Loco-regional progression,,,Binet staging system,T2b,M1,Stage IVAE,FOLLOW_UP_410,TREATMENT_410,,DONOR_10,SYNTHETIC-1,Biochemical progression,C17,N0(i-)
"{'month_interval': 32, 'day_interval': 960}",Loco-regional progression,"{'month_interval': 40, 'day_interval': 1200}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Binet staging system,,MX,Stage IA2,FOLLOW_UP_411,TREATMENT_411,,DONOR_11,SYNTHETIC-1,,,
"{'month_interval': 16, 'day_interval': 480}",,"{'month_interval': 29, 'day_interval': 870}",Assessment of symptom control (procedure)|Imaging (procedure),International Neuroblastoma Staging System,T4b(s),,,FOLLOW_UP_412,TREATMENT_412,,DONOR_12,SYNTHETIC-1,Local recurrence and distant metastasis,,N2b
"{'month_interval': 41, 'day_interval': 1230}",No evidence of disease,"{'month_interval': 17, 'day_interval': 510}",Tumor marker measurement (procedure),AJCC 6th edition,T1,,Stage IIC,FOLLOW_UP_413,TREATMENT_413,,DONOR_13,SYNTHETIC-1,Distant recurrence/metastasis,,N0(i-)
"{'month_interval': 49, 'day_interval': 1470}",Loco-regional progression,"{'month_interval': 29, 'day_interval': 870}",Laboratory data interpretation (procedure),SEER staging system,T2d,M1c(0),Stage I,FOLLOW_UP_414,TREATMENT_414,,DONOR_14,SYNTHETIC-1,Progression (liquid tumours),,N4
"{'month_interval': 40, 'day_interval': 1200}",Complete remission,"{'month_interval': 25, 'day_interval': 750}",,AJCC 6th edition,T1,M1a(1),,FOLLOW_UP_415,TREATMENT_415,,DONOR_15,SYNTHETIC-1,Local recurrence and distant metastasis,C10|C13,
"{'month_interval': 33, 'day_interval': 990}",Loco-regional progression,"{'month_interval': 43, 'day_interval': 1290}",Physical examination procedure (procedure)|Tumor marker measurement (procedure),FIGO staging system,Tis(Paget's),M0,Stage IIBE,FOLLOW_UP_416,TREATMENT_416,,DONOR_16,SYNTHETIC-1,Distant recurrence/metastasis,,N3a
,Distant progression,"{'month_interval': 48, 'day_interval': 1440}",Histopathology test (procedure),FIGO staging system,,M1b,Stage III,FOLLOW_UP_417,TREATMENT_417,,DONOR_17,SYNTHETIC-1,Progression (liquid tumours),,N3b
"{'month_interval': 47, 'day_interval': 1410}",Distant progression,"{'month_interval': 11, 'day_interval': 330}",Imaging (procedure),Durie-Salmon staging system,T1a,M1b(1),Stage IIES,FOLLOW_UP_418,TREATMENT_418,,DONOR_18,SYNTHETIC-1,Biochemical progression,C04|C02,N3b
"{'month_interval': 50, 'day_interval': 1500}",Progression not otherwise specified,,Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),AJCC 8th edition,T4b(s),,Stage 4S,FOLLOW_UP_419,TREATMENT_419,,DONOR_19,SYNTHETIC-1,Biochemical progression,C02|C18,
"{'month_interval': 7, 'day_interval': 210}",,"{'month_interval': 9, 'day_interval': 270}",Imaging (procedure),Revised International staging system (RISS),T3c,,Stage IIE,FOLLOW_UP_420,TREATMENT_420,,DONOR_20,SYNTHETIC-1,Progression (liquid tumours),,N2c
"{'month_interval': 47, 'day_interval': 1410}",Progression not otherwise specified,"{'month_interval': 12, 'day_interval': 360}",Laboratory data interpretation (procedure)|Imaging (procedure),,T4d,M0,Stage IIEA,FOLLOW_UP_421,TREATMENT_421,,DONOR_21,SYNTHETIC-1,Local recurrence,,
"{'month_interval': 27, 'day_interval': 810}",Relapse or recurrence,"{'month_interval': 3, 'day_interval': 90}",Assessment of symptom control (procedure),Binet staging system,T2a2,MX,Stage IB2,FOLLOW_UP_422,TREATMENT_422,,DONOR_22,SYNTHETIC-1,Biochemical progression,,N0
"{'month_interval': 8, 'day_interval': 240}",Relapse or recurrence,"{'month_interval': 33, 'day_interval': 990}",,Lugano staging system,Tis(DCIS),M1e,Stage IIS,FOLLOW_UP_423,TREATMENT_423,,DONOR_23,SYNTHETIC-1,Local recurrence,C11,N0a (biopsy)
,Stable,"{'month_interval': 26, 'day_interval': 780}",Imaging (procedure),,Tis(Paget's),M1e,,FOLLOW_UP_424,TREATMENT_424,,DONOR_24,SYNTHETIC-1,,C07|C09,N4
"{'month_interval': 2, 'day_interval': 60}",Complete remission,"{'month_interval': 5, 'day_interval': 150}",,Rai staging system,T1b,,Stage 2A,FOLLOW_UP_425,TREATMENT_425,,DONOR_25,SYNTHETIC-1,Local recurrence,C01,N2
"{'month_interval': 24, 'day_interval': 720}",Stable,"{'month_interval': 32, 'day_interval': 960}",,International Neuroblastoma Staging System,T4,M1c(0),Stage 4,FOLLOW_UP_426,TREATMENT_426,,DONOR_26,SYNTHETIC-1,Progression (liquid tumours),C18|C05,N3a
"{'month_interval': 17, 'day_interval': 510}",Partial remission,"{'month_interval': 18, 'day_interval': 540}",,AJCC 6th edition,T3(m),MX,Stage IVA,FOLLOW_UP_427,TREATMENT_427,,DONOR_27,SYNTHETIC-1,Local recurrence,C16,N1c
"{'month_interval': 28, 'day_interval': 840}",Loco-regional progression,"{'month_interval': 39, 'day_interval': 1170}",,Durie-Salmon staging system,Tis pu,M1b(0),Stage IIB,FOLLOW_UP_428,TREATMENT_428,,DONOR_28,SYNTHETIC-1,Biochemical progression,,N0
"{'month_interval': 28, 'day_interval': 840}",Complete remission,"{'month_interval': 14, 'day_interval': 420}",Physical examination procedure (procedure),,Ta,M1b(1),,FOLLOW_UP_429,TREATMENT_429,,DONOR_29,SYNTHETIC-1,,C03,N1mi
,Relapse or recurrence,"{'month_interval': 48, 'day_interval': 1440}",Tumor marker measurement (procedure),International Neuroblastoma Risk Group Staging System,T1a,M1d,Stage IIEB,FOLLOW_UP_430,TREATMENT_430,,DONOR_30,SYNTHETIC-1,Local recurrence and distant metastasis,,N2mi
"{'month_interval': 27, 'day_interval': 810}",Complete remission,"{'month_interval': 37, 'day_interval': 1110}",Laboratory data interpretation (procedure),International Neuroblastoma Staging System,Tis(LAMN),M0,Stage IVA,FOLLOW_UP_431,TREATMENT_431,,DONOR_31,SYNTHETIC-1,Biochemical progression,C20|C17,N2c
"{'month_interval': 11, 'day_interval': 330}",Loco-regional progression,"{'month_interval': 38, 'day_interval': 1140}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,Tis(Paget),M1d(1),Stage B,FOLLOW_UP_432,TREATMENT_432,,DONOR_32,SYNTHETIC-1,Biochemical progression,,N0a (biopsy)
"{'month_interval': 8, 'day_interval': 240}",,"{'month_interval': 9, 'day_interval': 270}",Histopathology test (procedure)|Imaging (procedure),International Neuroblastoma Risk Group Staging System,T2a2,M1,Occult Carcinoma,FOLLOW_UP_433,TREATMENT_433,,DONOR_33,SYNTHETIC-1,Biochemical progression,,N0
"{'month_interval': 50, 'day_interval': 1500}",Partial remission,"{'month_interval': 47, 'day_interval': 1410}",Physical examination procedure (procedure)|Histopathology test (procedure),AJCC 6th edition,,MX,Stage C,FOLLOW_UP_434,TREATMENT_434,,DONOR_34,SYNTHETIC-1,Progression (liquid tumours),,N3a
"{'month_interval': 15, 'day_interval': 450}",Progression not otherwise specified,"{'month_interval': 9, 'day_interval': 270}",Imaging (procedure),International Neuroblastoma Staging System,,M1d(1),Stage IVAS,FOLLOW_UP_435,TREATMENT_435,,DONOR_35,SYNTHETIC-1,Biochemical progression,C02|C14,N0
"{'month_interval': 12, 'day_interval': 360}",Loco-regional progression,"{'month_interval': 50, 'day_interval': 1500}",,International Neuroblastoma Risk Group Staging System,T2a1,M1d,Stage IIIC2,FOLLOW_UP_436,TREATMENT_436,,DONOR_36,SYNTHETIC-1,Progression (liquid tumours),C13|C08,N1c
,No evidence of disease,"{'month_interval': 18, 'day_interval': 540}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),AJCC 7th edition,T4b(s),M1e,Stage IC,FOLLOW_UP_437,TREATMENT_437,,DONOR_37,SYNTHETIC-1,Biochemical progression,,
"{'month_interval': 41, 'day_interval': 1230}",Progression not otherwise specified,"{'month_interval': 25, 'day_interval': 750}",Histopathology test (procedure),Rai staging system,Tis pd,M1a(1),,FOLLOW_UP_438,TREATMENT_438,,DONOR_38,SYNTHETIC-1,Biochemical progression,C18|C17,N1b
"{'month_interval': 31, 'day_interval': 930}",Stable,"{'month_interval': 24, 'day_interval': 720}",,AJCC 7th edition,Tis(LCIS),M1d(1),Stage 1A,FOLLOW_UP_439,TREATMENT_439,,DONOR_39,SYNTHETIC-1,Progression (liquid tumours),,N3b
"{'month_interval': 4, 'day_interval': 120}",Stable,"{'month_interval': 42, 'day_interval': 1260}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),St Jude staging system,Tis,M1c(0),Stage IVB,FOLLOW_UP_440,TREATMENT_440,,DONOR_40,SYNTHETIC-1,Local recurrence and distant metastasis,C16|C07,
"{'month_interval': 39, 'day_interval': 1170}",Complete remission,"{'month_interval': 41, 'day_interval': 1230}",,AJCC 6th edition,T1b,,Stage IAE,FOLLOW_UP_441,TREATMENT_441,,DONOR_1,SYNTHETIC-1,Progression (liquid tumours),,
"{'month_interval': 10, 'day_interval': 300}",Relapse or recurrence,,Assessment of symptom control (procedure)|Imaging (procedure),St Jude staging system,T4a(s),M1b(1),,FOLLOW_UP_442,TREATMENT_442,,DONOR_2,SYNTHETIC-1,,,N1a
"{'month_interval': 4, 'day_interval': 120}",No evidence of disease,"{'month_interval': 13, 'day_interval': 390}",Assessment of symptom control (procedure),,T4,M1b(1),Stage IIBES,FOLLOW_UP_443,TREATMENT_443,,DONOR_3,SYNTHETIC-1,Biochemical progression,C19,N1mi
"{'month_interval': 49, 'day_interval': 1470}",Progression not otherwise specified,"{'month_interval': 46, 'day_interval': 1380}",Histopathology test (procedure),SEER staging system,T2a1,M0(i+),Stage IVS,FOLLOW_UP_444,TREATMENT_444,,DONOR_4,SYNTHETIC-1,Biochemical progression,C16,N1c
"{'month_interval': 40, 'day_interval': 1200}",Complete remission,"{'month_interval': 35, 'day_interval': 1050}",,Ann Arbor staging system,Tis(Paget's),M0,,FOLLOW_UP_445,TREATMENT_445,,DONOR_5,SYNTHETIC-1,Progression (liquid tumours),C20,N2a
"{'month_interval': 36, 'day_interval': 1080}",Relapse or recurrence,"{'month_interval': 4, 'day_interval': 120}",,Revised International staging system (RISS),T4,M1,Stage IVAS,FOLLOW_UP_446,TREATMENT_446,,DONOR_6,SYNTHETIC-1,,C02,N1b
"{'month_interval': 20, 'day_interval': 600}",Stable,,,,T1b1,,Stage IV,FOLLOW_UP_447,TREATMENT_447,,DONOR_7,SYNTHETIC-1,Local recurrence,,N3b
"{'month_interval': 5, 'day_interval': 150}",Distant progression,"{'month_interval': 9, 'day_interval': 270}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),FIGO staging system,T2b,M0(i+),Stage IE,FOLLOW_UP_448,TREATMENT_448,,DONOR_8,SYNTHETIC-1,Distant recurrence/metastasis,C06|C12,N0a (biopsy)
"{'month_interval': 17, 'day_interval': 510}",Relapse or recurrence,"{'month_interval': 11, 'day_interval': 330}",,FIGO staging system,,,Stage IVB,FOLLOW_UP_449,TREATMENT_449,,DONOR_9,SYNTHETIC-1,Local recurrence,C05|C12,N0(i+)
"{'month_interval': 11, 'day_interval': 330}",,"{'month_interval': 18, 'day_interval': 540}",Assessment of symptom control (procedure),,T3(m),,Stage IA3,FOLLOW_UP_450,TREATMENT_450,,DONOR_10,SYNTHETIC-1,,C07|C12,N4
"{'month_interval': 39, 'day_interval': 1170}",Complete remission,,Assessment of symptom control (procedure),St Jude staging system,T4b,MX,Stage IEA,FOLLOW_UP_451,TREATMENT_451,,DONOR_11,SYNTHETIC-1,Progression (liquid tumours),,N1a
"{'month_interval': 28, 'day_interval': 840}",Distant progression,"{'month_interval': 18, 'day_interval': 540}",,,,,In situ,FOLLOW_UP_452,TREATMENT_452,,DONOR_12,SYNTHETIC-1,Local recurrence,C06|C20,
"{'month_interval': 2, 'day_interval': 60}",Progression not otherwise specified,"{'month_interval': 43, 'day_interval': 1290}",Laboratory data interpretation (procedure)|Imaging (procedure),,T2a,M1c,Stage IIIE,FOLLOW_UP_453,TREATMENT_453,,DONOR_13,SYNTHETIC-1,Biochemical progression,,N2mi
"{'month_interval': 48, 'day_interval': 1440}",Distant progression,"{'month_interval': 19, 'day_interval': 570}",,Revised International staging system (RISS),T0,M0,Stage 4,FOLLOW_UP_454,TREATMENT_454,,DONOR_14,SYNTHETIC-1,Local recurrence and distant metastasis,C18|C17,N1mi
"{'month_interval': 36, 'day_interval': 1080}",Stable,,,,T4e,,Stage IVA2,FOLLOW_UP_455,TREATMENT_455,,DONOR_15,SYNTHETIC-1,,C15,
"{'month_interval': 40, 'day_interval': 1200}",,"{'month_interval': 17, 'day_interval': 510}",,Durie-Salmon staging system,Tis(LCIS),M1d(1),Stage IIID,FOLLOW_UP_456,TREATMENT_456,,DONOR_16,SYNTHETIC-1,Biochemical progression,,
,Loco-regional progression,"{'month_interval': 18, 'day_interval': 540}",Histopathology test (procedure)|Assessment of symptom control (procedure),Rai staging system,T2b,,Stage IA3,FOLLOW_UP_457,TREATMENT_457,,DONOR_17,SYNTHETIC-1,Biochemical progression,,N3c
"{'month_interval': 3, 'day_interval': 90}",Complete remission,"{'month_interval': 42, 'day_interval': 1260}",Tumor marker measurement (procedure),Ann Arbor staging system,T4b(s),M1a(1),Stage IIEA,FOLLOW_UP_458,TREATMENT_458,,DONOR_18,SYNTHETIC-1,Local recurrence,C05,
,Stable,"{'month_interval': 25, 'day_interval': 750}",,AJCC 8th edition,T2a2,,,FOLLOW_UP_459,TREATMENT_459,,DONOR_19,SYNTHETIC-1,Local recurrence,,N1a
"{'month_interval': 24, 'day_interval': 720}",Distant progression,,Physical examination procedure (procedure),International Neuroblastoma Staging System,Tis pd,M1c,,FOLLOW_UP_460,TREATMENT_460,,DONOR_20,SYNTHETIC-1,Local recurrence,C14,N0a
,Progression not otherwise specified,"{'month_interval': 44, 'day_interval': 1320}",Tumor marker measurement (procedure),International Neuroblastoma Staging System,T1b2,MX,Stage IIIBE,FOLLOW_UP_461,TREATMENT_461,,DONOR_21,SYNTHETIC-1,Distant recurrence/metastasis,C13|C04,N0(mol+)
"{'month_interval': 30, 'day_interval': 900}",Progression not otherwise specified,"{'month_interval': 15, 'day_interval': 450}",Histopathology test (procedure),Lugano staging system,T3d,M1a(0),Stage 1A,FOLLOW_UP_462,TREATMENT_462,,DONOR_22,SYNTHETIC-1,Biochemical progression,C12|C05,
,No evidence of disease,"{'month_interval': 40, 'day_interval': 1200}",Physical examination procedure (procedure),Lugano staging system,,M1d,Stage IIA2,FOLLOW_UP_463,TREATMENT_463,,DONOR_23,SYNTHETIC-1,Local recurrence,,N1mi
"{'month_interval': 22, 'day_interval': 660}",No evidence of disease,"{'month_interval': 5, 'day_interval': 150}",Assessment of symptom control (procedure)|Histopathology test (procedure),International Neuroblastoma Risk Group Staging System,T1mi,M1b,Stage IIBES,FOLLOW_UP_464,TREATMENT_464,,DONOR_24,SYNTHETIC-1,Local recurrence and distant metastasis,C16,
"{'month_interval': 25, 'day_interval': 750}",Progression not otherwise specified,"{'month_interval': 30, 'day_interval': 900}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,,M1,Stage A,FOLLOW_UP_465,TREATMENT_465,,DONOR_25,SYNTHETIC-1,,C08,N0(mol+)
"{'month_interval': 25, 'day_interval': 750}",Loco-regional progression,"{'month_interval': 2, 'day_interval': 60}",,FIGO staging system,T4b(s),M1,,FOLLOW_UP_466,TREATMENT_466,,DONOR_26,SYNTHETIC-1,,C10|C13,N2a
"{'month_interval': 34, 'day_interval': 1020}",,"{'month_interval': 10, 'day_interval': 300}",Imaging (procedure),St Jude staging system,T0,M1c(0),,FOLLOW_UP_467,TREATMENT_467,,DONOR_27,SYNTHETIC-1,Distant recurrence/metastasis,,N0
"{'month_interval': 1, 'day_interval': 30}",Distant progression,"{'month_interval': 15, 'day_interval': 450}",,AJCC 6th edition,T4a(m),M1c,Stage 0,FOLLOW_UP_468,TREATMENT_468,,DONOR_28,SYNTHETIC-1,Biochemical progression,,N2
"{'month_interval': 15, 'day_interval': 450}",,"{'month_interval': 47, 'day_interval': 1410}",,Ann Arbor staging system,T4b,,Stage 0is,FOLLOW_UP_469,TREATMENT_469,,DONOR_29,SYNTHETIC-1,Distant recurrence/metastasis,C13|C19,N0(i-)
"{'month_interval': 29, 'day_interval': 870}",Distant progression,"{'month_interval': 24, 'day_interval': 720}",,Binet staging system,T1c,M1b,Stage IIIA2,FOLLOW_UP_470,TREATMENT_470,,DONOR_30,SYNTHETIC-1,,C05|C10,
"{'month_interval': 49, 'day_interval': 1470}",Partial remission,"{'month_interval': 42, 'day_interval': 1260}",Imaging (procedure),AJCC 7th edition,T3(s),M1c,Stage IIIAES,FOLLOW_UP_471,TREATMENT_471,,DONOR_31,SYNTHETIC-1,Distant recurrence/metastasis,,N1a
"{'month_interval': 23, 'day_interval': 690}",,"{'month_interval': 49, 'day_interval': 1470}",Imaging (procedure)|Histopathology test (procedure),Durie-Salmon staging system,T3b,M1e,Stage IIIAE,FOLLOW_UP_472,TREATMENT_472,,DONOR_32,SYNTHETIC-1,Local recurrence and distant metastasis,C20|C11,N1mi
"{'month_interval': 18, 'day_interval': 540}",Progression not otherwise specified,"{'month_interval': 20, 'day_interval': 600}",,Rai staging system,,M1d(1),Stage IVBS,FOLLOW_UP_473,TREATMENT_473,,DONOR_33,SYNTHETIC-1,Biochemical progression,C11,N1mi
"{'month_interval': 1, 'day_interval': 30}",Partial remission,,,St Jude staging system,T2b,,Stage IIEA,FOLLOW_UP_474,TREATMENT_474,,DONOR_34,SYNTHETIC-1,Distant recurrence/metastasis,C18|C04,N0
"{'month_interval': 40, 'day_interval': 1200}",Progression not otherwise specified,"{'month_interval': 34, 'day_interval': 1020}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,Tis(LCIS),,Stage IIIC,FOLLOW_UP_475,TREATMENT_475,,DONOR_35,SYNTHETIC-1,Biochemical progression,,N3a
"{'month_interval': 6, 'day_interval': 180}",No evidence of disease,"{'month_interval': 9, 'day_interval': 270}",,Rai staging system,T1,M1d(0),,FOLLOW_UP_476,TREATMENT_476,,DONOR_36,SYNTHETIC-1,Local recurrence,C13|C11,N1
"{'month_interval': 32, 'day_interval': 960}",Partial remission,"{'month_interval': 24, 'day_interval': 720}",Imaging (procedure),,T1a2,M1c(1),Stage IVC,FOLLOW_UP_477,TREATMENT_477,,DONOR_37,SYNTHETIC-1,Progression (liquid tumours),,N3
"{'month_interval': 1, 'day_interval': 30}",Stable,,,SEER staging system,T2(m),M1b(0),Localized,FOLLOW_UP_478,TREATMENT_478,,DONOR_38,SYNTHETIC-1,Progression (liquid tumours),C15|C11,N1a
"{'month_interval': 33, 'day_interval': 990}",Partial remission,"{'month_interval': 12, 'day_interval': 360}",Imaging (procedure),Binet staging system,T4c,M1d(0),Stage IVES,FOLLOW_UP_479,TREATMENT_479,,DONOR_39,SYNTHETIC-1,Progression (liquid tumours),C17,N0b
"{'month_interval': 26, 'day_interval': 780}",No evidence of disease,"{'month_interval': 34, 'day_interval': 1020}",Physical examination procedure (procedure),Revised International staging system (RISS),T1a2,,Stage IAB,FOLLOW_UP_480,TREATMENT_480,,DONOR_40,SYNTHETIC-1,Local recurrence,C07|C06,N0(mol-)
"{'month_interval': 35, 'day_interval': 1050}",Loco-regional progression,"{'month_interval': 40, 'day_interval': 1200}",,FIGO staging system,,M1b(0),Stage 4S,FOLLOW_UP_481,TREATMENT_481,,DONOR_1,SYNTHETIC-1,,,N2mi
"{'month_interval': 36, 'day_interval': 1080}",Loco-regional progression,"{'month_interval': 42, 'day_interval': 1260}",Laboratory data interpretation (procedure),FIGO staging system,T1a(s),M0,,FOLLOW_UP_482,TREATMENT_482,,DONOR_2,SYNTHETIC-1,Local recurrence,,N2a
,Complete remission,"{'month_interval': 31, 'day_interval': 930}",,International Neuroblastoma Staging System,T1a,,,FOLLOW_UP_483,TREATMENT_483,,DONOR_3,SYNTHETIC-1,Local recurrence and distant metastasis,,NX
,Partial remission,,,Rai staging system,T3a,M1b,Stage IVA2,FOLLOW_UP_484,TREATMENT_484,,DONOR_4,SYNTHETIC-1,Distant recurrence/metastasis,C17|C05,
"{'month_interval': 20, 'day_interval': 600}",Partial remission,"{'month_interval': 44, 'day_interval': 1320}",Histopathology test (procedure),FIGO staging system,T3c,M1e,Stage IIA,FOLLOW_UP_485,TREATMENT_485,,DONOR_5,SYNTHETIC-1,Local recurrence,,N0a (biopsy)
"{'month_interval': 13, 'day_interval': 390}",Relapse or recurrence,"{'month_interval': 34, 'day_interval': 1020}",Laboratory data interpretation (procedure),Rai staging system,T0,M1e,Regionalized,FOLLOW_UP_486,TREATMENT_486,,DONOR_6,SYNTHETIC-1,Distant recurrence/metastasis,C19|C04,N4
"{'month_interval': 42, 'day_interval': 1260}",Distant progression,,Tumor marker measurement (procedure)|Assessment of symptom control (procedure),Binet staging system,Tis(Paget),M1c(1),Stage IIAS,FOLLOW_UP_487,TREATMENT_487,,DONOR_7,SYNTHETIC-1,Local recurrence,,
"{'month_interval': 4, 'day_interval': 120}",No evidence of disease,"{'month_interval': 49, 'day_interval': 1470}",,,Ta,M1a(0),Stage IA2,FOLLOW_UP_488,TREATMENT_488,,DONOR_8,SYNTHETIC-1,Local recurrence and distant metastasis,,
"{'month_interval': 30, 'day_interval': 900}",Distant progression,"{'month_interval': 44, 'day_interval': 1320}",,FIGO staging system,T2c,M0,Stage C,FOLLOW_UP_489,TREATMENT_489,,DONOR_9,SYNTHETIC-1,Biochemical progression,C03,N2c
"{'month_interval': 5, 'day_interval': 150}",No evidence of disease,"{'month_interval': 18, 'day_interval': 540}",Imaging (procedure)|Histopathology test (procedure),Lugano staging system,T1c,M1d,Stage IBE,FOLLOW_UP_490,TREATMENT_490,,DONOR_10,SYNTHETIC-1,Biochemical progression,,N3b
"{'month_interval': 42, 'day_interval': 1260}",Progression not otherwise specified,"{'month_interval': 17, 'day_interval': 510}",Imaging (procedure)|Tumor marker measurement (procedure),AJCC 8th edition,T3e,M1b(0),Stage IIIAE,FOLLOW_UP_491,TREATMENT_491,,DONOR_11,SYNTHETIC-1,Local recurrence and distant metastasis,C02,NX
"{'month_interval': 15, 'day_interval': 450}",Relapse or recurrence,"{'month_interval': 8, 'day_interval': 240}",,AJCC 8th edition,Tis,M1,Stage IVA,FOLLOW_UP_492,TREATMENT_492,,DONOR_12,SYNTHETIC-1,Distant recurrence/metastasis,,
"{'month_interval': 12, 'day_interval': 360}",Loco-regional progression,"{'month_interval': 29, 'day_interval': 870}",Tumor marker measurement (procedure)|Imaging (procedure),,T3c,M1b(0),Stage 2B,FOLLOW_UP_493,TREATMENT_493,,DONOR_13,SYNTHETIC-1,Biochemical progression,C10|C11,N0(mol-)
"{'month_interval': 11, 'day_interval': 330}",Partial remission,,Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,T1mi,,Occult Carcinoma,FOLLOW_UP_494,TREATMENT_494,,DONOR_14,SYNTHETIC-1,Progression (liquid tumours),C15,N2mi
"{'month_interval': 23, 'day_interval': 690}",Partial remission,"{'month_interval': 21, 'day_interval': 630}",,International Neuroblastoma Staging System,T3c,M1a,Stage 3,FOLLOW_UP_495,TREATMENT_495,,DONOR_15,SYNTHETIC-1,Distant recurrence/metastasis,C01,N1c
,Distant progression,"{'month_interval': 15, 'day_interval': 450}",Assessment of symptom control (procedure)|Physical examination procedure (procedure),International Neuroblastoma Risk Group Staging System,Ta,M1b(1),Stage IIE,FOLLOW_UP_496,TREATMENT_496,,DONOR_16,SYNTHETIC-1,Local recurrence,C08,N1b
"{'month_interval': 13, 'day_interval': 390}",No evidence of disease,"{'month_interval': 29, 'day_interval': 870}",Imaging (procedure),Rai staging system,T4a(s),M1b(0),Stage IIEB,FOLLOW_UP_497,TREATMENT_497,,DONOR_17,SYNTHETIC-1,Progression (liquid tumours),,N3c
"{'month_interval': 43, 'day_interval': 1290}",Stable,"{'month_interval': 41, 'day_interval': 1230}",Tumor marker measurement (procedure),Lugano staging system,T3,,Stage Ms,FOLLOW_UP_498,TREATMENT_498,,DONOR_18,SYNTHETIC-1,Progression (liquid tumours),,NX
"{'month_interval': 28, 'day_interval': 840}",Partial remission,,Tumor marker measurement (procedure)|Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,T2a1,M0(i+),Stage IIBS,FOLLOW_UP_499,TREATMENT_499,,DONOR_19,SYNTHETIC-1,Distant recurrence/metastasis,C17,N0(mol-)
"{'month_interval': 47, 'day_interval': 1410}",Partial remission,,,AJCC 8th edition,,M1c(1),Stage IVB,FOLLOW_UP_500,TREATMENT_500,,DONOR_20,SYNTHETIC-1,Progression (liquid tumours),,
"{'month_interval': 22, 'day_interval': 660}",Progression not otherwise specified,"{'month_interval': 3, 'day_interval': 90}",Assessment of symptom control (procedure)|Imaging (procedure),,T1b1,M1,Stage 4S,FOLLOW_UP_501,TREATMENT_501,,DONOR_21,SYNTHETIC-1,Local recurrence and distant metastasis,C08,NX
"{'month_interval': 3, 'day_interval': 90}",Relapse or recurrence,"{'month_interval': 25, 'day_interval': 750}",Assessment of symptom control (procedure)|Physical examination procedure (procedure),,T2b,M0,Stage IIBES,FOLLOW_UP_502,TREATMENT_502,,DONOR_22,SYNTHETIC-1,Local recurrence and distant metastasis,C20|C18,N2mi
"{'month_interval': 29, 'day_interval': 870}",Loco-regional progression,"{'month_interval': 50, 'day_interval': 1500}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Binet staging system,T1a1,M1c(0),Stage IC,FOLLOW_UP_503,TREATMENT_503,,DONOR_23,SYNTHETIC-1,Local recurrence,,N1a(sn)
"{'month_interval': 13, 'day_interval': 390}",Partial remission,"{'month_interval': 28, 'day_interval': 840}",,Rai staging system,Tis(DCIS),M0(i+),Occult Carcinoma,FOLLOW_UP_504,TREATMENT_504,,DONOR_24,SYNTHETIC-1,,C12|C03,
"{'month_interval': 42, 'day_interval': 1260}",Loco-regional progression,"{'month_interval': 8, 'day_interval': 240}",Tumor marker measurement (procedure),AJCC 6th edition,T1b(m),M1a(1),,FOLLOW_UP_505,TREATMENT_505,,DONOR_25,SYNTHETIC-1,Biochemical progression,C05,N2mi
,Stable,"{'month_interval': 49, 'day_interval': 1470}",Imaging (procedure),Ann Arbor staging system,Ta,M1c,Stage IIIS,FOLLOW_UP_506,TREATMENT_506,,DONOR_26,SYNTHETIC-1,Biochemical progression,C06,N1
"{'month_interval': 45, 'day_interval': 1350}",Complete remission,"{'month_interval': 3, 'day_interval': 90}",Laboratory data interpretation (procedure),Durie-Salmon staging system,T2a2,M1b(0),Stage 2B,FOLLOW_UP_507,TREATMENT_507,,DONOR_27,SYNTHETIC-1,Progression (liquid tumours),C16,N0(mol+)
"{'month_interval': 18, 'day_interval': 540}",Stable,,,FIGO staging system,Tis(LAMN),M1,Stage IIAE,FOLLOW_UP_508,TREATMENT_508,,DONOR_28,SYNTHETIC-1,Distant recurrence/metastasis,C17|C14,N4
"{'month_interval': 10, 'day_interval': 300}",Stable,"{'month_interval': 25, 'day_interval': 750}",,Rai staging system,,M0(i+),Stage IB2,FOLLOW_UP_509,TREATMENT_509,,DONOR_29,SYNTHETIC-1,Local recurrence,C14|C19,N2b
"{'month_interval': 29, 'day_interval': 870}",Relapse or recurrence,,,AJCC 8th edition,T1b(s),M1b(1),,FOLLOW_UP_510,TREATMENT_510,,DONOR_30,SYNTHETIC-1,Progression (liquid tumours),C03|C13,N0(i-)
"{'month_interval': 29, 'day_interval': 870}",Distant progression,,,Rai staging system,T2,M1b,Stage IIIB,FOLLOW_UP_511,TREATMENT_511,,DONOR_31,SYNTHETIC-1,,C16|C19,N1c
"{'month_interval': 10, 'day_interval': 300}",Partial remission,"{'month_interval': 13, 'day_interval': 390}",Histopathology test (procedure)|Imaging (procedure),International Neuroblastoma Risk Group Staging System,TX,M1d,,FOLLOW_UP_512,TREATMENT_512,,DONOR_32,SYNTHETIC-1,Local recurrence,C09,N3b
"{'month_interval': 8, 'day_interval': 240}",Stable,"{'month_interval': 12, 'day_interval': 360}",,Lugano staging system,Tis(Paget's),M1a(1),,FOLLOW_UP_513,TREATMENT_513,,DONOR_33,SYNTHETIC-1,Local recurrence,C03|C18,N2c
"{'month_interval': 15, 'day_interval': 450}",Loco-regional progression,"{'month_interval': 4, 'day_interval': 120}",Assessment of symptom control (procedure)|Imaging (procedure),AJCC 7th edition,T4b,,Stage 1A,FOLLOW_UP_514,TREATMENT_514,,DONOR_34,SYNTHETIC-1,Biochemical progression,C04,N1a(sn)
"{'month_interval': 32, 'day_interval': 960}",Partial remission,"{'month_interval': 46, 'day_interval': 1380}",,Rai staging system,T1d,M1b,Stage IVA1,FOLLOW_UP_515,TREATMENT_515,,DONOR_35,SYNTHETIC-1,Distant recurrence/metastasis,C07|C04,N0b (no biopsy)
"{'month_interval': 4, 'day_interval': 120}",Loco-regional progression,"{'month_interval': 23, 'day_interval': 690}",,AJCC 7th edition,T3,M1d(1),,FOLLOW_UP_516,TREATMENT_516,,DONOR_36,SYNTHETIC-1,Progression (liquid tumours),,
"{'month_interval': 46, 'day_interval': 1380}",No evidence of disease,"{'month_interval': 4, 'day_interval': 120}",Tumor marker measurement (procedure),International Neuroblastoma Staging System,T1mi,,,FOLLOW_UP_517,TREATMENT_517,,DONOR_37,SYNTHETIC-1,Biochemical progression,C20,N0(mol-)
"{'month_interval': 3, 'day_interval': 90}",Relapse or recurrence,"{'month_interval': 33, 'day_interval': 990}",Assessment of symptom control (procedure),AJCC 7th edition,T1b2,M1b,Stage IVA,FOLLOW_UP_518,TREATMENT_518,,DONOR_38,SYNTHETIC-1,Local recurrence,C01|C02,
"{'month_interval': 37, 'day_interval': 1110}",Distant progression,"{'month_interval': 4, 'day_interval': 120}",,FIGO staging system,T4c,M1a,,FOLLOW_UP_519,TREATMENT_519,,DONOR_39,SYNTHETIC-1,Distant recurrence/metastasis,C17|C18,N1b
,Relapse or recurrence,,,International Neuroblastoma Risk Group Staging System,,M1c(1),Stage IIBE,FOLLOW_UP_520,TREATMENT_520,,DONOR_40,SYNTHETIC-1,Distant recurrence/metastasis,C04|C15,N0b
"{'month_interval': 14, 'day_interval': 420}",Loco-regional progression,"{'month_interval': 47, 'day_interval': 1410}",,AJCC 8th edition,T2a2,M1a,Stage IIBES,FOLLOW_UP_521,TREATMENT_521,,DONOR_1,SYNTHETIC-1,Progression (liquid tumours),,N0(mol+)
"{'month_interval': 37, 'day_interval': 1110}",Distant progression,,,SEER staging system,Tis pd,M1d,Stage IB1,FOLLOW_UP_522,TREATMENT_522,,DONOR_2,SYNTHETIC-1,Progression (liquid tumours),,N3b
"{'month_interval': 1, 'day_interval': 30}",Relapse or recurrence,,,Binet staging system,T3(s),M1a,Stage A,FOLLOW_UP_523,TREATMENT_523,,DONOR_3,SYNTHETIC-1,Biochemical progression,C09|C18,
,Loco-regional progression,"{'month_interval': 25, 'day_interval': 750}",Imaging (procedure),Durie-Salmon staging system,T4e,,Stage IEB,FOLLOW_UP_524,TREATMENT_524,,DONOR_4,SYNTHETIC-1,Local recurrence and distant metastasis,,N0b
,Relapse or recurrence,"{'month_interval': 37, 'day_interval': 1110}",Assessment of symptom control (procedure)|Histopathology test (procedure),Binet staging system,T4e,M1b(1),Stage 1B,FOLLOW_UP_525,TREATMENT_525,,DONOR_5,SYNTHETIC-1,Local recurrence and distant metastasis,,N0a
"{'month_interval': 3, 'day_interval': 90}",No evidence of disease,"{'month_interval': 26, 'day_interval': 780}",,Revised International staging system (RISS),TX,M1c,Stage IIBS,FOLLOW_UP_526,TREATMENT_526,,DONOR_6,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(i-)
"{'month_interval': 27, 'day_interval': 810}",Progression not otherwise specified,"{'month_interval': 7, 'day_interval': 210}",Assessment of symptom control (procedure)|Imaging (procedure),Lugano staging system,T1b(s),M1e,Stage IVA2,FOLLOW_UP_527,TREATMENT_527,,DONOR_7,SYNTHETIC-1,,C09,N0b (no biopsy)
"{'month_interval': 48, 'day_interval': 1440}",Stable,"{'month_interval': 29, 'day_interval': 870}",Assessment of symptom control (procedure),AJCC 7th edition,T3(m),M0(i+),,FOLLOW_UP_528,TREATMENT_528,,DONOR_8,SYNTHETIC-1,Local recurrence,C05|C02,N0(mol+)
"{'month_interval': 38, 'day_interval': 1140}",Relapse or recurrence,"{'month_interval': 36, 'day_interval': 1080}",Imaging (procedure)|Assessment of symptom control (procedure),Revised International staging system (RISS),,M1d(1),Stage 1B,FOLLOW_UP_529,TREATMENT_529,,DONOR_9,SYNTHETIC-1,Biochemical progression,C07|C14,N1c
"{'month_interval': 26, 'day_interval': 780}",Complete remission,"{'month_interval': 29, 'day_interval': 870}",Imaging (procedure)|Assessment of symptom control (procedure),Durie-Salmon staging system,T1,M0(i+),Stage IBE,FOLLOW_UP_530,TREATMENT_530,,DONOR_10,SYNTHETIC-1,Local recurrence,C10,N0(mol-)
,Complete remission,"{'month_interval': 5, 'day_interval': 150}",Imaging (procedure)|Assessment of symptom control (procedure),Revised International staging system (RISS),T2a2,,Stage IIIBS,FOLLOW_UP_531,TREATMENT_531,,DONOR_11,SYNTHETIC-1,Distant recurrence/metastasis,C20,N1mi
"{'month_interval': 29, 'day_interval': 870}",Stable,"{'month_interval': 47, 'day_interval': 1410}",Physical examination procedure (procedure),AJCC 8th edition,,MX,Stage Ms,FOLLOW_UP_532,TREATMENT_532,,DONOR_12,SYNTHETIC-1,Distant recurrence/metastasis,C02,N2
"{'month_interval': 24, 'day_interval': 720}",Loco-regional progression,,,Binet staging system,T3b,M0(i+),Stage IVB,FOLLOW_UP_533,TREATMENT_533,,DONOR_13,SYNTHETIC-1,Biochemical progression,C02,N2a
,Complete remission,"{'month_interval': 22, 'day_interval': 660}",,Rai staging system,T1d,M1b,,FOLLOW_UP_534,TREATMENT_534,,DONOR_14,SYNTHETIC-1,Biochemical progression,C19|C13,N3c
"{'month_interval': 9, 'day_interval': 270}",Complete remission,"{'month_interval': 45, 'day_interval': 1350}",,AJCC 7th edition,T3c,M1e,Stage IIES,FOLLOW_UP_535,TREATMENT_535,,DONOR_15,SYNTHETIC-1,Distant recurrence/metastasis,,N3
"{'month_interval': 33, 'day_interval': 990}",Distant progression,"{'month_interval': 28, 'day_interval': 840}",,Lugano staging system,T1a2,,,FOLLOW_UP_536,TREATMENT_536,,DONOR_16,SYNTHETIC-1,,C07|C10,N1
"{'month_interval': 28, 'day_interval': 840}",Relapse or recurrence,"{'month_interval': 40, 'day_interval': 1200}",,International Neuroblastoma Risk Group Staging System,,M1c(0),Stage C,FOLLOW_UP_537,TREATMENT_537,,DONOR_17,SYNTHETIC-1,,C03,
"{'month_interval': 3, 'day_interval': 90}",Distant progression,"{'month_interval': 13, 'day_interval': 390}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),Durie-Salmon staging system,T1a,M1b(0),Stage IIAE,FOLLOW_UP_538,TREATMENT_538,,DONOR_18,SYNTHETIC-1,Local recurrence and distant metastasis,C19|C03,
"{'month_interval': 8, 'day_interval': 240}",Stable,"{'month_interval': 20, 'day_interval': 600}",Histopathology test (procedure)|Physical examination procedure (procedure),Ann Arbor staging system,,M1c,Regionalized,FOLLOW_UP_539,TREATMENT_539,,DONOR_19,SYNTHETIC-1,Local recurrence and distant metastasis,,N0
"{'month_interval': 9, 'day_interval': 270}",Progression not otherwise specified,"{'month_interval': 13, 'day_interval': 390}",,Lugano staging system,,M1b,Localized,FOLLOW_UP_540,TREATMENT_540,,DONOR_20,SYNTHETIC-1,Local recurrence,C10,N0a (biopsy)
"{'month_interval': 19, 'day_interval': 570}",Complete remission,"{'month_interval': 7, 'day_interval': 210}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),Binet staging system,,M1c,Stage IAES,FOLLOW_UP_541,TREATMENT_541,,DONOR_21,SYNTHETIC-1,Local recurrence and distant metastasis,C17,N3a
,Partial remission,"{'month_interval': 47, 'day_interval': 1410}",Physical examination procedure (procedure)|Histopathology test (procedure),Durie-Salmon staging system,T1a(m),M1b(0),Stage IIIAS,FOLLOW_UP_542,TREATMENT_542,,DONOR_22,SYNTHETIC-1,Progression (liquid tumours),C13|C06,NX
"{'month_interval': 7, 'day_interval': 210}",Distant progression,"{'month_interval': 31, 'day_interval': 930}",Assessment of symptom control (procedure),,,M1b(1),Stage 1B,FOLLOW_UP_543,TREATMENT_543,,DONOR_23,SYNTHETIC-1,Biochemical progression,C13|C07,N1c
"{'month_interval': 16, 'day_interval': 480}",Partial remission,"{'month_interval': 8, 'day_interval': 240}",Laboratory data interpretation (procedure),FIGO staging system,Tis(LAMN),,Localized,FOLLOW_UP_544,TREATMENT_544,,DONOR_24,SYNTHETIC-1,Local recurrence,C07|C01,N1c
,Stable,"{'month_interval': 46, 'day_interval': 1380}",,,,M1d(1),,FOLLOW_UP_545,TREATMENT_545,,DONOR_25,SYNTHETIC-1,Progression (liquid tumours),C06,
"{'month_interval': 32, 'day_interval': 960}",No evidence of disease,"{'month_interval': 9, 'day_interval': 270}",Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,T1a1,M1d,Stage III,FOLLOW_UP_546,TREATMENT_546,,DONOR_26,SYNTHETIC-1,,,N3b
"{'month_interval': 20, 'day_interval': 600}",Progression not otherwise specified,"{'month_interval': 20, 'day_interval': 600}",Imaging (procedure),AJCC 7th edition,T1b(m),M1b,Localized,FOLLOW_UP_547,TREATMENT_547,,DONOR_27,SYNTHETIC-1,Local recurrence,,N0b (no biopsy)
"{'month_interval': 15, 'day_interval': 450}",Complete remission,"{'month_interval': 46, 'day_interval': 1380}",Imaging (procedure)|Tumor marker measurement (procedure),St Jude staging system,T2a1,M1b(0),Stage IVES,FOLLOW_UP_548,TREATMENT_548,,DONOR_28,SYNTHETIC-1,Biochemical progression,,N0
,Progression not otherwise specified,,,Revised International staging system (RISS),T2(s),M1a,Stage IBS,FOLLOW_UP_549,TREATMENT_549,,DONOR_29,SYNTHETIC-1,Distant recurrence/metastasis,,N1mi
"{'month_interval': 33, 'day_interval': 990}",Distant progression,"{'month_interval': 24, 'day_interval': 720}",Laboratory data interpretation (procedure),AJCC 7th edition,T4,M0,,FOLLOW_UP_550,TREATMENT_550,,DONOR_30,SYNTHETIC-1,,,N0b
"{'month_interval': 45, 'day_interval': 1350}",Relapse or recurrence,"{'month_interval': 24, 'day_interval': 720}",Laboratory data interpretation (procedure)|Tumor marker measurement (procedure),,T3(m),M1c(0),Stage IIIAES,FOLLOW_UP_551,TREATMENT_551,,DONOR_31,SYNTHETIC-1,Progression (liquid tumours),,N2mi
"{'month_interval': 6, 'day_interval': 180}",Relapse or recurrence,"{'month_interval': 5, 'day_interval': 150}",,AJCC 8th edition,T1a(m),M1c(1),Stage IIIA1,FOLLOW_UP_552,TREATMENT_552,,DONOR_32,SYNTHETIC-1,Local recurrence and distant metastasis,,N0a
"{'month_interval': 11, 'day_interval': 330}",Progression not otherwise specified,"{'month_interval': 40, 'day_interval': 1200}",Laboratory data interpretation (procedure),AJCC 6th edition,T3,M1a(0),Stage C,FOLLOW_UP_553,TREATMENT_553,,DONOR_33,SYNTHETIC-1,Distant recurrence/metastasis,,N2mi
"{'month_interval': 28, 'day_interval': 840}",Loco-regional progression,"{'month_interval': 18, 'day_interval': 540}",,Lugano staging system,T4b,M1c(0),Stage IVA,FOLLOW_UP_554,TREATMENT_554,,DONOR_34,SYNTHETIC-1,Distant recurrence/metastasis,C08,
"{'month_interval': 42, 'day_interval': 1260}",Progression not otherwise specified,"{'month_interval': 5, 'day_interval': 150}",,,T1b(m),,Stage 4S,FOLLOW_UP_555,TREATMENT_555,,DONOR_35,SYNTHETIC-1,Local recurrence and distant metastasis,C01|C16,N1c
"{'month_interval': 8, 'day_interval': 240}",Complete remission,"{'month_interval': 6, 'day_interval': 180}",Imaging (procedure),AJCC 6th edition,T3(m),M1d,Stage IVC,FOLLOW_UP_556,TREATMENT_556,,DONOR_36,SYNTHETIC-1,Local recurrence,C12,N3b
"{'month_interval': 3, 'day_interval': 90}",Partial remission,,Tumor marker measurement (procedure)|Imaging (procedure),St Jude staging system,T4b(s),M1d(0),Stage IA2,FOLLOW_UP_557,TREATMENT_557,,DONOR_37,SYNTHETIC-1,Distant recurrence/metastasis,C18,N2b
"{'month_interval': 20, 'day_interval': 600}",Partial remission,"{'month_interval': 11, 'day_interval': 330}",Histopathology test (procedure),St Jude staging system,,,Stage 1A,FOLLOW_UP_558,TREATMENT_558,,DONOR_38,SYNTHETIC-1,Distant recurrence/metastasis,,N2a
"{'month_interval': 16, 'day_interval': 480}",Complete remission,"{'month_interval': 16, 'day_interval': 480}",,SEER staging system,T2a1,M1c,Stage IAE,FOLLOW_UP_559,TREATMENT_559,,DONOR_39,SYNTHETIC-1,Local recurrence and distant metastasis,C13|C12,
,Stable,"{'month_interval': 47, 'day_interval': 1410}",,Binet staging system,,M1e,Stage II,FOLLOW_UP_560,TREATMENT_560,,DONOR_40,SYNTHETIC-1,,,N1b
"{'month_interval': 11, 'day_interval': 330}",Loco-regional progression,"{'month_interval': 31, 'day_interval': 930}",Histopathology test (procedure)|Imaging (procedure),AJCC 7th edition,Tis(LCIS),M1c(1),,FOLLOW_UP_561,TREATMENT_561,,DONOR_1,SYNTHETIC-1,Local recurrence,C14|C19,N3
"{'month_interval': 37, 'day_interval': 1110}",,"{'month_interval': 38, 'day_interval': 1140}",Physical examination procedure (procedure),Durie-Salmon staging system,T2(m),M1b,Stage IVES,FOLLOW_UP_562,TREATMENT_562,,DONOR_2,SYNTHETIC-1,Progression (liquid tumours),,N2
"{'month_interval': 26, 'day_interval': 780}",Stable,"{'month_interval': 2, 'day_interval': 60}",Physical examination procedure (procedure),St Jude staging system,T4a(s),M1c,Stage II bulky,FOLLOW_UP_563,TREATMENT_563,,DONOR_3,SYNTHETIC-1,Biochemical progression,,N2c
"{'month_interval': 40, 'day_interval': 1200}",Complete remission,"{'month_interval': 13, 'day_interval': 390}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),Binet staging system,T3b,M1a(1),Stage IIIBE,FOLLOW_UP_564,TREATMENT_564,,DONOR_4,SYNTHETIC-1,Distant recurrence/metastasis,C07|C13,N3a
"{'month_interval': 17, 'day_interval': 510}",Complete remission,"{'month_interval': 48, 'day_interval': 1440}",Assessment of symptom control (procedure)|Histopathology test (procedure),Revised International staging system (RISS),T3a,M1d(1),Stage IVAS,FOLLOW_UP_565,TREATMENT_565,,DONOR_5,SYNTHETIC-1,Biochemical progression,C04,N2b
"{'month_interval': 21, 'day_interval': 630}",Progression not otherwise specified,"{'month_interval': 25, 'day_interval': 750}",Physical examination procedure (procedure)|Imaging (procedure),Binet staging system,,M1c(0),Stage IIAE,FOLLOW_UP_566,TREATMENT_566,,DONOR_6,SYNTHETIC-1,,,NX
"{'month_interval': 22, 'day_interval': 660}",Partial remission,"{'month_interval': 47, 'day_interval': 1410}",Laboratory data interpretation (procedure),International Neuroblastoma Staging System,,,Stage IIIBS,FOLLOW_UP_567,TREATMENT_567,,DONOR_7,SYNTHETIC-1,Local recurrence and distant metastasis,,
"{'month_interval': 23, 'day_interval': 690}",Distant progression,"{'month_interval': 46, 'day_interval': 1380}",Histopathology test (procedure)|Laboratory data interpretation (procedure),,T1a,M1d(1),Stage IIBS,FOLLOW_UP_568,TREATMENT_568,,DONOR_8,SYNTHETIC-1,Local recurrence and distant metastasis,C01|C13,N1c
"{'month_interval': 22, 'day_interval': 660}",Progression not otherwise specified,"{'month_interval': 12, 'day_interval': 360}",Imaging (procedure),AJCC 7th edition,Tis pd,,Stage IIS,FOLLOW_UP_569,TREATMENT_569,,DONOR_9,SYNTHETIC-1,Local recurrence,C15|C07,N1c
"{'month_interval': 13, 'day_interval': 390}",Stable,"{'month_interval': 11, 'day_interval': 330}",,Revised International staging system (RISS),T2c,M1a(1),Stage 1A,FOLLOW_UP_570,TREATMENT_570,,DONOR_10,SYNTHETIC-1,Distant recurrence/metastasis,,N2a
"{'month_interval': 14, 'day_interval': 420}",Partial remission,"{'month_interval': 16, 'day_interval': 480}",Tumor marker measurement (procedure),St Jude staging system,Tis(Paget's),M1d(0),Stage IVE,FOLLOW_UP_571,TREATMENT_571,,DONOR_11,SYNTHETIC-1,Progression (liquid tumours),C11,N1a
,Stable,,,International Neuroblastoma Risk Group Staging System,T1b(s),M1d(1),Stage IIBS,FOLLOW_UP_572,TREATMENT_572,,DONOR_12,SYNTHETIC-1,Distant recurrence/metastasis,,N3
"{'month_interval': 28, 'day_interval': 840}",Complete remission,"{'month_interval': 22, 'day_interval': 660}",Tumor marker measurement (procedure),International Neuroblastoma Staging System,T4b(s),M0(i+),Stage IVS,FOLLOW_UP_573,TREATMENT_573,,DONOR_13,SYNTHETIC-1,Local recurrence and distant metastasis,C18,N3c
"{'month_interval': 32, 'day_interval': 960}",Complete remission,"{'month_interval': 5, 'day_interval': 150}",,FIGO staging system,,,Stage IVBS,FOLLOW_UP_574,TREATMENT_574,,DONOR_14,SYNTHETIC-1,Biochemical progression,,N1
"{'month_interval': 25, 'day_interval': 750}",Loco-regional progression,,Physical examination procedure (procedure)|Tumor marker measurement (procedure),Binet staging system,T1b2,M1b,Stage IVA,FOLLOW_UP_575,TREATMENT_575,,DONOR_15,SYNTHETIC-1,Distant recurrence/metastasis,C11|C20,N0b
"{'month_interval': 37, 'day_interval': 1110}",Stable,,,FIGO staging system,Tis pu,M1a,Stage M,FOLLOW_UP_576,TREATMENT_576,,DONOR_16,SYNTHETIC-1,Distant recurrence/metastasis,C14,N0(i+)
"{'month_interval': 37, 'day_interval': 1110}",No evidence of disease,"{'month_interval': 35, 'day_interval': 1050}",,,T1b(m),M1a,Stage IIIAE,FOLLOW_UP_577,TREATMENT_577,,DONOR_17,SYNTHETIC-1,Local recurrence and distant metastasis,C14,N2mi
"{'month_interval': 8, 'day_interval': 240}",Distant progression,"{'month_interval': 47, 'day_interval': 1410}",Assessment of symptom control (procedure)|Histopathology test (procedure),Binet staging system,Tis(DCIS),M1c,Stage 0is,FOLLOW_UP_578,TREATMENT_578,,DONOR_18,SYNTHETIC-1,Distant recurrence/metastasis,C10,N3b
"{'month_interval': 26, 'day_interval': 780}",Loco-regional progression,"{'month_interval': 30, 'day_interval': 900}",,FIGO staging system,T1a,,Stage IB2,FOLLOW_UP_579,TREATMENT_579,,DONOR_19,SYNTHETIC-1,,C18,N0(mol+)
"{'month_interval': 17, 'day_interval': 510}",Relapse or recurrence,"{'month_interval': 28, 'day_interval': 840}",Imaging (procedure)|Assessment of symptom control (procedure),Rai staging system,T4a,,Stage M,FOLLOW_UP_580,TREATMENT_580,,DONOR_20,SYNTHETIC-1,Distant recurrence/metastasis,C12,
"{'month_interval': 39, 'day_interval': 1170}",No evidence of disease,,Histopathology test (procedure),Lugano staging system,T2a1,,Stage IIS,FOLLOW_UP_581,TREATMENT_581,,DONOR_21,SYNTHETIC-1,Biochemical progression,C05,N3c
"{'month_interval': 8, 'day_interval': 240}",,,,St Jude staging system,Tis,M1b(1),Stage 0is,FOLLOW_UP_582,TREATMENT_582,,DONOR_22,SYNTHETIC-1,Local recurrence and distant metastasis,,N3a
"{'month_interval': 15, 'day_interval': 450}",Loco-regional progression,"{'month_interval': 14, 'day_interval': 420}",Histopathology test (procedure),AJCC 8th edition,Ta,M1c(0),Stage IVBES,FOLLOW_UP_583,TREATMENT_583,,DONOR_23,SYNTHETIC-1,Progression (liquid tumours),,N1a(sn)
,Partial remission,"{'month_interval': 28, 'day_interval': 840}",,Rai staging system,,M1a(1),Stage IVAS,FOLLOW_UP_584,TREATMENT_584,,DONOR_24,SYNTHETIC-1,Biochemical progression,,N0b (no biopsy)
"{'month_interval': 25, 'day_interval': 750}",,"{'month_interval': 48, 'day_interval': 1440}",Histopathology test (procedure),AJCC 8th edition,,M1c(1),Stage 2B,FOLLOW_UP_585,TREATMENT_585,,DONOR_25,SYNTHETIC-1,,,
"{'month_interval': 42, 'day_interval': 1260}",Relapse or recurrence,"{'month_interval': 37, 'day_interval': 1110}",,International Neuroblastoma Staging System,T4e,M1,Stage IIIA2,FOLLOW_UP_586,TREATMENT_586,,DONOR_26,SYNTHETIC-1,Distant recurrence/metastasis,,N0
"{'month_interval': 29, 'day_interval': 870}",Distant progression,"{'month_interval': 3, 'day_interval': 90}",Tumor marker measurement (procedure)|Histopathology test (procedure),Ann Arbor staging system,,M1a(0),Stage IAS,FOLLOW_UP_587,TREATMENT_587,,DONOR_27,SYNTHETIC-1,Progression (liquid tumours),C11,N0(mol+)
"{'month_interval': 30, 'day_interval': 900}",Partial remission,"{'month_interval': 9, 'day_interval': 270}",Tumor marker measurement (procedure),International Neuroblastoma Staging System,T1b,M1e,Stage IC,FOLLOW_UP_588,TREATMENT_588,,DONOR_28,SYNTHETIC-1,Local recurrence,C16|C11,N4
"{'month_interval': 11, 'day_interval': 330}",Loco-regional progression,,Assessment of symptom control (procedure)|Physical examination procedure (procedure),Binet staging system,,,Stage IAE,FOLLOW_UP_589,TREATMENT_589,,DONOR_29,SYNTHETIC-1,Progression (liquid tumours),C05|C04,
"{'month_interval': 24, 'day_interval': 720}",No evidence of disease,"{'month_interval': 14, 'day_interval': 420}",,FIGO staging system,,M0,Localized,FOLLOW_UP_590,TREATMENT_590,,DONOR_30,SYNTHETIC-1,Local recurrence and distant metastasis,,N2a
"{'month_interval': 45, 'day_interval': 1350}",,"{'month_interval': 20, 'day_interval': 600}",,AJCC 7th edition,T2a,,Stage IIB,FOLLOW_UP_591,TREATMENT_591,,DONOR_31,SYNTHETIC-1,Local recurrence,,N2
"{'month_interval': 26, 'day_interval': 780}",Progression not otherwise specified,"{'month_interval': 30, 'day_interval': 900}",Imaging (procedure),Revised International staging system (RISS),Tis(DCIS),M1a,Stage IIIA,FOLLOW_UP_592,TREATMENT_592,,DONOR_32,SYNTHETIC-1,Distant recurrence/metastasis,C13|C18,N0a (biopsy)
"{'month_interval': 10, 'day_interval': 300}",Relapse or recurrence,"{'month_interval': 22, 'day_interval': 660}",Tumor marker measurement (procedure)|Imaging (procedure),International Neuroblastoma Staging System,,M1a(1),Stage IIAES,FOLLOW_UP_593,TREATMENT_593,,DONOR_33,SYNTHETIC-1,,C13|C02,N2mi
"{'month_interval': 22, 'day_interval': 660}",,"{'month_interval': 41, 'day_interval': 1230}",,,,,,FOLLOW_UP_594,TREATMENT_594,,DONOR_34,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(i+)
"{'month_interval': 6, 'day_interval': 180}",Relapse or recurrence,"{'month_interval': 39, 'day_interval': 1170}",,Revised International staging system (RISS),,,Stage IVA1,FOLLOW_UP_595,TREATMENT_595,,DONOR_35,SYNTHETIC-1,Biochemical progression,,NX
"{'month_interval': 2, 'day_interval': 60}",Progression not otherwise specified,"{'month_interval': 23, 'day_interval': 690}",Tumor marker measurement (procedure),,T1a,M0(i+),Localized,FOLLOW_UP_596,TREATMENT_596,,DONOR_36,SYNTHETIC-1,Local recurrence and distant metastasis,C07|C19,N4
"{'month_interval': 30, 'day_interval': 900}",,"{'month_interval': 40, 'day_interval': 1200}",,St Jude staging system,T1,M1,Stage L2,FOLLOW_UP_597,TREATMENT_597,,DONOR_37,SYNTHETIC-1,Distant recurrence/metastasis,C01|C06,N2c
"{'month_interval': 37, 'day_interval': 1110}",Partial remission,"{'month_interval': 28, 'day_interval': 840}",,Durie-Salmon staging system,T2,M1,Stage IIAES,FOLLOW_UP_598,TREATMENT_598,,DONOR_38,SYNTHETIC-1,Local recurrence and distant metastasis,,N3
"{'month_interval': 3, 'day_interval': 90}",Complete remission,"{'month_interval': 3, 'day_interval': 90}",Tumor marker measurement (procedure)|Histopathology test (procedure),,T4a(s),M1a(1),Stage IVAS,FOLLOW_UP_599,TREATMENT_599,,DONOR_39,SYNTHETIC-1,,C18|C07,N2mi
"{'month_interval': 1, 'day_interval': 30}",Complete remission,"{'month_interval': 4, 'day_interval': 120}",,Ann Arbor staging system,,,Stage IE,FOLLOW_UP_600,TREATMENT_600,,DONOR_40,SYNTHETIC-1,Local recurrence and distant metastasis,C12,N0a
"{'month_interval': 13, 'day_interval': 390}",Loco-regional progression,"{'month_interval': 5, 'day_interval': 150}",Laboratory data interpretation (procedure)|Histopathology test (procedure),Binet staging system,Tis pd,MX,Stage IA3,FOLLOW_UP_601,TREATMENT_601,,DONOR_1,SYNTHETIC-1,,,N2b
"{'month_interval': 28, 'day_interval': 840}",Stable,"{'month_interval': 34, 'day_interval': 1020}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),St Jude staging system,Tis,M1d(1),,FOLLOW_UP_602,TREATMENT_602,,DONOR_2,SYNTHETIC-1,Biochemical progression,C09,N3
"{'month_interval': 1, 'day_interval': 30}",Relapse or recurrence,"{'month_interval': 21, 'day_interval': 630}",Histopathology test (procedure)|Physical examination procedure (procedure),,T2(s),M1d(0),Stage 1,FOLLOW_UP_603,TREATMENT_603,,DONOR_3,SYNTHETIC-1,Local recurrence,C15|C07,N3b
"{'month_interval': 27, 'day_interval': 810}",Relapse or recurrence,"{'month_interval': 45, 'day_interval': 1350}",Histopathology test (procedure),,T1b,M1d(0),Stage IIIAS,FOLLOW_UP_604,TREATMENT_604,,DONOR_4,SYNTHETIC-1,Local recurrence,C18,N2
"{'month_interval': 19, 'day_interval': 570}",Relapse or recurrence,"{'month_interval': 18, 'day_interval': 540}",Histopathology test (procedure),Revised International staging system (RISS),T4b(s),M1c(0),Stage IE,FOLLOW_UP_605,TREATMENT_605,,DONOR_5,SYNTHETIC-1,Progression (liquid tumours),,N3a
"{'month_interval': 42, 'day_interval': 1260}",Partial remission,,Laboratory data interpretation (procedure)|Physical examination procedure (procedure),,T1b1,M1c(1),,FOLLOW_UP_606,TREATMENT_606,,DONOR_6,SYNTHETIC-1,Distant recurrence/metastasis,,N1b
"{'month_interval': 43, 'day_interval': 1290}",Progression not otherwise specified,,Physical examination procedure (procedure)|Tumor marker measurement (procedure),Revised International staging system (RISS),T3(m),,Stage IIS,FOLLOW_UP_607,TREATMENT_607,,DONOR_7,SYNTHETIC-1,Distant recurrence/metastasis,,NX
"{'month_interval': 11, 'day_interval': 330}",Partial remission,"{'month_interval': 5, 'day_interval': 150}",Imaging (procedure),,T4a,M0,Stage IC,FOLLOW_UP_608,TREATMENT_608,,DONOR_8,SYNTHETIC-1,Local recurrence,C19|C12,N0b
"{'month_interval': 26, 'day_interval': 780}",No evidence of disease,,Histopathology test (procedure),AJCC 6th edition,,M0(i+),,FOLLOW_UP_609,TREATMENT_609,,DONOR_9,SYNTHETIC-1,Local recurrence,C11|C20,N1mi
"{'month_interval': 47, 'day_interval': 1410}",No evidence of disease,,,SEER staging system,T4a(m),M1a(1),Stage IIIE,FOLLOW_UP_610,TREATMENT_610,,DONOR_10,SYNTHETIC-1,Progression (liquid tumours),C12,N3
"{'month_interval': 7, 'day_interval': 210}",Complete remission,"{'month_interval': 1, 'day_interval': 30}",Assessment of symptom control (procedure),Lugano staging system,T3e,M1b,,FOLLOW_UP_611,TREATMENT_611,,DONOR_11,SYNTHETIC-1,,,N0
"{'month_interval': 23, 'day_interval': 690}",Relapse or recurrence,"{'month_interval': 33, 'day_interval': 990}",,,T1d,M1e,Occult Carcinoma,FOLLOW_UP_612,TREATMENT_612,,DONOR_12,SYNTHETIC-1,Local recurrence,,N0(i-)
"{'month_interval': 4, 'day_interval': 120}",Partial remission,"{'month_interval': 24, 'day_interval': 720}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Staging System,T2a,,Stage IEB,FOLLOW_UP_613,TREATMENT_613,,DONOR_13,SYNTHETIC-1,Local recurrence,C04,
"{'month_interval': 26, 'day_interval': 780}",Stable,"{'month_interval': 9, 'day_interval': 270}",,SEER staging system,T1mi,M1a(1),,FOLLOW_UP_614,TREATMENT_614,,DONOR_14,SYNTHETIC-1,Local recurrence and distant metastasis,C08,N0a (biopsy)
"{'month_interval': 13, 'day_interval': 390}",Stable,,Imaging (procedure),,T4c,M1a(0),Stage IVBES,FOLLOW_UP_615,TREATMENT_615,,DONOR_15,SYNTHETIC-1,Distant recurrence/metastasis,C06|C08,
"{'month_interval': 22, 'day_interval': 660}",No evidence of disease,"{'month_interval': 20, 'day_interval': 600}",,AJCC 7th edition,Tis,M1a,,FOLLOW_UP_616,TREATMENT_616,,DONOR_16,SYNTHETIC-1,Biochemical progression,C18,N0a (biopsy)
"{'month_interval': 40, 'day_interval': 1200}",Stable,"{'month_interval': 18, 'day_interval': 540}",Histopathology test (procedure),Lugano staging system,,M1e,,FOLLOW_UP_617,TREATMENT_617,,DONOR_17,SYNTHETIC-1,Local recurrence and distant metastasis,,N0(mol-)
,Relapse or recurrence,"{'month_interval': 29, 'day_interval': 870}",Histopathology test (procedure)|Imaging (procedure),Binet staging system,T4d,M1,Stage IIIES,FOLLOW_UP_618,TREATMENT_618,,DONOR_18,SYNTHETIC-1,Distant recurrence/metastasis,,N0(mol+)
"{'month_interval': 24, 'day_interval': 720}",Partial remission,,Assessment of symptom control (procedure),SEER staging system,T4e,M1e,Stage IAS,FOLLOW_UP_619,TREATMENT_619,,DONOR_19,SYNTHETIC-1,Distant recurrence/metastasis,C13|C14,N0b (no biopsy)
"{'month_interval': 14, 'day_interval': 420}",Progression not otherwise specified,"{'month_interval': 4, 'day_interval': 120}",Assessment of symptom control (procedure)|Histopathology test (procedure),International Neuroblastoma Risk Group Staging System,T2a1,,,FOLLOW_UP_620,TREATMENT_620,,DONOR_20,SYNTHETIC-1,,C14,N2
"{'month_interval': 22, 'day_interval': 660}",Partial remission,"{'month_interval': 37, 'day_interval': 1110}",Physical examination procedure (procedure),International Neuroblastoma Staging System,T1b(s),M1c(1),Stage 1B,FOLLOW_UP_621,TREATMENT_621,,DONOR_21,SYNTHETIC-1,,C16|C06,N2b
"{'month_interval': 21, 'day_interval': 630}",Progression not otherwise specified,"{'month_interval': 47, 'day_interval': 1410}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),FIGO staging system,T2a,MX,Stage IIC,FOLLOW_UP_622,TREATMENT_622,,DONOR_22,SYNTHETIC-1,Biochemical progression,C02,N2
"{'month_interval': 20, 'day_interval': 600}",Loco-regional progression,,Imaging (procedure)|Assessment of symptom control (procedure),,T1d,M0,Stage IEA,FOLLOW_UP_623,TREATMENT_623,,DONOR_23,SYNTHETIC-1,Distant recurrence/metastasis,,N1a(sn)
,Partial remission,"{'month_interval': 4, 'day_interval': 120}",Imaging (procedure)|Tumor marker measurement (procedure),Ann Arbor staging system,T2b,M1c(1),,FOLLOW_UP_624,TREATMENT_624,,DONOR_24,SYNTHETIC-1,Progression (liquid tumours),,N3c
"{'month_interval': 27, 'day_interval': 810}",Relapse or recurrence,"{'month_interval': 50, 'day_interval': 1500}",Physical examination procedure (procedure)|Tumor marker measurement (procedure),Durie-Salmon staging system,T4b(s),,Stage IA1,FOLLOW_UP_625,TREATMENT_625,,DONOR_25,SYNTHETIC-1,Biochemical progression,C03,
"{'month_interval': 27, 'day_interval': 810}",Relapse or recurrence,"{'month_interval': 3, 'day_interval': 90}",Laboratory data interpretation (procedure),Binet staging system,T1a1,,,FOLLOW_UP_626,TREATMENT_626,,DONOR_26,SYNTHETIC-1,Local recurrence,C10,N1c
"{'month_interval': 37, 'day_interval': 1110}",Stable,,Assessment of symptom control (procedure),Revised International staging system (RISS),T1d,M1c,Stage I,FOLLOW_UP_627,TREATMENT_627,,DONOR_27,SYNTHETIC-1,Local recurrence and distant metastasis,C03,N1
"{'month_interval': 41, 'day_interval': 1230}",Relapse or recurrence,"{'month_interval': 5, 'day_interval': 150}",Physical examination procedure (procedure),,T2c,M1d(1),Stage IIIBS,FOLLOW_UP_628,TREATMENT_628,,DONOR_28,SYNTHETIC-1,Biochemical progression,C11|C19,N3
,Relapse or recurrence,,Physical examination procedure (procedure),International Neuroblastoma Staging System,T1a1,,Stage IIIC2,FOLLOW_UP_629,TREATMENT_629,,DONOR_29,SYNTHETIC-1,Local recurrence,,N0a (biopsy)
"{'month_interval': 30, 'day_interval': 900}",No evidence of disease,"{'month_interval': 22, 'day_interval': 660}",,SEER staging system,T3d,M0(i+),Stage IIID,FOLLOW_UP_630,TREATMENT_630,,DONOR_30,SYNTHETIC-1,,C09|C04,N0b
"{'month_interval': 2, 'day_interval': 60}",Relapse or recurrence,"{'month_interval': 15, 'day_interval': 450}",Physical examination procedure (procedure)|Tumor marker measurement (procedure),AJCC 8th edition,T2c,,Stage IA2,FOLLOW_UP_631,TREATMENT_631,,DONOR_31,SYNTHETIC-1,,C20|C14,N0(mol+)
"{'month_interval': 30, 'day_interval': 900}",Partial remission,"{'month_interval': 24, 'day_interval': 720}",Laboratory data interpretation (procedure),,T4a,M1c,,FOLLOW_UP_632,TREATMENT_632,,DONOR_32,SYNTHETIC-1,Local recurrence and distant metastasis,C09|C12,N2mi
"{'month_interval': 50, 'day_interval': 1500}",Distant progression,"{'month_interval': 8, 'day_interval': 240}",Assessment of symptom control (procedure)|Histopathology test (procedure),Ann Arbor staging system,T1a,M1e,,FOLLOW_UP_633,TREATMENT_633,,DONOR_33,SYNTHETIC-1,Progression (liquid tumours),,NX
"{'month_interval': 47, 'day_interval': 1410}",Relapse or recurrence,"{'month_interval': 31, 'day_interval': 930}",Imaging (procedure)|Histopathology test (procedure),FIGO staging system,T1a2,,,FOLLOW_UP_634,TREATMENT_634,,DONOR_34,SYNTHETIC-1,Local recurrence and distant metastasis,C18,N4
,No evidence of disease,"{'month_interval': 9, 'day_interval': 270}",Histopathology test (procedure)|Physical examination procedure (procedure),,Tis pd,M1d,Stage IIAS,FOLLOW_UP_635,TREATMENT_635,,DONOR_35,SYNTHETIC-1,Progression (liquid tumours),C18|C02,N4
"{'month_interval': 20, 'day_interval': 600}",No evidence of disease,"{'month_interval': 9, 'day_interval': 270}",,Binet staging system,T4,M0(i+),Stage 3,FOLLOW_UP_636,TREATMENT_636,,DONOR_36,SYNTHETIC-1,Distant recurrence/metastasis,,N0b
"{'month_interval': 6, 'day_interval': 180}",Relapse or recurrence,,Physical examination procedure (procedure)|Imaging (procedure),AJCC 7th edition,,M1d,Stage IVE,FOLLOW_UP_637,TREATMENT_637,,DONOR_37,SYNTHETIC-1,Distant recurrence/metastasis,C06|C20,N0(mol-)
"{'month_interval': 39, 'day_interval': 1170}",Progression not otherwise specified,,Assessment of symptom control (procedure),Ann Arbor staging system,T1a2,M1d(0),,FOLLOW_UP_638,TREATMENT_638,,DONOR_38,SYNTHETIC-1,,C20,N3
"{'month_interval': 31, 'day_interval': 930}",Progression not otherwise specified,"{'month_interval': 39, 'day_interval': 1170}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),Ann Arbor staging system,T3,M1b(1),Regionalized,FOLLOW_UP_639,TREATMENT_639,,DONOR_39,SYNTHETIC-1,,C07|C15,N3c
"{'month_interval': 16, 'day_interval': 480}",Loco-regional progression,"{'month_interval': 39, 'day_interval': 1170}",Tumor marker measurement (procedure),Rai staging system,T2b,,,FOLLOW_UP_640,TREATMENT_640,,DONOR_40,SYNTHETIC-1,Biochemical progression,C16,N1mi
"{'month_interval': 32, 'day_interval': 960}",Loco-regional progression,"{'month_interval': 29, 'day_interval': 870}",Imaging (procedure)|Laboratory data interpretation (procedure),St Jude staging system,T3c,M1d(0),Stage IVA2,FOLLOW_UP_641,TREATMENT_641,,DONOR_41,SYNTHETIC-2,Local recurrence and distant metastasis,,N0a (biopsy)
"{'month_interval': 9, 'day_interval': 270}",Relapse or recurrence,"{'month_interval': 46, 'day_interval': 1380}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Staging System,T4a,,Stage IEB,FOLLOW_UP_642,TREATMENT_642,,DONOR_42,SYNTHETIC-2,Local recurrence and distant metastasis,C13|C19,N0(i+)
"{'month_interval': 31, 'day_interval': 930}",Progression not otherwise specified,"{'month_interval': 1, 'day_interval': 30}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),FIGO staging system,,M1c(0),,FOLLOW_UP_643,TREATMENT_643,,DONOR_43,SYNTHETIC-2,Local recurrence,,
"{'month_interval': 41, 'day_interval': 1230}",Progression not otherwise specified,"{'month_interval': 33, 'day_interval': 990}",Assessment of symptom control (procedure),Durie-Salmon staging system,Tis(Paget),M1c(0),Stage IEA,FOLLOW_UP_644,TREATMENT_644,,DONOR_44,SYNTHETIC-2,Local recurrence,C19,N0b
"{'month_interval': 2, 'day_interval': 60}",Progression not otherwise specified,"{'month_interval': 5, 'day_interval': 150}",Assessment of symptom control (procedure),AJCC 8th edition,T2a,M1b(0),Stage IVAE,FOLLOW_UP_645,TREATMENT_645,,DONOR_45,SYNTHETIC-2,Distant recurrence/metastasis,C08,N0(mol-)
"{'month_interval': 3, 'day_interval': 90}",,"{'month_interval': 32, 'day_interval': 960}",Imaging (procedure)|Tumor marker measurement (procedure),Revised International staging system (RISS),T1b(s),M1d(1),Stage 1B,FOLLOW_UP_646,TREATMENT_646,,DONOR_46,SYNTHETIC-2,,C18,N0(i-)
"{'month_interval': 27, 'day_interval': 810}",Progression not otherwise specified,"{'month_interval': 3, 'day_interval': 90}",,AJCC 7th edition,T4c,M1b(1),Localized,FOLLOW_UP_647,TREATMENT_647,,DONOR_47,SYNTHETIC-2,Local recurrence and distant metastasis,C07,N0(mol+)
"{'month_interval': 36, 'day_interval': 1080}",Progression not otherwise specified,,Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),Ann Arbor staging system,T1a(m),M1b(1),Occult Carcinoma,FOLLOW_UP_648,TREATMENT_648,,DONOR_48,SYNTHETIC-2,Distant recurrence/metastasis,C07|C08,N0(mol+)
"{'month_interval': 26, 'day_interval': 780}",Partial remission,"{'month_interval': 2, 'day_interval': 60}",Physical examination procedure (procedure),AJCC 6th edition,TX,M0(i+),Stage IIIAES,FOLLOW_UP_649,TREATMENT_649,,DONOR_49,SYNTHETIC-2,Local recurrence,C09,N3c
"{'month_interval': 7, 'day_interval': 210}",Stable,,Laboratory data interpretation (procedure)|Physical examination procedure (procedure),Revised International staging system (RISS),T3(m),M1a(1),Stage IIIBES,FOLLOW_UP_650,TREATMENT_650,,DONOR_50,SYNTHETIC-2,Biochemical progression,,N0(mol-)
,Stable,"{'month_interval': 30, 'day_interval': 900}",,Lugano staging system,Tis(DCIS),,,FOLLOW_UP_651,TREATMENT_651,,DONOR_51,SYNTHETIC-2,Local recurrence,C15,N1c
"{'month_interval': 18, 'day_interval': 540}",Stable,"{'month_interval': 30, 'day_interval': 900}",,AJCC 6th edition,,,Stage IIIBE,FOLLOW_UP_652,TREATMENT_652,,DONOR_52,SYNTHETIC-2,Local recurrence,,N2b
,Complete remission,,Tumor marker measurement (procedure),International Neuroblastoma Risk Group Staging System,T1d,,Stage IVBS,FOLLOW_UP_653,TREATMENT_653,,DONOR_53,SYNTHETIC-2,Distant recurrence/metastasis,,N3c
,Relapse or recurrence,"{'month_interval': 12, 'day_interval': 360}",Laboratory data interpretation (procedure),Lugano staging system,Tis(Paget's),M1a,Stage IA,FOLLOW_UP_654,TREATMENT_654,,DONOR_54,SYNTHETIC-2,Local recurrence and distant metastasis,C06|C11,N0a (biopsy)
"{'month_interval': 18, 'day_interval': 540}",Progression not otherwise specified,,Laboratory data interpretation (procedure),SEER staging system,T1c,M1a,Stage IIIBS,FOLLOW_UP_655,TREATMENT_655,,DONOR_55,SYNTHETIC-2,Local recurrence and distant metastasis,,N0(i+)
"{'month_interval': 42, 'day_interval': 1260}",Stable,"{'month_interval': 38, 'day_interval': 1140}",Assessment of symptom control (procedure),Revised International staging system (RISS),T2a2,M1b(0),Stage IIA1,FOLLOW_UP_656,TREATMENT_656,,DONOR_56,SYNTHETIC-2,Local recurrence and distant metastasis,,N1a
"{'month_interval': 21, 'day_interval': 630}",Relapse or recurrence,"{'month_interval': 2, 'day_interval': 60}",,AJCC 6th edition,T4a,MX,,FOLLOW_UP_657,TREATMENT_657,,DONOR_57,SYNTHETIC-2,Progression (liquid tumours),,N3b
"{'month_interval': 21, 'day_interval': 630}",Stable,"{'month_interval': 32, 'day_interval': 960}",,,T3(m),M1d,Stage 1A,FOLLOW_UP_658,TREATMENT_658,,DONOR_58,SYNTHETIC-2,Local recurrence and distant metastasis,C02,N4
"{'month_interval': 8, 'day_interval': 240}",Partial remission,"{'month_interval': 49, 'day_interval': 1470}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),Revised International staging system (RISS),T1d,,Stage IB,FOLLOW_UP_659,TREATMENT_659,,DONOR_59,SYNTHETIC-2,Local recurrence,,
"{'month_interval': 2, 'day_interval': 60}",Stable,,,Ann Arbor staging system,T2d,M0(i+),Stage IIIAS,FOLLOW_UP_660,TREATMENT_660,,DONOR_60,SYNTHETIC-2,Biochemical progression,C03,N1b
"{'month_interval': 12, 'day_interval': 360}",Complete remission,"{'month_interval': 27, 'day_interval': 810}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),Binet staging system,,,,FOLLOW_UP_661,TREATMENT_661,,DONOR_61,SYNTHETIC-2,Local recurrence and distant metastasis,,N3a
"{'month_interval': 50, 'day_interval': 1500}",No evidence of disease,"{'month_interval': 41, 'day_interval': 1230}",,Revised International staging system (RISS),T1b2,,Stage IC,FOLLOW_UP_662,TREATMENT_662,,DONOR_62,SYNTHETIC-2,Local recurrence,,N1c
"{'month_interval': 28, 'day_interval': 840}",,"{'month_interval': 42, 'day_interval': 1260}",,Binet staging system,T1b(s),M1c(1),,FOLLOW_UP_663,TREATMENT_663,,DONOR_63,SYNTHETIC-2,Progression (liquid tumours),,N3b
,Relapse or recurrence,"{'month_interval': 2, 'day_interval': 60}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),AJCC 6th edition,,M1c,Stage 1,FOLLOW_UP_664,TREATMENT_664,,DONOR_64,SYNTHETIC-2,Local recurrence,,N1
"{'month_interval': 13, 'day_interval': 390}",Partial remission,"{'month_interval': 44, 'day_interval': 1320}",Imaging (procedure)|Histopathology test (procedure),Rai staging system,T4d,M0,Stage IEB,FOLLOW_UP_665,TREATMENT_665,,DONOR_65,SYNTHETIC-2,Local recurrence,,
"{'month_interval': 44, 'day_interval': 1320}",Distant progression,"{'month_interval': 9, 'day_interval': 270}",Assessment of symptom control (procedure),St Jude staging system,T4d,M0,,FOLLOW_UP_666,TREATMENT_666,,DONOR_66,SYNTHETIC-2,Progression (liquid tumours),C14,N4
"{'month_interval': 10, 'day_interval': 300}",Relapse or recurrence,"{'month_interval': 9, 'day_interval': 270}",Imaging (procedure),AJCC 7th edition,T1,M1b(1),Stage 3,FOLLOW_UP_667,TREATMENT_667,,DONOR_67,SYNTHETIC-2,Local recurrence and distant metastasis,C05,N0
"{'month_interval': 35, 'day_interval': 1050}",Progression not otherwise specified,"{'month_interval': 47, 'day_interval': 1410}",Imaging (procedure),Lugano staging system,T4d,M1d,Stage IVB,FOLLOW_UP_668,TREATMENT_668,,DONOR_68,SYNTHETIC-2,Distant recurrence/metastasis,C13|C05,N0(i+)
"{'month_interval': 26, 'day_interval': 780}",Progression not otherwise specified,"{'month_interval': 30, 'day_interval': 900}",Imaging (procedure)|Laboratory data interpretation (procedure),FIGO staging system,T4d,M1b(0),Stage 1A,FOLLOW_UP_669,TREATMENT_669,,DONOR_69,SYNTHETIC-2,,,N3c
"{'month_interval': 38, 'day_interval': 1140}",Progression not otherwise specified,,,Binet staging system,Ta,MX,Stage II,FOLLOW_UP_670,TREATMENT_670,,DONOR_70,SYNTHETIC-2,Local recurrence and distant metastasis,C11,N3
"{'month_interval': 27, 'day_interval': 810}",Stable,"{'month_interval': 34, 'day_interval': 1020}",,FIGO staging system,,M1b,Stage II,FOLLOW_UP_671,TREATMENT_671,,DONOR_41,SYNTHETIC-2,Biochemical progression,C10|C08,N4
"{'month_interval': 31, 'day_interval': 930}",Loco-regional progression,,Imaging (procedure),Durie-Salmon staging system,TX,M1b,Stage IIAES,FOLLOW_UP_672,TREATMENT_672,,DONOR_42,SYNTHETIC-2,Biochemical progression,C03,N2
"{'month_interval': 45, 'day_interval': 1350}",Complete remission,"{'month_interval': 13, 'day_interval': 390}",,Rai staging system,,M1d(1),Stage IIE,FOLLOW_UP_673,TREATMENT_673,,DONOR_43,SYNTHETIC-2,Biochemical progression,,N2c
"{'month_interval': 28, 'day_interval': 840}",Complete remission,"{'month_interval': 32, 'day_interval': 960}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),International Neuroblastoma Risk Group Staging System,,M1a,Stage IIID,FOLLOW_UP_674,TREATMENT_674,,DONOR_44,SYNTHETIC-2,Progression (liquid tumours),C11,N0a (biopsy)
"{'month_interval': 42, 'day_interval': 1260}",Partial remission,"{'month_interval': 5, 'day_interval': 150}",Physical examination procedure (procedure),Durie-Salmon staging system,,M0,Stage IIE,FOLLOW_UP_675,TREATMENT_675,,DONOR_45,SYNTHETIC-2,Local recurrence and distant metastasis,C17|C10,N1a(sn)
"{'month_interval': 25, 'day_interval': 750}",Distant progression,"{'month_interval': 49, 'day_interval': 1470}",Laboratory data interpretation (procedure),Durie-Salmon staging system,Tis(Paget's),,Stage IAES,FOLLOW_UP_676,TREATMENT_676,,DONOR_46,SYNTHETIC-2,Local recurrence,,N2
"{'month_interval': 28, 'day_interval': 840}",Stable,"{'month_interval': 3, 'day_interval': 90}",Imaging (procedure)|Tumor marker measurement (procedure),,,M1c,Stage I,FOLLOW_UP_677,TREATMENT_677,,DONOR_47,SYNTHETIC-2,,C03|C08,N4
"{'month_interval': 33, 'day_interval': 990}",Loco-regional progression,"{'month_interval': 5, 'day_interval': 150}",Laboratory data interpretation (procedure),Rai staging system,T2,M1b(1),Stage 2A,FOLLOW_UP_678,TREATMENT_678,,DONOR_48,SYNTHETIC-2,Progression (liquid tumours),C14|C06,N0
"{'month_interval': 12, 'day_interval': 360}",Loco-regional progression,"{'month_interval': 34, 'day_interval': 1020}",Tumor marker measurement (procedure),St Jude staging system,T1a(s),M1c,Stage IIAES,FOLLOW_UP_679,TREATMENT_679,,DONOR_49,SYNTHETIC-2,Distant recurrence/metastasis,C07|C16,
"{'month_interval': 8, 'day_interval': 240}",Progression not otherwise specified,"{'month_interval': 50, 'day_interval': 1500}",Tumor marker measurement (procedure),Durie-Salmon staging system,,M0,Stage IA3,FOLLOW_UP_680,TREATMENT_680,,DONOR_50,SYNTHETIC-2,,,N0a
"{'month_interval': 37, 'day_interval': 1110}",Partial remission,"{'month_interval': 50, 'day_interval': 1500}",Histopathology test (procedure),St Jude staging system,T4b(s),M1b(1),,FOLLOW_UP_681,TREATMENT_681,,DONOR_51,SYNTHETIC-2,Local recurrence,,
"{'month_interval': 7, 'day_interval': 210}",Loco-regional progression,"{'month_interval': 14, 'day_interval': 420}",Imaging (procedure),St Jude staging system,T4a,M0,Stage B,FOLLOW_UP_682,TREATMENT_682,,DONOR_52,SYNTHETIC-2,Biochemical progression,,N1b
"{'month_interval': 42, 'day_interval': 1260}",Loco-regional progression,"{'month_interval': 32, 'day_interval': 960}",Assessment of symptom control (procedure),FIGO staging system,T2a2,M1c,Stage IVA2,FOLLOW_UP_683,TREATMENT_683,,DONOR_53,SYNTHETIC-2,Local recurrence and distant metastasis,,N1
"{'month_interval': 35, 'day_interval': 1050}",No evidence of disease,"{'month_interval': 10, 'day_interval': 300}",Imaging (procedure)|Assessment of symptom control (procedure),Durie-Salmon staging system,T4a(s),M1a(1),,FOLLOW_UP_684,TREATMENT_684,,DONOR_54,SYNTHETIC-2,Distant recurrence/metastasis,,N0(mol-)
,,"{'month_interval': 20, 'day_interval': 600}",Histopathology test (procedure)|Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,T3e,M1b(0),,FOLLOW_UP_685,TREATMENT_685,,DONOR_55,SYNTHETIC-2,Local recurrence,,N2a
"{'month_interval': 25, 'day_interval': 750}",Partial remission,,Tumor marker measurement (procedure),Durie-Salmon staging system,T1mi,,Stage 2B,FOLLOW_UP_686,TREATMENT_686,,DONOR_56,SYNTHETIC-2,Biochemical progression,,N2
"{'month_interval': 5, 'day_interval': 150}",Loco-regional progression,"{'month_interval': 41, 'day_interval': 1230}",,Rai staging system,,M1c,Stage IV,FOLLOW_UP_687,TREATMENT_687,,DONOR_57,SYNTHETIC-2,Local recurrence,,N1c
"{'month_interval': 26, 'day_interval': 780}",Relapse or recurrence,"{'month_interval': 49, 'day_interval': 1470}",Imaging (procedure)|Assessment of symptom control (procedure),SEER staging system,T1b,,Stage IVE,FOLLOW_UP_688,TREATMENT_688,,DONOR_58,SYNTHETIC-2,Biochemical progression,,N1mi
"{'month_interval': 37, 'day_interval': 1110}",,"{'month_interval': 2, 'day_interval': 60}",Assessment of symptom control (procedure)|Histopathology test (procedure),Ann Arbor staging system,T1b,M1d(1),Stage II,FOLLOW_UP_689,TREATMENT_689,,DONOR_59,SYNTHETIC-2,Biochemical progression,C04|C07,N3b
"{'month_interval': 22, 'day_interval': 660}",Stable,"{'month_interval': 36, 'day_interval': 1080}",,Ann Arbor staging system,Tis(LAMN),M1d(1),,FOLLOW_UP_690,TREATMENT_690,,DONOR_60,SYNTHETIC-2,,,
,Distant progression,"{'month_interval': 9, 'day_interval': 270}",Histopathology test (procedure)|Tumor marker measurement (procedure),Ann Arbor staging system,T3(m),MX,Stage IIIA2,FOLLOW_UP_691,TREATMENT_691,,DONOR_61,SYNTHETIC-2,Local recurrence,C12,NX
,Stable,"{'month_interval': 17, 'day_interval': 510}",,Binet staging system,T1a1,,Stage IIIC1,FOLLOW_UP_692,TREATMENT_692,,DONOR_62,SYNTHETIC-2,Biochemical progression,C16,N3a
"{'month_interval': 18, 'day_interval': 540}",No evidence of disease,"{'month_interval': 24, 'day_interval': 720}",,St Jude staging system,T4c,M1b(1),In situ,FOLLOW_UP_693,TREATMENT_693,,DONOR_63,SYNTHETIC-2,,C02|C14,N2c
"{'month_interval': 1, 'day_interval': 30}",Complete remission,"{'month_interval': 20, 'day_interval': 600}",Tumor marker measurement (procedure)|Imaging (procedure),AJCC 7th edition,,M1a(0),Stage IVBS,FOLLOW_UP_694,TREATMENT_694,,DONOR_64,SYNTHETIC-2,Local recurrence,C16,N1
"{'month_interval': 26, 'day_interval': 780}",Partial remission,"{'month_interval': 39, 'day_interval': 1170}",Assessment of symptom control (procedure)|Imaging (procedure),International Neuroblastoma Staging System,Tis,M0,In situ,FOLLOW_UP_695,TREATMENT_695,,DONOR_65,SYNTHETIC-2,Distant recurrence/metastasis,C20|C18,N1b
"{'month_interval': 47, 'day_interval': 1410}",Complete remission,"{'month_interval': 40, 'day_interval': 1200}",Tumor marker measurement (procedure),,T4b(s),,Stage IA,FOLLOW_UP_696,TREATMENT_696,,DONOR_66,SYNTHETIC-2,Local recurrence and distant metastasis,,N3b
"{'month_interval': 15, 'day_interval': 450}",No evidence of disease,"{'month_interval': 6, 'day_interval': 180}",,Revised International staging system (RISS),T1a,M1b(1),Stage IIIA,FOLLOW_UP_697,TREATMENT_697,,DONOR_67,SYNTHETIC-2,Biochemical progression,C03,
,No evidence of disease,,Physical examination procedure (procedure),,Tis pu,,Stage IIAS,FOLLOW_UP_698,TREATMENT_698,,DONOR_68,SYNTHETIC-2,Local recurrence,C12,N3b
"{'month_interval': 7, 'day_interval': 210}",No evidence of disease,"{'month_interval': 47, 'day_interval': 1410}",Laboratory data interpretation (procedure),AJCC 8th edition,T4b,,Stage IIA2,FOLLOW_UP_699,TREATMENT_699,,DONOR_69,SYNTHETIC-2,Progression (liquid tumours),C16|C02,N1a(sn)
"{'month_interval': 47, 'day_interval': 1410}",Distant progression,"{'month_interval': 25, 'day_interval': 750}",Assessment of symptom control (procedure),AJCC 6th edition,T1,M1b(1),,FOLLOW_UP_700,TREATMENT_700,,DONOR_70,SYNTHETIC-2,Biochemical progression,C16|C19,N1
"{'month_interval': 9, 'day_interval': 270}",Complete remission,"{'month_interval': 32, 'day_interval': 960}",Physical examination procedure (procedure),Lugano staging system,T1a(m),M1c(0),Stage IIIES,FOLLOW_UP_701,TREATMENT_701,,DONOR_41,SYNTHETIC-2,Biochemical progression,C20|C08,
,Partial remission,"{'month_interval': 46, 'day_interval': 1380}",,International Neuroblastoma Risk Group Staging System,T2,M1a(1),Stage IIES,FOLLOW_UP_702,TREATMENT_702,,DONOR_42,SYNTHETIC-2,Distant recurrence/metastasis,C08,N2a
"{'month_interval': 41, 'day_interval': 1230}",Relapse or recurrence,"{'month_interval': 40, 'day_interval': 1200}",Imaging (procedure),,T1b1,,Stage IIIBS,FOLLOW_UP_703,TREATMENT_703,,DONOR_43,SYNTHETIC-2,Local recurrence,C10|C12,N1c
"{'month_interval': 50, 'day_interval': 1500}",Progression not otherwise specified,"{'month_interval': 31, 'day_interval': 930}",Tumor marker measurement (procedure),AJCC 6th edition,Tis,M1d(0),Stage 4,FOLLOW_UP_704,TREATMENT_704,,DONOR_44,SYNTHETIC-2,Biochemical progression,C12,N3c
"{'month_interval': 37, 'day_interval': 1110}",Progression not otherwise specified,"{'month_interval': 9, 'day_interval': 270}",Imaging (procedure)|Assessment of symptom control (procedure),Durie-Salmon staging system,T1d,M0,Stage IIIA,FOLLOW_UP_705,TREATMENT_705,,DONOR_45,SYNTHETIC-2,Local recurrence,C13,N1a
"{'month_interval': 5, 'day_interval': 150}",Distant progression,"{'month_interval': 5, 'day_interval': 150}",Laboratory data interpretation (procedure),AJCC 8th edition,T3e,M1c(1),,FOLLOW_UP_706,TREATMENT_706,,DONOR_46,SYNTHETIC-2,Biochemical progression,C05|C19,N1a(sn)
"{'month_interval': 18, 'day_interval': 540}",Complete remission,"{'month_interval': 10, 'day_interval': 300}",,Revised International staging system (RISS),T3,M1d,Stage IAE,FOLLOW_UP_707,TREATMENT_707,,DONOR_47,SYNTHETIC-2,Biochemical progression,C03,N4
"{'month_interval': 46, 'day_interval': 1380}",Partial remission,"{'month_interval': 15, 'day_interval': 450}",Imaging (procedure)|Tumor marker measurement (procedure),,,M1,Stage 1,FOLLOW_UP_708,TREATMENT_708,,DONOR_48,SYNTHETIC-2,,,N1a
"{'month_interval': 1, 'day_interval': 30}",Distant progression,"{'month_interval': 2, 'day_interval': 60}",Tumor marker measurement (procedure)|Imaging (procedure),Durie-Salmon staging system,,,Stage IIAES,FOLLOW_UP_709,TREATMENT_709,,DONOR_49,SYNTHETIC-2,Biochemical progression,,N0(i-)
"{'month_interval': 1, 'day_interval': 30}",Partial remission,"{'month_interval': 36, 'day_interval': 1080}",Histopathology test (procedure),International Neuroblastoma Risk Group Staging System,,M1,Stage M,FOLLOW_UP_710,TREATMENT_710,,DONOR_50,SYNTHETIC-2,Local recurrence and distant metastasis,,
,Relapse or recurrence,"{'month_interval': 20, 'day_interval': 600}",,AJCC 7th edition,T4a,MX,Stage A,FOLLOW_UP_711,TREATMENT_711,,DONOR_51,SYNTHETIC-2,Biochemical progression,,
"{'month_interval': 30, 'day_interval': 900}",,"{'month_interval': 35, 'day_interval': 1050}",,,T0,,Stage IEB,FOLLOW_UP_712,TREATMENT_712,,DONOR_52,SYNTHETIC-2,Distant recurrence/metastasis,,N3a
"{'month_interval': 40, 'day_interval': 1200}",Distant progression,"{'month_interval': 28, 'day_interval': 840}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Revised International staging system (RISS),T4b(s),M1d(0),Distant,FOLLOW_UP_713,TREATMENT_713,,DONOR_53,SYNTHETIC-2,Distant recurrence/metastasis,C07,
"{'month_interval': 9, 'day_interval': 270}",Relapse or recurrence,,Tumor marker measurement (procedure),Binet staging system,T4c,M0,,FOLLOW_UP_714,TREATMENT_714,,DONOR_54,SYNTHETIC-2,Progression (liquid tumours),,
"{'month_interval': 48, 'day_interval': 1440}",Loco-regional progression,"{'month_interval': 13, 'day_interval': 390}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),,,M1a,Stage IVBE,FOLLOW_UP_715,TREATMENT_715,,DONOR_55,SYNTHETIC-2,Local recurrence,C12,
"{'month_interval': 40, 'day_interval': 1200}",No evidence of disease,,,AJCC 8th edition,T4a,M1a(0),Stage IIC,FOLLOW_UP_716,TREATMENT_716,,DONOR_56,SYNTHETIC-2,Local recurrence and distant metastasis,,N3b
"{'month_interval': 24, 'day_interval': 720}",Stable,"{'month_interval': 36, 'day_interval': 1080}",,AJCC 6th edition,,M1c,Stage IIES,FOLLOW_UP_717,TREATMENT_717,,DONOR_57,SYNTHETIC-2,Biochemical progression,C06|C01,N0(mol+)
"{'month_interval': 39, 'day_interval': 1170}",Distant progression,"{'month_interval': 3, 'day_interval': 90}",Assessment of symptom control (procedure),Ann Arbor staging system,Tis pu,M0(i+),Stage IIBES,FOLLOW_UP_718,TREATMENT_718,,DONOR_58,SYNTHETIC-2,Local recurrence,C01|C04,
"{'month_interval': 8, 'day_interval': 240}",Partial remission,,Physical examination procedure (procedure),Lugano staging system,,,Stage IIIAS,FOLLOW_UP_719,TREATMENT_719,,DONOR_59,SYNTHETIC-2,Local recurrence,C17|C11,N0(i-)
"{'month_interval': 45, 'day_interval': 1350}",Loco-regional progression,"{'month_interval': 3, 'day_interval': 90}",Laboratory data interpretation (procedure),AJCC 6th edition,Tis pd,,Stage IVE,FOLLOW_UP_720,TREATMENT_720,,DONOR_60,SYNTHETIC-2,Distant recurrence/metastasis,C11,N0a (biopsy)
"{'month_interval': 17, 'day_interval': 510}",Partial remission,"{'month_interval': 32, 'day_interval': 960}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Binet staging system,T4b(s),M1d(0),Stage IIEA,FOLLOW_UP_721,TREATMENT_721,,DONOR_61,SYNTHETIC-2,Biochemical progression,C04|C03,
"{'month_interval': 28, 'day_interval': 840}",Distant progression,"{'month_interval': 22, 'day_interval': 660}",Physical examination procedure (procedure),AJCC 6th edition,T2,,Stage IEA,FOLLOW_UP_722,TREATMENT_722,,DONOR_62,SYNTHETIC-2,Progression (liquid tumours),C11,
,,"{'month_interval': 29, 'day_interval': 870}",Imaging (procedure),SEER staging system,T1,M1d(1),,FOLLOW_UP_723,TREATMENT_723,,DONOR_63,SYNTHETIC-2,Distant recurrence/metastasis,,N0a
"{'month_interval': 38, 'day_interval': 1140}",Relapse or recurrence,"{'month_interval': 31, 'day_interval': 930}",,AJCC 7th edition,T2b,,Stage IIIA2,FOLLOW_UP_724,TREATMENT_724,,DONOR_64,SYNTHETIC-2,,C20|C18,
,Relapse or recurrence,"{'month_interval': 19, 'day_interval': 570}",Imaging (procedure)|Assessment of symptom control (procedure),AJCC 7th edition,T4b(s),M1d(1),Stage IVAS,FOLLOW_UP_725,TREATMENT_725,,DONOR_65,SYNTHETIC-2,,C18|C06,N0b (no biopsy)
"{'month_interval': 17, 'day_interval': 510}",,"{'month_interval': 6, 'day_interval': 180}",Assessment of symptom control (procedure),International Neuroblastoma Staging System,,M1c(1),Stage IES,FOLLOW_UP_726,TREATMENT_726,,DONOR_66,SYNTHETIC-2,Progression (liquid tumours),,
"{'month_interval': 31, 'day_interval': 930}",Loco-regional progression,"{'month_interval': 16, 'day_interval': 480}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),Binet staging system,T4,,Stage IBE,FOLLOW_UP_727,TREATMENT_727,,DONOR_67,SYNTHETIC-2,Biochemical progression,C03,N0(i-)
"{'month_interval': 18, 'day_interval': 540}",Complete remission,"{'month_interval': 14, 'day_interval': 420}",,International Neuroblastoma Staging System,,M1c(1),Stage IIIBS,FOLLOW_UP_728,TREATMENT_728,,DONOR_68,SYNTHETIC-2,Distant recurrence/metastasis,,NX
"{'month_interval': 46, 'day_interval': 1380}",Stable,"{'month_interval': 8, 'day_interval': 240}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),Ann Arbor staging system,T1c,M1a,Stage IIIC1,FOLLOW_UP_729,TREATMENT_729,,DONOR_69,SYNTHETIC-2,Progression (liquid tumours),C16|C15,N3
"{'month_interval': 5, 'day_interval': 150}",Complete remission,"{'month_interval': 43, 'day_interval': 1290}",Laboratory data interpretation (procedure),Ann Arbor staging system,Tis pu,M1a,Stage IIIC1,FOLLOW_UP_730,TREATMENT_730,,DONOR_70,SYNTHETIC-2,Distant recurrence/metastasis,,N0a
"{'month_interval': 18, 'day_interval': 540}",Progression not otherwise specified,"{'month_interval': 25, 'day_interval': 750}",,SEER staging system,Tis(LAMN),M1c,Stage IVAES,FOLLOW_UP_731,TREATMENT_731,,DONOR_41,SYNTHETIC-2,Local recurrence,C04,N0b
"{'month_interval': 40, 'day_interval': 1200}",Distant progression,"{'month_interval': 38, 'day_interval': 1140}",Assessment of symptom control (procedure),Rai staging system,,MX,Stage IIIBS,FOLLOW_UP_732,TREATMENT_732,,DONOR_42,SYNTHETIC-2,,,N0(i-)
"{'month_interval': 4, 'day_interval': 120}",Stable,"{'month_interval': 3, 'day_interval': 90}",Assessment of symptom control (procedure),Lugano staging system,T4c,M1e,Stage IIIBS,FOLLOW_UP_733,TREATMENT_733,,DONOR_43,SYNTHETIC-2,Biochemical progression,,
"{'month_interval': 40, 'day_interval': 1200}",Progression not otherwise specified,"{'month_interval': 20, 'day_interval': 600}",,FIGO staging system,T1c,,Stage 4,FOLLOW_UP_734,TREATMENT_734,,DONOR_44,SYNTHETIC-2,Local recurrence and distant metastasis,C17|C06,
"{'month_interval': 14, 'day_interval': 420}",,"{'month_interval': 38, 'day_interval': 1140}",,St Jude staging system,T1c,M1a(0),Stage IIID,FOLLOW_UP_735,TREATMENT_735,,DONOR_45,SYNTHETIC-2,Progression (liquid tumours),,N2mi
"{'month_interval': 34, 'day_interval': 1020}",Stable,"{'month_interval': 30, 'day_interval': 900}",Imaging (procedure),Rai staging system,,M1c(1),Stage IIIC,FOLLOW_UP_736,TREATMENT_736,,DONOR_46,SYNTHETIC-2,Local recurrence,C14,N0(i+)
"{'month_interval': 17, 'day_interval': 510}",,"{'month_interval': 47, 'day_interval': 1410}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Lugano staging system,,M1c(0),,FOLLOW_UP_737,TREATMENT_737,,DONOR_47,SYNTHETIC-2,Biochemical progression,C02,N2b
,Relapse or recurrence,"{'month_interval': 35, 'day_interval': 1050}",Histopathology test (procedure)|Tumor marker measurement (procedure),,T4b(s),M1a(0),Stage IE,FOLLOW_UP_738,TREATMENT_738,,DONOR_48,SYNTHETIC-2,Local recurrence,,N1b
"{'month_interval': 43, 'day_interval': 1290}",Partial remission,"{'month_interval': 38, 'day_interval': 1140}",Tumor marker measurement (procedure),Binet staging system,T3b,M1c(1),Stage IVAE,FOLLOW_UP_739,TREATMENT_739,,DONOR_49,SYNTHETIC-2,Local recurrence,C05|C13,N1a
"{'month_interval': 15, 'day_interval': 450}",Distant progression,"{'month_interval': 4, 'day_interval': 120}",,Binet staging system,T0,,Stage B,FOLLOW_UP_740,TREATMENT_740,,DONOR_50,SYNTHETIC-2,Local recurrence,C20,N3b
"{'month_interval': 35, 'day_interval': 1050}",Complete remission,"{'month_interval': 33, 'day_interval': 990}",Histopathology test (procedure)|Physical examination procedure (procedure),AJCC 8th edition,T1mi,,,FOLLOW_UP_741,TREATMENT_741,,DONOR_51,SYNTHETIC-2,Local recurrence and distant metastasis,,N1mi
"{'month_interval': 18, 'day_interval': 540}",Stable,"{'month_interval': 16, 'day_interval': 480}",Histopathology test (procedure)|Imaging (procedure),Binet staging system,,M0,Stage IIIE,FOLLOW_UP_742,TREATMENT_742,,DONOR_52,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 19, 'day_interval': 570}",Partial remission,,Physical examination procedure (procedure)|Imaging (procedure),AJCC 7th edition,T4a(s),,Stage IVES,FOLLOW_UP_743,TREATMENT_743,,DONOR_53,SYNTHETIC-2,,,N1a(sn)
"{'month_interval': 6, 'day_interval': 180}",No evidence of disease,"{'month_interval': 12, 'day_interval': 360}",,International Neuroblastoma Staging System,,M1a(0),Stage Ms,FOLLOW_UP_744,TREATMENT_744,,DONOR_54,SYNTHETIC-2,Local recurrence,C06,N0(mol-)
"{'month_interval': 10, 'day_interval': 300}",Relapse or recurrence,,,AJCC 7th edition,T2(m),M1,Stage IVB,FOLLOW_UP_745,TREATMENT_745,,DONOR_55,SYNTHETIC-2,Distant recurrence/metastasis,C20,N1
"{'month_interval': 38, 'day_interval': 1140}",Partial remission,,Histopathology test (procedure),,T1a1,M1d,Stage IAB,FOLLOW_UP_746,TREATMENT_746,,DONOR_56,SYNTHETIC-2,Local recurrence and distant metastasis,C11,N3c
,Relapse or recurrence,"{'month_interval': 5, 'day_interval': 150}",Physical examination procedure (procedure),Ann Arbor staging system,T2b,,Stage IIES,FOLLOW_UP_747,TREATMENT_747,,DONOR_57,SYNTHETIC-2,Distant recurrence/metastasis,C07|C20,N1
"{'month_interval': 24, 'day_interval': 720}",Complete remission,"{'month_interval': 37, 'day_interval': 1110}",,Lugano staging system,,,Stage IVB,FOLLOW_UP_748,TREATMENT_748,,DONOR_58,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 40, 'day_interval': 1200}",Loco-regional progression,"{'month_interval': 29, 'day_interval': 870}",,Ann Arbor staging system,Ta,M1c,Stage IIIES,FOLLOW_UP_749,TREATMENT_749,,DONOR_59,SYNTHETIC-2,Distant recurrence/metastasis,C02,N1a(sn)
"{'month_interval': 35, 'day_interval': 1050}",Complete remission,"{'month_interval': 15, 'day_interval': 450}",Laboratory data interpretation (procedure),FIGO staging system,T3(m),M1d,,FOLLOW_UP_750,TREATMENT_750,,DONOR_60,SYNTHETIC-2,Progression (liquid tumours),,N3c
"{'month_interval': 32, 'day_interval': 960}",Progression not otherwise specified,,,AJCC 8th edition,T2c,M1d(1),Stage 1A,FOLLOW_UP_751,TREATMENT_751,,DONOR_61,SYNTHETIC-2,Progression (liquid tumours),,N1a(sn)
"{'month_interval': 42, 'day_interval': 1260}",Distant progression,"{'month_interval': 24, 'day_interval': 720}",Physical examination procedure (procedure),Rai staging system,T2(m),M1d(1),Stage IIIBE,FOLLOW_UP_752,TREATMENT_752,,DONOR_62,SYNTHETIC-2,,,N1mi
"{'month_interval': 38, 'day_interval': 1140}",Partial remission,"{'month_interval': 41, 'day_interval': 1230}",Laboratory data interpretation (procedure),International Neuroblastoma Staging System,T4d,M0(i+),,FOLLOW_UP_753,TREATMENT_753,,DONOR_63,SYNTHETIC-2,Distant recurrence/metastasis,,N2c
"{'month_interval': 47, 'day_interval': 1410}",Stable,,,Rai staging system,T4b(s),M1c(0),Stage 1A,FOLLOW_UP_754,TREATMENT_754,,DONOR_64,SYNTHETIC-2,Distant recurrence/metastasis,,N1a(sn)
"{'month_interval': 46, 'day_interval': 1380}",Partial remission,"{'month_interval': 44, 'day_interval': 1320}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),AJCC 6th edition,Tis(Paget),M1d(1),Stage IES,FOLLOW_UP_755,TREATMENT_755,,DONOR_65,SYNTHETIC-2,Local recurrence and distant metastasis,C16,N0(mol-)
"{'month_interval': 30, 'day_interval': 900}",,"{'month_interval': 3, 'day_interval': 90}",Laboratory data interpretation (procedure),AJCC 7th edition,T3(m),M1a(0),,FOLLOW_UP_756,TREATMENT_756,,DONOR_66,SYNTHETIC-2,Local recurrence,,N0(i-)
"{'month_interval': 22, 'day_interval': 660}",Distant progression,"{'month_interval': 9, 'day_interval': 270}",Laboratory data interpretation (procedure)|Physical examination procedure (procedure),,,M1d(1),Stage IA1,FOLLOW_UP_757,TREATMENT_757,,DONOR_67,SYNTHETIC-2,Distant recurrence/metastasis,C07|C16,N4
"{'month_interval': 2, 'day_interval': 60}",Partial remission,"{'month_interval': 5, 'day_interval': 150}",Tumor marker measurement (procedure),,T3e,M1b,Stage 4S,FOLLOW_UP_758,TREATMENT_758,,DONOR_68,SYNTHETIC-2,Local recurrence,,N3b
"{'month_interval': 21, 'day_interval': 630}",Complete remission,"{'month_interval': 46, 'day_interval': 1380}",,St Jude staging system,T1d,M1d,Stage IIAE,FOLLOW_UP_759,TREATMENT_759,,DONOR_69,SYNTHETIC-2,Progression (liquid tumours),C10|C18,NX
"{'month_interval': 5, 'day_interval': 150}",,"{'month_interval': 19, 'day_interval': 570}",,,Ta,,Stage 4,FOLLOW_UP_760,TREATMENT_760,,DONOR_70,SYNTHETIC-2,,C03|C06,N3
,Complete remission,"{'month_interval': 34, 'day_interval': 1020}",Laboratory data interpretation (procedure),Ann Arbor staging system,T3d,M1a,Stage III,FOLLOW_UP_761,TREATMENT_761,,DONOR_41,SYNTHETIC-2,,C18|C11,N0b (no biopsy)
"{'month_interval': 11, 'day_interval': 330}",,"{'month_interval': 36, 'day_interval': 1080}",Laboratory data interpretation (procedure),St Jude staging system,T4e,M1e,Stage IVAES,FOLLOW_UP_762,TREATMENT_762,,DONOR_42,SYNTHETIC-2,Distant recurrence/metastasis,C05|C17,
"{'month_interval': 17, 'day_interval': 510}",Progression not otherwise specified,"{'month_interval': 12, 'day_interval': 360}",,Lugano staging system,T1d,,,FOLLOW_UP_763,TREATMENT_763,,DONOR_43,SYNTHETIC-2,Biochemical progression,C02,N0a (biopsy)
"{'month_interval': 20, 'day_interval': 600}",Distant progression,"{'month_interval': 8, 'day_interval': 240}",Laboratory data interpretation (procedure)|Histopathology test (procedure),AJCC 8th edition,T3c,M1c(1),,FOLLOW_UP_764,TREATMENT_764,,DONOR_44,SYNTHETIC-2,Local recurrence and distant metastasis,C02|C05,N3b
"{'month_interval': 7, 'day_interval': 210}",Complete remission,"{'month_interval': 46, 'day_interval': 1380}",Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,T2,M1a,Stage IIES,FOLLOW_UP_765,TREATMENT_765,,DONOR_45,SYNTHETIC-2,,C12,N0
"{'month_interval': 5, 'day_interval': 150}",Complete remission,"{'month_interval': 44, 'day_interval': 1320}",,AJCC 8th edition,T2a,M1d(0),Stage IIIAES,FOLLOW_UP_766,TREATMENT_766,,DONOR_46,SYNTHETIC-2,Biochemical progression,C12,N3b
"{'month_interval': 29, 'day_interval': 870}",No evidence of disease,,Histopathology test (procedure),,T1b,M1d(0),Stage IAES,FOLLOW_UP_767,TREATMENT_767,,DONOR_47,SYNTHETIC-2,Progression (liquid tumours),,N1a
"{'month_interval': 5, 'day_interval': 150}",Progression not otherwise specified,,Imaging (procedure)|Tumor marker measurement (procedure),,Tis pu,M1a(0),Stage IIIC2,FOLLOW_UP_768,TREATMENT_768,,DONOR_48,SYNTHETIC-2,Progression (liquid tumours),C20,N1mi
,Stable,"{'month_interval': 4, 'day_interval': 120}",,Binet staging system,T1a,M1a(0),,FOLLOW_UP_769,TREATMENT_769,,DONOR_49,SYNTHETIC-2,Local recurrence and distant metastasis,C17,N1a(sn)
"{'month_interval': 43, 'day_interval': 1290}",Progression not otherwise specified,"{'month_interval': 48, 'day_interval': 1440}",,Rai staging system,T1a,M1c,Stage III,FOLLOW_UP_770,TREATMENT_770,,DONOR_50,SYNTHETIC-2,Progression (liquid tumours),,N0(i+)
"{'month_interval': 11, 'day_interval': 330}",Stable,"{'month_interval': 41, 'day_interval': 1230}",Assessment of symptom control (procedure)|Physical examination procedure (procedure),FIGO staging system,T2d,M1a,Stage 0is,FOLLOW_UP_771,TREATMENT_771,,DONOR_51,SYNTHETIC-2,Distant recurrence/metastasis,,N3a
"{'month_interval': 41, 'day_interval': 1230}",Loco-regional progression,"{'month_interval': 3, 'day_interval': 90}",,Rai staging system,T2(m),M1b(0),Stage IVE,FOLLOW_UP_772,TREATMENT_772,,DONOR_52,SYNTHETIC-2,Local recurrence,,N3a
,Loco-regional progression,"{'month_interval': 16, 'day_interval': 480}",,Rai staging system,T4b,,Stage I,FOLLOW_UP_773,TREATMENT_773,,DONOR_53,SYNTHETIC-2,Local recurrence,C05,
"{'month_interval': 19, 'day_interval': 570}",Distant progression,"{'month_interval': 22, 'day_interval': 660}",Laboratory data interpretation (procedure),International Neuroblastoma Staging System,T1,MX,Stage IIIA,FOLLOW_UP_774,TREATMENT_774,,DONOR_54,SYNTHETIC-2,Progression (liquid tumours),C06,N1a
"{'month_interval': 22, 'day_interval': 660}",Relapse or recurrence,"{'month_interval': 22, 'day_interval': 660}",,Ann Arbor staging system,,,Stage IAB,FOLLOW_UP_775,TREATMENT_775,,DONOR_55,SYNTHETIC-2,Local recurrence and distant metastasis,C04,
"{'month_interval': 19, 'day_interval': 570}",,"{'month_interval': 46, 'day_interval': 1380}",Histopathology test (procedure)|Assessment of symptom control (procedure),FIGO staging system,T3d,M1e,Localized,FOLLOW_UP_776,TREATMENT_776,,DONOR_56,SYNTHETIC-2,Local recurrence,,N1c
"{'month_interval': 31, 'day_interval': 930}",Distant progression,"{'month_interval': 50, 'day_interval': 1500}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),Binet staging system,Tis pu,M1b(1),Stage IIIA1,FOLLOW_UP_777,TREATMENT_777,,DONOR_57,SYNTHETIC-2,Biochemical progression,,N1a(sn)
"{'month_interval': 3, 'day_interval': 90}",No evidence of disease,"{'month_interval': 26, 'day_interval': 780}",Assessment of symptom control (procedure),Durie-Salmon staging system,T1b,M1d,Stage IA1,FOLLOW_UP_778,TREATMENT_778,,DONOR_58,SYNTHETIC-2,Biochemical progression,C07|C14,
"{'month_interval': 18, 'day_interval': 540}",Partial remission,"{'month_interval': 22, 'day_interval': 660}",Imaging (procedure)|Tumor marker measurement (procedure),,,M1d(1),Stage C,FOLLOW_UP_779,TREATMENT_779,,DONOR_59,SYNTHETIC-2,Distant recurrence/metastasis,C11|C13,N2b
"{'month_interval': 22, 'day_interval': 660}",Relapse or recurrence,"{'month_interval': 23, 'day_interval': 690}",Histopathology test (procedure)|Assessment of symptom control (procedure),Binet staging system,T1b1,M1d,,FOLLOW_UP_780,TREATMENT_780,,DONOR_60,SYNTHETIC-2,Local recurrence,,N2a
"{'month_interval': 30, 'day_interval': 900}",,,Imaging (procedure)|Laboratory data interpretation (procedure),Durie-Salmon staging system,T2a2,M1,Localized,FOLLOW_UP_781,TREATMENT_781,,DONOR_61,SYNTHETIC-2,,C06|C19,
"{'month_interval': 27, 'day_interval': 810}",Loco-regional progression,"{'month_interval': 30, 'day_interval': 900}",Imaging (procedure)|Laboratory data interpretation (procedure),Lugano staging system,Tis(DCIS),,Stage IV,FOLLOW_UP_782,TREATMENT_782,,DONOR_62,SYNTHETIC-2,Local recurrence and distant metastasis,C14|C06,N2a
"{'month_interval': 4, 'day_interval': 120}",Relapse or recurrence,"{'month_interval': 49, 'day_interval': 1470}",,,Tis(Paget),M1a(0),Stage 1B,FOLLOW_UP_783,TREATMENT_783,,DONOR_63,SYNTHETIC-2,Local recurrence and distant metastasis,C05,N2b
"{'month_interval': 43, 'day_interval': 1290}",Stable,"{'month_interval': 6, 'day_interval': 180}",Imaging (procedure)|Tumor marker measurement (procedure),International Neuroblastoma Risk Group Staging System,T4,MX,,FOLLOW_UP_784,TREATMENT_784,,DONOR_64,SYNTHETIC-2,Local recurrence and distant metastasis,,
"{'month_interval': 17, 'day_interval': 510}",Loco-regional progression,,Laboratory data interpretation (procedure),International Neuroblastoma Staging System,Tis,M1d(1),Stage 0,FOLLOW_UP_785,TREATMENT_785,,DONOR_65,SYNTHETIC-2,Local recurrence,,N2
"{'month_interval': 6, 'day_interval': 180}",,"{'month_interval': 13, 'day_interval': 390}",,AJCC 8th edition,T1a2,M0,Stage IB2,FOLLOW_UP_786,TREATMENT_786,,DONOR_66,SYNTHETIC-2,Biochemical progression,,N2c
"{'month_interval': 22, 'day_interval': 660}",Complete remission,,Tumor marker measurement (procedure)|Histopathology test (procedure),Ann Arbor staging system,Tis pu,M1a(0),Stage L1,FOLLOW_UP_787,TREATMENT_787,,DONOR_67,SYNTHETIC-2,Biochemical progression,C16|C15,N1b
,Complete remission,"{'month_interval': 22, 'day_interval': 660}",,Ann Arbor staging system,Tis pd,M1e,Stage IA1,FOLLOW_UP_788,TREATMENT_788,,DONOR_68,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 6, 'day_interval': 180}",Complete remission,"{'month_interval': 5, 'day_interval': 150}",Histopathology test (procedure),Durie-Salmon staging system,T2b,,Stage IIIB,FOLLOW_UP_789,TREATMENT_789,,DONOR_69,SYNTHETIC-2,Progression (liquid tumours),C15|C10,N0(i+)
"{'month_interval': 26, 'day_interval': 780}",Partial remission,"{'month_interval': 26, 'day_interval': 780}",Tumor marker measurement (procedure)|Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,T2a2,M1a(0),Stage IVA,FOLLOW_UP_790,TREATMENT_790,,DONOR_70,SYNTHETIC-2,Local recurrence and distant metastasis,,N1a
"{'month_interval': 4, 'day_interval': 120}",Distant progression,"{'month_interval': 15, 'day_interval': 450}",,AJCC 8th edition,Tis(LCIS),M1e,Stage IA,FOLLOW_UP_791,TREATMENT_791,,DONOR_41,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 8, 'day_interval': 240}",Distant progression,,Laboratory data interpretation (procedure)|Imaging (procedure),SEER staging system,,M1d(0),Stage IIIAS,FOLLOW_UP_792,TREATMENT_792,,DONOR_42,SYNTHETIC-2,Distant recurrence/metastasis,C02,N0
"{'month_interval': 14, 'day_interval': 420}",,"{'month_interval': 32, 'day_interval': 960}",Physical examination procedure (procedure),AJCC 6th edition,Tis pu,M1a,Stage IIIA2,FOLLOW_UP_793,TREATMENT_793,,DONOR_43,SYNTHETIC-2,Local recurrence,C09|C15,N0(mol-)
"{'month_interval': 7, 'day_interval': 210}",Progression not otherwise specified,"{'month_interval': 20, 'day_interval': 600}",Assessment of symptom control (procedure),,T4a(s),M1c(0),Stage IC,FOLLOW_UP_794,TREATMENT_794,,DONOR_44,SYNTHETIC-2,Distant recurrence/metastasis,C13|C19,N3b
"{'month_interval': 37, 'day_interval': 1110}",Progression not otherwise specified,"{'month_interval': 35, 'day_interval': 1050}",Laboratory data interpretation (procedure)|Histopathology test (procedure),International Neuroblastoma Risk Group Staging System,T0,,Stage IIIE,FOLLOW_UP_795,TREATMENT_795,,DONOR_45,SYNTHETIC-2,Distant recurrence/metastasis,C20,N3a
"{'month_interval': 17, 'day_interval': 510}",No evidence of disease,"{'month_interval': 24, 'day_interval': 720}",,Rai staging system,,,,FOLLOW_UP_796,TREATMENT_796,,DONOR_46,SYNTHETIC-2,Local recurrence and distant metastasis,C06,N3a
"{'month_interval': 7, 'day_interval': 210}",Progression not otherwise specified,"{'month_interval': 50, 'day_interval': 1500}",Tumor marker measurement (procedure),AJCC 7th edition,T1d,M1a(0),Stage IIEB,FOLLOW_UP_797,TREATMENT_797,,DONOR_47,SYNTHETIC-2,Local recurrence,,N0(mol-)
"{'month_interval': 17, 'day_interval': 510}",No evidence of disease,"{'month_interval': 42, 'day_interval': 1260}",Imaging (procedure),,,,Stage IIIBE,FOLLOW_UP_798,TREATMENT_798,,DONOR_48,SYNTHETIC-2,Distant recurrence/metastasis,C15|C06,N2a
"{'month_interval': 42, 'day_interval': 1260}",Progression not otherwise specified,"{'month_interval': 8, 'day_interval': 240}",Imaging (procedure)|Tumor marker measurement (procedure),AJCC 6th edition,T4b(s),,Stage A,FOLLOW_UP_799,TREATMENT_799,,DONOR_49,SYNTHETIC-2,Local recurrence,C14,N0b
"{'month_interval': 14, 'day_interval': 420}",Stable,"{'month_interval': 5, 'day_interval': 150}",Laboratory data interpretation (procedure)|Imaging (procedure),Lugano staging system,TX,M0,Stage IEB,FOLLOW_UP_800,TREATMENT_800,,DONOR_50,SYNTHETIC-2,Biochemical progression,,N1a
"{'month_interval': 29, 'day_interval': 870}",Partial remission,,,Binet staging system,T3a,M1d(0),Stage IAE,FOLLOW_UP_801,TREATMENT_801,,DONOR_51,SYNTHETIC-2,Biochemical progression,,
"{'month_interval': 43, 'day_interval': 1290}",Loco-regional progression,"{'month_interval': 24, 'day_interval': 720}",,St Jude staging system,T4b(s),M1e,Stage IVC,FOLLOW_UP_802,TREATMENT_802,,DONOR_52,SYNTHETIC-2,Local recurrence,C13,NX
"{'month_interval': 3, 'day_interval': 90}",Relapse or recurrence,"{'month_interval': 1, 'day_interval': 30}",Histopathology test (procedure)|Assessment of symptom control (procedure),Ann Arbor staging system,T4,M0,Stage IIIA2,FOLLOW_UP_803,TREATMENT_803,,DONOR_53,SYNTHETIC-2,Biochemical progression,,N1a
"{'month_interval': 3, 'day_interval': 90}",Progression not otherwise specified,"{'month_interval': 15, 'day_interval': 450}",,,T3,M1b(0),Stage IIID,FOLLOW_UP_804,TREATMENT_804,,DONOR_54,SYNTHETIC-2,Local recurrence,C16,
"{'month_interval': 9, 'day_interval': 270}",No evidence of disease,"{'month_interval': 2, 'day_interval': 60}",Assessment of symptom control (procedure),SEER staging system,T2d,M1a(0),Stage IIBS,FOLLOW_UP_805,TREATMENT_805,,DONOR_55,SYNTHETIC-2,Biochemical progression,,
"{'month_interval': 48, 'day_interval': 1440}",Distant progression,"{'month_interval': 11, 'day_interval': 330}",Histopathology test (procedure)|Assessment of symptom control (procedure),Revised International staging system (RISS),,M1a(0),Stage I,FOLLOW_UP_806,TREATMENT_806,,DONOR_56,SYNTHETIC-2,Progression (liquid tumours),,
"{'month_interval': 12, 'day_interval': 360}",Partial remission,"{'month_interval': 13, 'day_interval': 390}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Durie-Salmon staging system,,,,FOLLOW_UP_807,TREATMENT_807,,DONOR_57,SYNTHETIC-2,Local recurrence,,N2a
"{'month_interval': 7, 'day_interval': 210}",No evidence of disease,,Physical examination procedure (procedure)|Assessment of symptom control (procedure),AJCC 6th edition,T3a,M1b(0),Stage IIIC,FOLLOW_UP_808,TREATMENT_808,,DONOR_58,SYNTHETIC-2,Local recurrence and distant metastasis,C08|C07,N0(i-)
"{'month_interval': 20, 'day_interval': 600}",Relapse or recurrence,"{'month_interval': 14, 'day_interval': 420}",,Binet staging system,TX,MX,,FOLLOW_UP_809,TREATMENT_809,,DONOR_59,SYNTHETIC-2,Progression (liquid tumours),,
"{'month_interval': 32, 'day_interval': 960}",,"{'month_interval': 27, 'day_interval': 810}",Histopathology test (procedure),AJCC 8th edition,T2c,,Stage 1A,FOLLOW_UP_810,TREATMENT_810,,DONOR_60,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 32, 'day_interval': 960}",Complete remission,"{'month_interval': 39, 'day_interval': 1170}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),AJCC 6th edition,,M0(i+),Stage IVAS,FOLLOW_UP_811,TREATMENT_811,,DONOR_61,SYNTHETIC-2,Local recurrence and distant metastasis,C16|C01,N3a
"{'month_interval': 1, 'day_interval': 30}",Progression not otherwise specified,,,,Tis pu,M1d(1),Stage IVBE,FOLLOW_UP_812,TREATMENT_812,,DONOR_62,SYNTHETIC-2,Progression (liquid tumours),C02|C11,N1b
"{'month_interval': 5, 'day_interval': 150}",Stable,"{'month_interval': 24, 'day_interval': 720}",Physical examination procedure (procedure),Binet staging system,Tis pd,M1d(1),Stage IB1,FOLLOW_UP_813,TREATMENT_813,,DONOR_63,SYNTHETIC-2,Distant recurrence/metastasis,,N1mi
"{'month_interval': 18, 'day_interval': 540}",Progression not otherwise specified,"{'month_interval': 22, 'day_interval': 660}",,Revised International staging system (RISS),T0,,Stage IAES,FOLLOW_UP_814,TREATMENT_814,,DONOR_64,SYNTHETIC-2,Distant recurrence/metastasis,C15,N1c
"{'month_interval': 45, 'day_interval': 1350}",Partial remission,"{'month_interval': 38, 'day_interval': 1140}",Imaging (procedure)|Histopathology test (procedure),International Neuroblastoma Risk Group Staging System,T1,M1c,,FOLLOW_UP_815,TREATMENT_815,,DONOR_65,SYNTHETIC-2,Progression (liquid tumours),C11|C05,N0a
"{'month_interval': 30, 'day_interval': 900}",Complete remission,,,St Jude staging system,T2a,M1b(1),Stage IIIE,FOLLOW_UP_816,TREATMENT_816,,DONOR_66,SYNTHETIC-2,Local recurrence and distant metastasis,C18|C04,
"{'month_interval': 44, 'day_interval': 1320}",No evidence of disease,,Physical examination procedure (procedure),Lugano staging system,T1b(m),,Stage IIBS,FOLLOW_UP_817,TREATMENT_817,,DONOR_67,SYNTHETIC-2,Local recurrence and distant metastasis,,N0
"{'month_interval': 46, 'day_interval': 1380}",Complete remission,"{'month_interval': 45, 'day_interval': 1350}",Physical examination procedure (procedure)|Tumor marker measurement (procedure),,Tis pd,M1c,Localized,FOLLOW_UP_818,TREATMENT_818,,DONOR_68,SYNTHETIC-2,Progression (liquid tumours),,N2c
"{'month_interval': 15, 'day_interval': 450}",No evidence of disease,"{'month_interval': 44, 'day_interval': 1320}",Imaging (procedure)|Physical examination procedure (procedure),,,M1e,Stage IIA,FOLLOW_UP_819,TREATMENT_819,,DONOR_69,SYNTHETIC-2,Progression (liquid tumours),C10,N3b
"{'month_interval': 7, 'day_interval': 210}",Loco-regional progression,"{'month_interval': 17, 'day_interval': 510}",,Lugano staging system,T1d,MX,Stage IVE,FOLLOW_UP_820,TREATMENT_820,,DONOR_70,SYNTHETIC-2,,,N1a(sn)
"{'month_interval': 32, 'day_interval': 960}",Loco-regional progression,"{'month_interval': 10, 'day_interval': 300}",Histopathology test (procedure)|Physical examination procedure (procedure),AJCC 8th edition,T4b(s),M1a,,FOLLOW_UP_821,TREATMENT_821,,DONOR_41,SYNTHETIC-2,Progression (liquid tumours),C15|C20,
"{'month_interval': 1, 'day_interval': 30}",Relapse or recurrence,,Histopathology test (procedure),AJCC 8th edition,T1mi,M1c(1),Stage IIID,FOLLOW_UP_822,TREATMENT_822,,DONOR_42,SYNTHETIC-2,Local recurrence,,N1a(sn)
,Relapse or recurrence,,,Durie-Salmon staging system,T2a,M1c(1),Stage 2B,FOLLOW_UP_823,TREATMENT_823,,DONOR_43,SYNTHETIC-2,Local recurrence,C14,N1
,,"{'month_interval': 16, 'day_interval': 480}",,Ann Arbor staging system,T3(s),M1d(0),Stage IIBES,FOLLOW_UP_824,TREATMENT_824,,DONOR_44,SYNTHETIC-2,,,N1b
"{'month_interval': 21, 'day_interval': 630}",Relapse or recurrence,"{'month_interval': 8, 'day_interval': 240}",,Rai staging system,T1d,M1c(0),Stage IS,FOLLOW_UP_825,TREATMENT_825,,DONOR_45,SYNTHETIC-2,,C02,N1mi
"{'month_interval': 32, 'day_interval': 960}",Stable,"{'month_interval': 7, 'day_interval': 210}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),SEER staging system,T2c,M1b(1),Distant,FOLLOW_UP_826,TREATMENT_826,,DONOR_46,SYNTHETIC-2,Distant recurrence/metastasis,,N2
"{'month_interval': 4, 'day_interval': 120}",Distant progression,"{'month_interval': 14, 'day_interval': 420}",,Revised International staging system (RISS),T4b(s),M1e,Stage IB2,FOLLOW_UP_827,TREATMENT_827,,DONOR_47,SYNTHETIC-2,Biochemical progression,C07|C18,N3c
"{'month_interval': 36, 'day_interval': 1080}",Progression not otherwise specified,"{'month_interval': 32, 'day_interval': 960}",Histopathology test (procedure),SEER staging system,,M1b,Stage IIEB,FOLLOW_UP_828,TREATMENT_828,,DONOR_48,SYNTHETIC-2,Progression (liquid tumours),C19|C02,N0(mol+)
"{'month_interval': 2, 'day_interval': 60}",No evidence of disease,"{'month_interval': 31, 'day_interval': 930}",Tumor marker measurement (procedure)|Laboratory data interpretation (procedure),AJCC 7th edition,,M1b(0),Stage 0,FOLLOW_UP_829,TREATMENT_829,,DONOR_49,SYNTHETIC-2,,,N0b (no biopsy)
,No evidence of disease,"{'month_interval': 10, 'day_interval': 300}",Tumor marker measurement (procedure)|Imaging (procedure),AJCC 7th edition,T1mi,M1a(0),Stage 3,FOLLOW_UP_830,TREATMENT_830,,DONOR_50,SYNTHETIC-2,Local recurrence and distant metastasis,C19|C10,N0(i+)
"{'month_interval': 33, 'day_interval': 990}",Loco-regional progression,"{'month_interval': 1, 'day_interval': 30}",Tumor marker measurement (procedure)|Histopathology test (procedure),Revised International staging system (RISS),,M1d,Stage IIIC2,FOLLOW_UP_831,TREATMENT_831,,DONOR_51,SYNTHETIC-2,,C04,
,,"{'month_interval': 46, 'day_interval': 1380}",Tumor marker measurement (procedure)|Histopathology test (procedure),,T1a,M1b(0),Stage IIIAE,FOLLOW_UP_832,TREATMENT_832,,DONOR_52,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 15, 'day_interval': 450}",Partial remission,,Imaging (procedure),,T4a(m),M1c(1),Stage IIC,FOLLOW_UP_833,TREATMENT_833,,DONOR_53,SYNTHETIC-2,Biochemical progression,,N0b
"{'month_interval': 32, 'day_interval': 960}",No evidence of disease,"{'month_interval': 2, 'day_interval': 60}",Imaging (procedure),AJCC 8th edition,,M1d(1),Stage IVAS,FOLLOW_UP_834,TREATMENT_834,,DONOR_54,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 17, 'day_interval': 510}",Partial remission,"{'month_interval': 45, 'day_interval': 1350}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),,T4a,M1c,Stage III,FOLLOW_UP_835,TREATMENT_835,,DONOR_55,SYNTHETIC-2,Distant recurrence/metastasis,C01,N1
"{'month_interval': 41, 'day_interval': 1230}",Progression not otherwise specified,"{'month_interval': 9, 'day_interval': 270}",Laboratory data interpretation (procedure),AJCC 8th edition,T1mi,,Stage IVA1,FOLLOW_UP_836,TREATMENT_836,,DONOR_56,SYNTHETIC-2,Distant recurrence/metastasis,C06,N0b (no biopsy)
"{'month_interval': 27, 'day_interval': 810}",Relapse or recurrence,"{'month_interval': 28, 'day_interval': 840}",Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,Tis pu,M1c(1),Stage IVA1,FOLLOW_UP_837,TREATMENT_837,,DONOR_57,SYNTHETIC-2,Local recurrence,,N2c
"{'month_interval': 24, 'day_interval': 720}",,"{'month_interval': 49, 'day_interval': 1470}",Imaging (procedure)|Tumor marker measurement (procedure),AJCC 7th edition,Tis(DCIS),M1b(0),Stage IVS,FOLLOW_UP_838,TREATMENT_838,,DONOR_58,SYNTHETIC-2,Local recurrence,C19,N2mi
"{'month_interval': 44, 'day_interval': 1320}",Progression not otherwise specified,"{'month_interval': 12, 'day_interval': 360}",,,,M0(i+),Stage 1A,FOLLOW_UP_839,TREATMENT_839,,DONOR_59,SYNTHETIC-2,Progression (liquid tumours),,N1mi
"{'month_interval': 25, 'day_interval': 750}",Distant progression,"{'month_interval': 24, 'day_interval': 720}",Histopathology test (procedure),SEER staging system,T3d,M1e,,FOLLOW_UP_840,TREATMENT_840,,DONOR_60,SYNTHETIC-2,Progression (liquid tumours),,N3b
"{'month_interval': 12, 'day_interval': 360}",Loco-regional progression,"{'month_interval': 30, 'day_interval': 900}",,Ann Arbor staging system,Tis,MX,,FOLLOW_UP_841,TREATMENT_841,,DONOR_61,SYNTHETIC-2,Biochemical progression,C18|C13,N2b
"{'month_interval': 40, 'day_interval': 1200}",Partial remission,,,,T1,M1d(0),Stage I,FOLLOW_UP_842,TREATMENT_842,,DONOR_62,SYNTHETIC-2,,,N2mi
"{'month_interval': 2, 'day_interval': 60}",,,,SEER staging system,T3(s),M1d(1),Stage 1A,FOLLOW_UP_843,TREATMENT_843,,DONOR_63,SYNTHETIC-2,,C20|C11,N4
"{'month_interval': 1, 'day_interval': 30}",,"{'month_interval': 12, 'day_interval': 360}",Histopathology test (procedure)|Assessment of symptom control (procedure),FIGO staging system,T2a,M1d(0),Stage 4S,FOLLOW_UP_844,TREATMENT_844,,DONOR_64,SYNTHETIC-2,Biochemical progression,C10|C04,N1a
"{'month_interval': 40, 'day_interval': 1200}",Distant progression,"{'month_interval': 28, 'day_interval': 840}",Laboratory data interpretation (procedure)|Tumor marker measurement (procedure),AJCC 8th edition,T1c,M1d,Stage IIEA,FOLLOW_UP_845,TREATMENT_845,,DONOR_65,SYNTHETIC-2,Biochemical progression,,N0a (biopsy)
"{'month_interval': 40, 'day_interval': 1200}",Stable,"{'month_interval': 3, 'day_interval': 90}",Imaging (procedure)|Histopathology test (procedure),SEER staging system,T2a,M1d(0),Stage IIIAE,FOLLOW_UP_846,TREATMENT_846,,DONOR_66,SYNTHETIC-2,Biochemical progression,C19,
"{'month_interval': 44, 'day_interval': 1320}",Progression not otherwise specified,"{'month_interval': 1, 'day_interval': 30}",,International Neuroblastoma Staging System,T4a(m),,,FOLLOW_UP_847,TREATMENT_847,,DONOR_67,SYNTHETIC-2,,C11,N2a
"{'month_interval': 32, 'day_interval': 960}",Progression not otherwise specified,"{'month_interval': 16, 'day_interval': 480}",Tumor marker measurement (procedure),,T1mi,M1b(0),Stage 4S,FOLLOW_UP_848,TREATMENT_848,,DONOR_68,SYNTHETIC-2,Progression (liquid tumours),C06,N1a
"{'month_interval': 4, 'day_interval': 120}",No evidence of disease,,Physical examination procedure (procedure)|Assessment of symptom control (procedure),,T3b,M1d,,FOLLOW_UP_849,TREATMENT_849,,DONOR_69,SYNTHETIC-2,Progression (liquid tumours),C18,N3
"{'month_interval': 39, 'day_interval': 1170}",Distant progression,"{'month_interval': 48, 'day_interval': 1440}",Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,,M1c(1),Stage IVAE,FOLLOW_UP_850,TREATMENT_850,,DONOR_70,SYNTHETIC-2,Biochemical progression,C19,N2a
"{'month_interval': 41, 'day_interval': 1230}",Stable,"{'month_interval': 3, 'day_interval': 90}",Laboratory data interpretation (procedure),Binet staging system,,M0,Stage IIID,FOLLOW_UP_851,TREATMENT_851,,DONOR_41,SYNTHETIC-2,Biochemical progression,C04,
"{'month_interval': 29, 'day_interval': 870}",Relapse or recurrence,"{'month_interval': 7, 'day_interval': 210}",,Durie-Salmon staging system,T2c,M1,Stage IIIB,FOLLOW_UP_852,TREATMENT_852,,DONOR_42,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 11, 'day_interval': 330}",Partial remission,"{'month_interval': 38, 'day_interval': 1140}",,AJCC 6th edition,T1d,M1a,,FOLLOW_UP_853,TREATMENT_853,,DONOR_43,SYNTHETIC-2,Local recurrence,,N1a(sn)
"{'month_interval': 7, 'day_interval': 210}",,"{'month_interval': 44, 'day_interval': 1320}",Imaging (procedure)|Laboratory data interpretation (procedure),SEER staging system,Tis(LCIS),M1d(0),Stage IIIB,FOLLOW_UP_854,TREATMENT_854,,DONOR_44,SYNTHETIC-2,Biochemical progression,,N1c
"{'month_interval': 49, 'day_interval': 1470}",,"{'month_interval': 28, 'day_interval': 840}",Imaging (procedure)|Physical examination procedure (procedure),AJCC 7th edition,,M1c(1),Stage 4S,FOLLOW_UP_855,TREATMENT_855,,DONOR_45,SYNTHETIC-2,Progression (liquid tumours),C18|C17,
"{'month_interval': 19, 'day_interval': 570}",Progression not otherwise specified,"{'month_interval': 18, 'day_interval': 540}",Tumor marker measurement (procedure)|Imaging (procedure),,T2a2,,Stage 0a,FOLLOW_UP_856,TREATMENT_856,,DONOR_46,SYNTHETIC-2,Local recurrence,,N3c
"{'month_interval': 32, 'day_interval': 960}",No evidence of disease,"{'month_interval': 47, 'day_interval': 1410}",,AJCC 6th edition,,M1,Stage IVA2,FOLLOW_UP_857,TREATMENT_857,,DONOR_47,SYNTHETIC-2,,C19|C12,N1b
"{'month_interval': 13, 'day_interval': 390}",Loco-regional progression,"{'month_interval': 2, 'day_interval': 60}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),AJCC 8th edition,Tis(Paget's),M1b,Distant,FOLLOW_UP_858,TREATMENT_858,,DONOR_48,SYNTHETIC-2,Progression (liquid tumours),,N2
"{'month_interval': 8, 'day_interval': 240}",Complete remission,"{'month_interval': 15, 'day_interval': 450}",Assessment of symptom control (procedure),AJCC 7th edition,,M1c,Stage IIIA2,FOLLOW_UP_859,TREATMENT_859,,DONOR_49,SYNTHETIC-2,Biochemical progression,C01|C02,NX
"{'month_interval': 2, 'day_interval': 60}",Stable,"{'month_interval': 22, 'day_interval': 660}",Histopathology test (procedure)|Tumor marker measurement (procedure),FIGO staging system,Tis pu,M1d,Stage II,FOLLOW_UP_860,TREATMENT_860,,DONOR_50,SYNTHETIC-2,,C10,
"{'month_interval': 29, 'day_interval': 870}",Partial remission,"{'month_interval': 8, 'day_interval': 240}",,AJCC 7th edition,T2a2,M1a(1),Stage IIIA2,FOLLOW_UP_861,TREATMENT_861,,DONOR_51,SYNTHETIC-2,Local recurrence,C08,N1mi
"{'month_interval': 38, 'day_interval': 1140}",Distant progression,"{'month_interval': 32, 'day_interval': 960}",Assessment of symptom control (procedure),,,M1d(1),,FOLLOW_UP_862,TREATMENT_862,,DONOR_52,SYNTHETIC-2,Local recurrence,,N2a
"{'month_interval': 50, 'day_interval': 1500}",Stable,"{'month_interval': 30, 'day_interval': 900}",,Durie-Salmon staging system,,M1c(0),Stage IB2,FOLLOW_UP_863,TREATMENT_863,,DONOR_53,SYNTHETIC-2,,,N0a (biopsy)
"{'month_interval': 35, 'day_interval': 1050}",,"{'month_interval': 27, 'day_interval': 810}",Laboratory data interpretation (procedure)|Imaging (procedure),International Neuroblastoma Staging System,,M1a(0),Stage IIBS,FOLLOW_UP_864,TREATMENT_864,,DONOR_54,SYNTHETIC-2,Local recurrence and distant metastasis,,N1b
"{'month_interval': 38, 'day_interval': 1140}",,"{'month_interval': 49, 'day_interval': 1470}",,AJCC 8th edition,,M1a(0),Stage IIIAES,FOLLOW_UP_865,TREATMENT_865,,DONOR_55,SYNTHETIC-2,Local recurrence,,
"{'month_interval': 8, 'day_interval': 240}",Stable,"{'month_interval': 9, 'day_interval': 270}",Imaging (procedure),Lugano staging system,,,Stage IVS,FOLLOW_UP_866,TREATMENT_866,,DONOR_56,SYNTHETIC-2,Biochemical progression,,N2c
"{'month_interval': 44, 'day_interval': 1320}",Distant progression,"{'month_interval': 11, 'day_interval': 330}",Imaging (procedure)|Tumor marker measurement (procedure),SEER staging system,T1a2,,Stage IVS,FOLLOW_UP_867,TREATMENT_867,,DONOR_57,SYNTHETIC-2,Local recurrence,C06|C17,
"{'month_interval': 39, 'day_interval': 1170}",Relapse or recurrence,"{'month_interval': 38, 'day_interval': 1140}",,SEER staging system,T1,,Stage IIAS,FOLLOW_UP_868,TREATMENT_868,,DONOR_58,SYNTHETIC-2,Distant recurrence/metastasis,C13,N1c
"{'month_interval': 40, 'day_interval': 1200}",No evidence of disease,"{'month_interval': 12, 'day_interval': 360}",Imaging (procedure),Lugano staging system,T3(s),M1d,Stage II bulky,FOLLOW_UP_869,TREATMENT_869,,DONOR_59,SYNTHETIC-2,Local recurrence and distant metastasis,,
"{'month_interval': 16, 'day_interval': 480}",Complete remission,"{'month_interval': 36, 'day_interval': 1080}",,International Neuroblastoma Risk Group Staging System,,,Stage IIIAE,FOLLOW_UP_870,TREATMENT_870,,DONOR_60,SYNTHETIC-2,Progression (liquid tumours),C18,N0
"{'month_interval': 23, 'day_interval': 690}",Distant progression,"{'month_interval': 50, 'day_interval': 1500}",Tumor marker measurement (procedure)|Histopathology test (procedure),AJCC 8th edition,T1b(m),M1e,Stage 1A,FOLLOW_UP_871,TREATMENT_871,,DONOR_61,SYNTHETIC-2,Local recurrence,,N0(i-)
,,"{'month_interval': 30, 'day_interval': 900}",Physical examination procedure (procedure)|Histopathology test (procedure),,Tis,M1d(1),Stage 3,FOLLOW_UP_872,TREATMENT_872,,DONOR_62,SYNTHETIC-2,Progression (liquid tumours),C07|C09,N1mi
"{'month_interval': 45, 'day_interval': 1350}",Relapse or recurrence,"{'month_interval': 38, 'day_interval': 1140}",Histopathology test (procedure)|Tumor marker measurement (procedure),AJCC 8th edition,,,Stage IA,FOLLOW_UP_873,TREATMENT_873,,DONOR_63,SYNTHETIC-2,Biochemical progression,,N1
"{'month_interval': 10, 'day_interval': 300}",Relapse or recurrence,"{'month_interval': 24, 'day_interval': 720}",,Ann Arbor staging system,T1b1,M1b,Stage IIIA,FOLLOW_UP_874,TREATMENT_874,,DONOR_64,SYNTHETIC-2,,C13,N3c
"{'month_interval': 40, 'day_interval': 1200}",Distant progression,"{'month_interval': 37, 'day_interval': 1110}",Laboratory data interpretation (procedure),Binet staging system,T1a,M1d,Stage IES,FOLLOW_UP_875,TREATMENT_875,,DONOR_65,SYNTHETIC-2,Local recurrence and distant metastasis,C03|C09,N0b
"{'month_interval': 22, 'day_interval': 660}",Relapse or recurrence,"{'month_interval': 24, 'day_interval': 720}",,Binet staging system,T2b,M1b(1),Stage IVA,FOLLOW_UP_876,TREATMENT_876,,DONOR_66,SYNTHETIC-2,Biochemical progression,C20,NX
"{'month_interval': 9, 'day_interval': 270}",,"{'month_interval': 8, 'day_interval': 240}",Imaging (procedure),St Jude staging system,T1b,M1b,,FOLLOW_UP_877,TREATMENT_877,,DONOR_67,SYNTHETIC-2,Local recurrence,C18,N3a
,Distant progression,"{'month_interval': 1, 'day_interval': 30}",Laboratory data interpretation (procedure),,T1b2,M1b(1),Stage IIIAES,FOLLOW_UP_878,TREATMENT_878,,DONOR_68,SYNTHETIC-2,,C06|C16,
"{'month_interval': 2, 'day_interval': 60}",Progression not otherwise specified,"{'month_interval': 4, 'day_interval': 120}",,Rai staging system,T3(s),,,FOLLOW_UP_879,TREATMENT_879,,DONOR_69,SYNTHETIC-2,Biochemical progression,C19|C20,N3c
"{'month_interval': 15, 'day_interval': 450}",Progression not otherwise specified,"{'month_interval': 40, 'day_interval': 1200}",Imaging (procedure),Durie-Salmon staging system,T1a(s),MX,Stage IIAS,FOLLOW_UP_880,TREATMENT_880,,DONOR_70,SYNTHETIC-2,Local recurrence and distant metastasis,,N0(mol-)
"{'month_interval': 17, 'day_interval': 510}",,,,,T3b,M0(i+),,FOLLOW_UP_881,TREATMENT_881,,DONOR_41,SYNTHETIC-2,Biochemical progression,,N2b
"{'month_interval': 4, 'day_interval': 120}",Distant progression,"{'month_interval': 2, 'day_interval': 60}",Assessment of symptom control (procedure)|Physical examination procedure (procedure),,,,Stage IVB,FOLLOW_UP_882,TREATMENT_882,,DONOR_42,SYNTHETIC-2,Local recurrence,C10|C19,N2a
,Complete remission,"{'month_interval': 33, 'day_interval': 990}",Histopathology test (procedure),International Neuroblastoma Staging System,,M1b,Stage IIE,FOLLOW_UP_883,TREATMENT_883,,DONOR_43,SYNTHETIC-2,Biochemical progression,C12|C04,N0b
"{'month_interval': 31, 'day_interval': 930}",Stable,"{'month_interval': 25, 'day_interval': 750}",,AJCC 8th edition,T2(m),M1c(1),,FOLLOW_UP_884,TREATMENT_884,,DONOR_44,SYNTHETIC-2,Progression (liquid tumours),,
"{'month_interval': 31, 'day_interval': 930}",Partial remission,"{'month_interval': 34, 'day_interval': 1020}",,Rai staging system,Tis,M1a(1),Stage IIIA1,FOLLOW_UP_885,TREATMENT_885,,DONOR_45,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 45, 'day_interval': 1350}",Complete remission,"{'month_interval': 32, 'day_interval': 960}",,Revised International staging system (RISS),T1a(s),MX,Stage 3,FOLLOW_UP_886,TREATMENT_886,,DONOR_46,SYNTHETIC-2,Progression (liquid tumours),C05|C09,N3b
"{'month_interval': 49, 'day_interval': 1470}",Relapse or recurrence,"{'month_interval': 37, 'day_interval': 1110}",Physical examination procedure (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,Tis,M1a,Stage IBE,FOLLOW_UP_887,TREATMENT_887,,DONOR_47,SYNTHETIC-2,Biochemical progression,C11,N4
"{'month_interval': 35, 'day_interval': 1050}",Progression not otherwise specified,"{'month_interval': 19, 'day_interval': 570}",,AJCC 6th edition,T1,M1d,Stage 3,FOLLOW_UP_888,TREATMENT_888,,DONOR_48,SYNTHETIC-2,Local recurrence,C18,N0
"{'month_interval': 12, 'day_interval': 360}",Complete remission,"{'month_interval': 31, 'day_interval': 930}",,AJCC 6th edition,T4a(s),M0,Stage 0is,FOLLOW_UP_889,TREATMENT_889,,DONOR_49,SYNTHETIC-2,Local recurrence,C13,N1b
"{'month_interval': 15, 'day_interval': 450}",Complete remission,"{'month_interval': 11, 'day_interval': 330}",Imaging (procedure)|Laboratory data interpretation (procedure),SEER staging system,T2a2,M1c(0),Stage IIE,FOLLOW_UP_890,TREATMENT_890,,DONOR_50,SYNTHETIC-2,Distant recurrence/metastasis,,N1mi
"{'month_interval': 16, 'day_interval': 480}",Complete remission,"{'month_interval': 43, 'day_interval': 1290}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Rai staging system,T1b(s),M1d,Stage 0,FOLLOW_UP_891,TREATMENT_891,,DONOR_51,SYNTHETIC-2,Local recurrence and distant metastasis,,NX
"{'month_interval': 48, 'day_interval': 1440}",Stable,"{'month_interval': 25, 'day_interval': 750}",Assessment of symptom control (procedure)|Physical examination procedure (procedure),Revised International staging system (RISS),T4b,MX,Stage II bulky,FOLLOW_UP_892,TREATMENT_892,,DONOR_52,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 21, 'day_interval': 630}",No evidence of disease,"{'month_interval': 17, 'day_interval': 510}",Tumor marker measurement (procedure),,T1a,M1a,Stage 3,FOLLOW_UP_893,TREATMENT_893,,DONOR_53,SYNTHETIC-2,Local recurrence,,
"{'month_interval': 2, 'day_interval': 60}",Partial remission,"{'month_interval': 44, 'day_interval': 1320}",,,T2c,,Stage IVAS,FOLLOW_UP_894,TREATMENT_894,,DONOR_54,SYNTHETIC-2,Local recurrence and distant metastasis,C13,N0b
"{'month_interval': 28, 'day_interval': 840}",,"{'month_interval': 22, 'day_interval': 660}",Imaging (procedure),AJCC 7th edition,T3(s),,Stage IB1,FOLLOW_UP_895,TREATMENT_895,,DONOR_55,SYNTHETIC-2,Local recurrence,,
"{'month_interval': 36, 'day_interval': 1080}",No evidence of disease,"{'month_interval': 26, 'day_interval': 780}",Imaging (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Staging System,T1,M1a,Stage IB2,FOLLOW_UP_896,TREATMENT_896,,DONOR_56,SYNTHETIC-2,Distant recurrence/metastasis,C07,N2mi
,Distant progression,"{'month_interval': 5, 'day_interval': 150}",Physical examination procedure (procedure),Binet staging system,,M1d(1),Stage IAB,FOLLOW_UP_897,TREATMENT_897,,DONOR_57,SYNTHETIC-2,Local recurrence,C06,N1a
"{'month_interval': 4, 'day_interval': 120}",Loco-regional progression,"{'month_interval': 3, 'day_interval': 90}",Tumor marker measurement (procedure),St Jude staging system,T1a(s),MX,Stage IAB,FOLLOW_UP_898,TREATMENT_898,,DONOR_58,SYNTHETIC-2,Local recurrence,C06,N0(i+)
"{'month_interval': 31, 'day_interval': 930}",Partial remission,"{'month_interval': 4, 'day_interval': 120}",Histopathology test (procedure),Revised International staging system (RISS),T1,M1c(0),Stage IEB,FOLLOW_UP_899,TREATMENT_899,,DONOR_59,SYNTHETIC-2,Local recurrence,C14|C06,N0
,,,Histopathology test (procedure)|Laboratory data interpretation (procedure),St Jude staging system,,M0,,FOLLOW_UP_900,TREATMENT_900,,DONOR_60,SYNTHETIC-2,Biochemical progression,C11,N0b (no biopsy)
"{'month_interval': 35, 'day_interval': 1050}",Loco-regional progression,,Physical examination procedure (procedure),,T1b(m),M1a(0),,FOLLOW_UP_901,TREATMENT_901,,DONOR_61,SYNTHETIC-2,Distant recurrence/metastasis,C08|C09,
"{'month_interval': 32, 'day_interval': 960}",,,Tumor marker measurement (procedure)|Physical examination procedure (procedure),Durie-Salmon staging system,,M1b(0),Stage IIIC1,FOLLOW_UP_902,TREATMENT_902,,DONOR_62,SYNTHETIC-2,Local recurrence and distant metastasis,,N3a
"{'month_interval': 12, 'day_interval': 360}",Stable,"{'month_interval': 2, 'day_interval': 60}",Tumor marker measurement (procedure),St Jude staging system,,M1a(1),,FOLLOW_UP_903,TREATMENT_903,,DONOR_63,SYNTHETIC-2,Biochemical progression,,
"{'month_interval': 9, 'day_interval': 270}",,"{'month_interval': 5, 'day_interval': 150}",Imaging (procedure)|Histopathology test (procedure),,Tis(LCIS),M1d(0),Stage L1,FOLLOW_UP_904,TREATMENT_904,,DONOR_64,SYNTHETIC-2,Biochemical progression,,N0b
"{'month_interval': 24, 'day_interval': 720}",Distant progression,"{'month_interval': 6, 'day_interval': 180}",,Revised International staging system (RISS),T1d,,Stage IAE,FOLLOW_UP_905,TREATMENT_905,,DONOR_65,SYNTHETIC-2,Local recurrence,C17,N0(i-)
"{'month_interval': 38, 'day_interval': 1140}",Distant progression,"{'month_interval': 50, 'day_interval': 1500}",,AJCC 8th edition,Tis(LCIS),M1e,Stage IB1,FOLLOW_UP_906,TREATMENT_906,,DONOR_66,SYNTHETIC-2,Distant recurrence/metastasis,,
"{'month_interval': 28, 'day_interval': 840}",Stable,"{'month_interval': 42, 'day_interval': 1260}",Imaging (procedure),St Jude staging system,,M1c(0),Stage IIIC2,FOLLOW_UP_907,TREATMENT_907,,DONOR_67,SYNTHETIC-2,Biochemical progression,,N2
"{'month_interval': 31, 'day_interval': 930}",Progression not otherwise specified,"{'month_interval': 16, 'day_interval': 480}",Histopathology test (procedure),,Tis(Paget),M1b(1),,FOLLOW_UP_908,TREATMENT_908,,DONOR_68,SYNTHETIC-2,Biochemical progression,,N1a(sn)
"{'month_interval': 48, 'day_interval': 1440}",Distant progression,,Laboratory data interpretation (procedure),AJCC 6th edition,T4b(s),M0(i+),,FOLLOW_UP_909,TREATMENT_909,,DONOR_69,SYNTHETIC-2,Local recurrence,,N2mi
"{'month_interval': 3, 'day_interval': 90}",No evidence of disease,"{'month_interval': 2, 'day_interval': 60}",,International Neuroblastoma Risk Group Staging System,T1a2,M1d(1),Stage IIIA2,FOLLOW_UP_910,TREATMENT_910,,DONOR_70,SYNTHETIC-2,Local recurrence,C12|C19,N0(mol-)
"{'month_interval': 6, 'day_interval': 180}",Loco-regional progression,"{'month_interval': 26, 'day_interval': 780}",Laboratory data interpretation (procedure),SEER staging system,T1a(m),MX,Stage IB,FOLLOW_UP_911,TREATMENT_911,,DONOR_71,SYNTHETIC-3,Local recurrence and distant metastasis,,N1
"{'month_interval': 27, 'day_interval': 810}",No evidence of disease,,,AJCC 7th edition,T1,MX,Stage IA1,FOLLOW_UP_912,TREATMENT_912,,DONOR_72,SYNTHETIC-3,Distant recurrence/metastasis,,N2c
"{'month_interval': 9, 'day_interval': 270}",Relapse or recurrence,"{'month_interval': 31, 'day_interval': 930}",,Lugano staging system,T1a(s),M1d(1),,FOLLOW_UP_913,TREATMENT_913,,DONOR_73,SYNTHETIC-3,,C19|C12,N1
"{'month_interval': 14, 'day_interval': 420}",No evidence of disease,"{'month_interval': 7, 'day_interval': 210}",,International Neuroblastoma Risk Group Staging System,Tis pd,M1,In situ,FOLLOW_UP_914,TREATMENT_914,,DONOR_74,SYNTHETIC-3,Progression (liquid tumours),,
"{'month_interval': 4, 'day_interval': 120}",Relapse or recurrence,"{'month_interval': 9, 'day_interval': 270}",,FIGO staging system,T0,M1d(0),Stage IIB,FOLLOW_UP_915,TREATMENT_915,,DONOR_75,SYNTHETIC-3,Distant recurrence/metastasis,,
"{'month_interval': 40, 'day_interval': 1200}",Partial remission,"{'month_interval': 20, 'day_interval': 600}",,International Neuroblastoma Staging System,T1a2,M1d(1),Stage 1B,FOLLOW_UP_916,TREATMENT_916,,DONOR_76,SYNTHETIC-3,Progression (liquid tumours),,N2
"{'month_interval': 32, 'day_interval': 960}",Loco-regional progression,"{'month_interval': 41, 'day_interval': 1230}",Tumor marker measurement (procedure),AJCC 6th edition,T3c,M1d(0),Stage IC,FOLLOW_UP_917,TREATMENT_917,,DONOR_77,SYNTHETIC-3,,,N2a
"{'month_interval': 8, 'day_interval': 240}",,"{'month_interval': 18, 'day_interval': 540}",Histopathology test (procedure)|Physical examination procedure (procedure),AJCC 7th edition,Tis(LAMN),M1a(1),Stage IAB,FOLLOW_UP_918,TREATMENT_918,,DONOR_78,SYNTHETIC-3,Biochemical progression,,N2mi
"{'month_interval': 42, 'day_interval': 1260}",,"{'month_interval': 5, 'day_interval': 150}",,Durie-Salmon staging system,Tis(LCIS),M1,Stage IVBES,FOLLOW_UP_919,TREATMENT_919,,DONOR_79,SYNTHETIC-3,Biochemical progression,C11,N2c
"{'month_interval': 32, 'day_interval': 960}",,"{'month_interval': 16, 'day_interval': 480}",,Ann Arbor staging system,Tis pu,M1b,Stage IIIBS,FOLLOW_UP_920,TREATMENT_920,,DONOR_80,SYNTHETIC-3,Biochemical progression,,N3b
"{'month_interval': 24, 'day_interval': 720}",,"{'month_interval': 6, 'day_interval': 180}",Histopathology test (procedure)|Physical examination procedure (procedure),AJCC 8th edition,T1b,M1e,Stage IA1,FOLLOW_UP_921,TREATMENT_921,,DONOR_81,SYNTHETIC-3,Biochemical progression,C09|C19,N1c
"{'month_interval': 30, 'day_interval': 900}",Stable,"{'month_interval': 34, 'day_interval': 1020}",Laboratory data interpretation (procedure)|Imaging (procedure),,T2(s),M1,Stage IE,FOLLOW_UP_922,TREATMENT_922,,DONOR_82,SYNTHETIC-3,Progression (liquid tumours),C11,N0(i-)
"{'month_interval': 41, 'day_interval': 1230}",Loco-regional progression,"{'month_interval': 48, 'day_interval': 1440}",,FIGO staging system,,M1e,Stage IVB,FOLLOW_UP_923,TREATMENT_923,,DONOR_83,SYNTHETIC-3,Local recurrence and distant metastasis,,N4
"{'month_interval': 33, 'day_interval': 990}",No evidence of disease,,Physical examination procedure (procedure),Revised International staging system (RISS),Tis(DCIS),M1b(0),,FOLLOW_UP_924,TREATMENT_924,,DONOR_84,SYNTHETIC-3,Local recurrence,C12|C19,N1a(sn)
"{'month_interval': 7, 'day_interval': 210}",No evidence of disease,,Assessment of symptom control (procedure)|Physical examination procedure (procedure),International Neuroblastoma Risk Group Staging System,,M1c,Stage IIES,FOLLOW_UP_925,TREATMENT_925,,DONOR_85,SYNTHETIC-3,Progression (liquid tumours),C19|C13,N0(mol+)
"{'month_interval': 31, 'day_interval': 930}",Stable,"{'month_interval': 23, 'day_interval': 690}",,,T3d,M1e,Stage IIIS,FOLLOW_UP_926,TREATMENT_926,,DONOR_86,SYNTHETIC-3,Distant recurrence/metastasis,,N0(mol-)
"{'month_interval': 38, 'day_interval': 1140}",Relapse or recurrence,,Physical examination procedure (procedure),,T2b,,,FOLLOW_UP_927,TREATMENT_927,,DONOR_87,SYNTHETIC-3,,,N1mi
"{'month_interval': 31, 'day_interval': 930}",No evidence of disease,"{'month_interval': 23, 'day_interval': 690}",,Durie-Salmon staging system,,M1a(1),,FOLLOW_UP_928,TREATMENT_928,,DONOR_88,SYNTHETIC-3,Distant recurrence/metastasis,C01,
,Stable,"{'month_interval': 9, 'day_interval': 270}",Assessment of symptom control (procedure)|Tumor marker measurement (procedure),Lugano staging system,T1c,M1c,Stage I,FOLLOW_UP_929,TREATMENT_929,,DONOR_89,SYNTHETIC-3,Biochemical progression,,N0(mol-)
"{'month_interval': 23, 'day_interval': 690}",,"{'month_interval': 31, 'day_interval': 930}",,Ann Arbor staging system,T2a1,,Stage IBS,FOLLOW_UP_930,TREATMENT_930,,DONOR_90,SYNTHETIC-3,,,N1a
"{'month_interval': 15, 'day_interval': 450}",Relapse or recurrence,"{'month_interval': 40, 'day_interval': 1200}",,International Neuroblastoma Risk Group Staging System,Tis pu,M0,Stage IVAS,FOLLOW_UP_931,TREATMENT_931,,DONOR_71,SYNTHETIC-3,Local recurrence,,N1c
"{'month_interval': 36, 'day_interval': 1080}",Partial remission,"{'month_interval': 47, 'day_interval': 1410}",,International Neuroblastoma Staging System,T4a(s),M1c(1),Stage II,FOLLOW_UP_932,TREATMENT_932,,DONOR_72,SYNTHETIC-3,Distant recurrence/metastasis,,
"{'month_interval': 42, 'day_interval': 1260}",Stable,"{'month_interval': 36, 'day_interval': 1080}",Histopathology test (procedure),Binet staging system,T1a1,M1b(1),,FOLLOW_UP_933,TREATMENT_933,,DONOR_73,SYNTHETIC-3,Biochemical progression,C03|C19,N0(mol+)
"{'month_interval': 25, 'day_interval': 750}",Distant progression,"{'month_interval': 42, 'day_interval': 1260}",,St Jude staging system,T3(s),,Stage IVBS,FOLLOW_UP_934,TREATMENT_934,,DONOR_74,SYNTHETIC-3,Progression (liquid tumours),,
"{'month_interval': 20, 'day_interval': 600}",Distant progression,"{'month_interval': 26, 'day_interval': 780}",,Binet staging system,T1mi,MX,,FOLLOW_UP_935,TREATMENT_935,,DONOR_75,SYNTHETIC-3,Biochemical progression,C14|C12,N2a
"{'month_interval': 28, 'day_interval': 840}",Complete remission,"{'month_interval': 41, 'day_interval': 1230}",Histopathology test (procedure),St Jude staging system,Tis(Paget's),M1d,,FOLLOW_UP_936,TREATMENT_936,,DONOR_76,SYNTHETIC-3,Distant recurrence/metastasis,C14|C12,N1a(sn)
"{'month_interval': 49, 'day_interval': 1470}",Relapse or recurrence,,Imaging (procedure)|Tumor marker measurement (procedure),International Neuroblastoma Staging System,,M1a,Stage IBS,FOLLOW_UP_937,TREATMENT_937,,DONOR_77,SYNTHETIC-3,Local recurrence and distant metastasis,,N0
"{'month_interval': 50, 'day_interval': 1500}",Loco-regional progression,"{'month_interval': 42, 'day_interval': 1260}",Imaging (procedure)|Assessment of symptom control (procedure),AJCC 6th edition,,,,FOLLOW_UP_938,TREATMENT_938,,DONOR_78,SYNTHETIC-3,Distant recurrence/metastasis,,N0
"{'month_interval': 34, 'day_interval': 1020}",No evidence of disease,,,International Neuroblastoma Risk Group Staging System,Tis(DCIS),M1c,Stage IIIBS,FOLLOW_UP_939,TREATMENT_939,,DONOR_79,SYNTHETIC-3,Local recurrence and distant metastasis,C01,N2
"{'month_interval': 28, 'day_interval': 840}",Partial remission,"{'month_interval': 36, 'day_interval': 1080}",Physical examination procedure (procedure)|Assessment of symptom control (procedure),Ann Arbor staging system,T4b(s),M1d,Stage 3,FOLLOW_UP_940,TREATMENT_940,,DONOR_80,SYNTHETIC-3,Distant recurrence/metastasis,,N0
"{'month_interval': 32, 'day_interval': 960}",,"{'month_interval': 20, 'day_interval': 600}",,,T1a(m),M1a(1),Stage IIA1,FOLLOW_UP_941,TREATMENT_941,,DONOR_81,SYNTHETIC-3,Progression (liquid tumours),C18|C07,N1a(sn)
"{'month_interval': 32, 'day_interval': 960}",,"{'month_interval': 38, 'day_interval': 1140}",,,T4d,M0,Stage IIAES,FOLLOW_UP_942,TREATMENT_942,,DONOR_82,SYNTHETIC-3,Local recurrence,C09|C11,N4
"{'month_interval': 8, 'day_interval': 240}",Progression not otherwise specified,"{'month_interval': 17, 'day_interval': 510}",Laboratory data interpretation (procedure)|Assessment of symptom control (procedure),Ann Arbor staging system,T1a2,M1b(1),,FOLLOW_UP_943,TREATMENT_943,,DONOR_83,SYNTHETIC-3,Local recurrence and distant metastasis,,N1c
"{'month_interval': 6, 'day_interval': 180}",No evidence of disease,"{'month_interval': 25, 'day_interval': 750}",Imaging (procedure)|Laboratory data interpretation (procedure),Revised International staging system (RISS),T3(m),M1a(0),Stage IVA2,FOLLOW_UP_944,TREATMENT_944,,DONOR_84,SYNTHETIC-3,Progression (liquid tumours),,N1a
"{'month_interval': 28, 'day_interval': 840}",Stable,"{'month_interval': 44, 'day_interval': 1320}",,,T4b,M0(i+),Stage IES,FOLLOW_UP_945,TREATMENT_945,,DONOR_85,SYNTHETIC-3,Progression (liquid tumours),,N2c
,Partial remission,"{'month_interval': 38, 'day_interval': 1140}",Tumor marker measurement (procedure),Lugano staging system,T2a,M1c(1),Stage C,FOLLOW_UP_946,TREATMENT_946,,DONOR_86,SYNTHETIC-3,Local recurrence,,
"{'month_interval': 20, 'day_interval': 600}",Stable,"{'month_interval': 30, 'day_interval': 900}",Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,T2c,M1a(1),Stage IIAES,FOLLOW_UP_947,TREATMENT_947,,DONOR_87,SYNTHETIC-3,Biochemical progression,,N1b
"{'month_interval': 27, 'day_interval': 810}",,,Assessment of symptom control (procedure),Rai staging system,T1d,M1c(0),Stage IIIA1,FOLLOW_UP_948,TREATMENT_948,,DONOR_88,SYNTHETIC-3,Local recurrence,C15,
"{'month_interval': 10, 'day_interval': 300}",Partial remission,"{'month_interval': 39, 'day_interval': 1170}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Rai staging system,T1b(m),M1b(0),Stage IBES,FOLLOW_UP_949,TREATMENT_949,,DONOR_89,SYNTHETIC-3,Progression (liquid tumours),,N0(i+)
"{'month_interval': 2, 'day_interval': 60}",Complete remission,"{'month_interval': 18, 'day_interval': 540}",Laboratory data interpretation (procedure)|Tumor marker measurement (procedure),Rai staging system,T1a(m),M0,Stage IIAES,FOLLOW_UP_950,TREATMENT_950,,DONOR_90,SYNTHETIC-3,Local recurrence,C06,N3b
"{'month_interval': 20, 'day_interval': 600}",No evidence of disease,"{'month_interval': 24, 'day_interval': 720}",,AJCC 6th edition,T1,M1b(1),,FOLLOW_UP_951,TREATMENT_951,,DONOR_71,SYNTHETIC-3,Local recurrence and distant metastasis,,N1b
"{'month_interval': 34, 'day_interval': 1020}",No evidence of disease,"{'month_interval': 25, 'day_interval': 750}",Laboratory data interpretation (procedure)|Imaging (procedure),St Jude staging system,,M1b(0),,FOLLOW_UP_952,TREATMENT_952,,DONOR_72,SYNTHETIC-3,Distant recurrence/metastasis,,N1b
"{'month_interval': 2, 'day_interval': 60}",Partial remission,"{'month_interval': 41, 'day_interval': 1230}",Assessment of symptom control (procedure)|Laboratory data interpretation (procedure),Durie-Salmon staging system,,M1a(0),Stage III,FOLLOW_UP_953,TREATMENT_953,,DONOR_73,SYNTHETIC-3,Biochemical progression,C20,N2a
"{'month_interval': 36, 'day_interval': 1080}",Complete remission,"{'month_interval': 5, 'day_interval': 150}",Imaging (procedure)|Physical examination procedure (procedure),Revised International staging system (RISS),T4a(m),M1c,Stage IIA,FOLLOW_UP_954,TREATMENT_954,,DONOR_74,SYNTHETIC-3,Local recurrence,C05,N3a
"{'month_interval': 1, 'day_interval': 30}",Loco-regional progression,"{'month_interval': 41, 'day_interval': 1230}",Physical examination procedure (procedure),,T2b,M1c(1),Stage A,FOLLOW_UP_955,TREATMENT_955,,DONOR_75,SYNTHETIC-3,Local recurrence and distant metastasis,C03,N3c
"{'month_interval': 45, 'day_interval': 1350}",Stable,"{'month_interval': 3, 'day_interval': 90}",Tumor marker measurement (procedure),Ann Arbor staging system,T1b,M1d(0),Stage IIBS,FOLLOW_UP_956,TREATMENT_956,,DONOR_76,SYNTHETIC-3,Local recurrence and distant metastasis,C20|C14,N0(i+)
"{'month_interval': 14, 'day_interval': 420}",Complete remission,"{'month_interval': 30, 'day_interval': 900}",Tumor marker measurement (procedure),International Neuroblastoma Staging System,,,Stage IVA,FOLLOW_UP_957,TREATMENT_957,,DONOR_77,SYNTHETIC-3,Local recurrence and distant metastasis,C08|C18,
"{'month_interval': 33, 'day_interval': 990}",No evidence of disease,,Imaging (procedure)|Assessment of symptom control (procedure),,T4a(m),M1a(1),Stage III,FOLLOW_UP_958,TREATMENT_958,,DONOR_78,SYNTHETIC-3,,,N4
"{'month_interval': 18, 'day_interval': 540}",Distant progression,,,,Tis(Paget),M1b(1),Stage 1A,FOLLOW_UP_959,TREATMENT_959,,DONOR_79,SYNTHETIC-3,Local recurrence,C01|C04,N2c
"{'month_interval': 36, 'day_interval': 1080}",Stable,"{'month_interval': 5, 'day_interval': 150}",,Ann Arbor staging system,T2a,,Stage IIA1,FOLLOW_UP_960,TREATMENT_960,,DONOR_80,SYNTHETIC-3,Local recurrence,C06,N1a(sn)
"{'month_interval': 27, 'day_interval': 810}",,"{'month_interval': 12, 'day_interval': 360}",Tumor marker measurement (procedure)|Physical examination procedure (procedure),Revised International staging system (RISS),T4d,M0,Stage IB2,FOLLOW_UP_961,TREATMENT_961,,DONOR_81,SYNTHETIC-3,Local recurrence,C07|C09,N1a
"{'month_interval': 21, 'day_interval': 630}",No evidence of disease,"{'month_interval': 30, 'day_interval': 900}",Assessment of symptom control (procedure),AJCC 6th edition,Tis(LAMN),M0(i+),Stage IIE,FOLLOW_UP_962,TREATMENT_962,,DONOR_82,SYNTHETIC-3,Biochemical progression,,N0b
"{'month_interval': 33, 'day_interval': 990}",Stable,"{'month_interval': 38, 'day_interval': 1140}",Imaging (procedure),Lugano staging system,,,Stage IS,FOLLOW_UP_963,TREATMENT_963,,DONOR_83,SYNTHETIC-3,Distant recurrence/metastasis,,N3c
"{'month_interval': 42, 'day_interval': 1260}",Partial remission,"{'month_interval': 46, 'day_interval': 1380}",Physical examination procedure (procedure),,T2b,M1b(1),Stage 3,FOLLOW_UP_964,TREATMENT_964,,DONOR_84,SYNTHETIC-3,Local recurrence and distant metastasis,,N0(mol+)
"{'month_interval': 47, 'day_interval': 1410}",Complete remission,"{'month_interval': 3, 'day_interval': 90}",,,Tis pu,M1c(0),Stage IA2,FOLLOW_UP_965,TREATMENT_965,,DONOR_85,SYNTHETIC-3,,,N0(i-)
"{'month_interval': 49, 'day_interval': 1470}",Partial remission,"{'month_interval': 6, 'day_interval': 180}",,AJCC 8th edition,Tis(LCIS),M1a,Stage IBS,FOLLOW_UP_966,TREATMENT_966,,DONOR_86,SYNTHETIC-3,Local recurrence,C18,N1b
"{'month_interval': 50, 'day_interval': 1500}",Loco-regional progression,"{'month_interval': 1, 'day_interval': 30}",,Revised International staging system (RISS),T1c,M1b,Stage 4S,FOLLOW_UP_967,TREATMENT_967,,DONOR_87,SYNTHETIC-3,Local recurrence and distant metastasis,,N3a
"{'month_interval': 7, 'day_interval': 210}",Progression not otherwise specified,,Assessment of symptom control (procedure),International Neuroblastoma Risk Group Staging System,T1a(m),M1a(0),Distant,FOLLOW_UP_968,TREATMENT_968,,DONOR_88,SYNTHETIC-3,,C03,N0a
"{'month_interval': 47, 'day_interval': 1410}",Relapse or recurrence,"{'month_interval': 24, 'day_interval': 720}",,AJCC 7th edition,T1a(m),M1c(1),,FOLLOW_UP_969,TREATMENT_969,,DONOR_89,SYNTHETIC-3,,,N2b
"{'month_interval': 35, 'day_interval': 1050}",Partial remission,"{'month_interval': 9, 'day_interval': 270}",,Durie-Salmon staging system,Ta,M0,Stage IIB,FOLLOW_UP_970,TREATMENT_970,,DONOR_90,SYNTHETIC-3,Local recurrence and distant metastasis,C03,N3c
"{'month_interval': 39, 'day_interval': 1170}",No evidence of disease,,Tumor marker measurement (procedure)|Histopathology test (procedure),AJCC 7th edition,Tis(Paget's),,Stage IIB,FOLLOW_UP_971,TREATMENT_971,,DONOR_71,SYNTHETIC-3,Distant recurrence/metastasis,C02,N3b
"{'month_interval': 20, 'day_interval': 600}",Loco-regional progression,"{'month_interval': 36, 'day_interval': 1080}",Histopathology test (procedure),AJCC 7th edition,T1d,M1d(1),Stage IVA2,FOLLOW_UP_972,TREATMENT_972,,DONOR_72,SYNTHETIC-3,,,
"{'month_interval': 24, 'day_interval': 720}",,"{'month_interval': 9, 'day_interval': 270}",Laboratory data interpretation (procedure),AJCC 7th edition,T4a(m),M1a(0),Stage IIIC1,FOLLOW_UP_973,TREATMENT_973,,DONOR_73,SYNTHETIC-3,Distant recurrence/metastasis,C03,N0(mol+)
"{'month_interval': 26, 'day_interval': 780}",Complete remission,,Histopathology test (procedure)|Assessment of symptom control (procedure),AJCC 6th edition,T1b(m),M1d,Stage IVA2,FOLLOW_UP_974,TREATMENT_974,,DONOR_74,SYNTHETIC-3,,C05,N3
,Loco-regional progression,"{'month_interval': 26, 'day_interval': 780}",Tumor marker measurement (procedure),SEER staging system,,M1b(0),Stage IB,FOLLOW_UP_975,TREATMENT_975,,DONOR_75,SYNTHETIC-3,,,N1a(sn)
"{'month_interval': 16, 'day_interval': 480}",Partial remission,"{'month_interval': 24, 'day_interval': 720}",,International Neuroblastoma Risk Group Staging System,,M1e,Stage IIEB,FOLLOW_UP_976,TREATMENT_976,,DONOR_76,SYNTHETIC-3,Local recurrence,C20,N4
"{'month_interval': 42, 'day_interval': 1260}",Relapse or recurrence,"{'month_interval': 1, 'day_interval': 30}",,Ann Arbor staging system,T2b,M1e,Stage IIEB,FOLLOW_UP_977,TREATMENT_977,,DONOR_77,SYNTHETIC-3,Local recurrence and distant metastasis,,N0(mol-)
"{'month_interval': 43, 'day_interval': 1290}",No evidence of disease,"{'month_interval': 34, 'day_interval': 1020}",Histopathology test (procedure),International Neuroblastoma Staging System,T2,M1a(1),Stage IIAES,FOLLOW_UP_978,TREATMENT_978,,DONOR_78,SYNTHETIC-3,Biochemical progression,C19,NX
"{'month_interval': 17, 'day_interval': 510}",No evidence of disease,"{'month_interval': 31, 'day_interval': 930}",Histopathology test (procedure)|Laboratory data interpretation (procedure),Durie-Salmon staging system,,,,FOLLOW_UP_979,TREATMENT_979,,DONOR_79,SYNTHETIC-3,Progression (liquid tumours),C03|C08,N0(i-)
"{'month_interval': 9, 'day_interval': 270}",Progression not otherwise specified,"{'month_interval': 43, 'day_interval': 1290}",Histopathology test (procedure)|Laboratory data interpretation (procedure),International Neuroblastoma Risk Group Staging System,T2a1,M1,Distant,FOLLOW_UP_980,TREATMENT_980,,DONOR_80,SYNTHETIC-3,Distant recurrence/metastasis,C03|C01,N0a (biopsy)
,Loco-regional progression,"{'month_interval': 45, 'day_interval': 1350}",Histopathology test (procedure)|Assessment of symptom control (procedure),Lugano staging system,T3c,M1c(1),Stage IVBE,FOLLOW_UP_981,TREATMENT_981,,DONOR_81,SYNTHETIC-3,Biochemical progression,C04|C11,
,Loco-regional progression,,Physical examination procedure (procedure)|Assessment of symptom control (procedure),,,,Stage A,FOLLOW_UP_982,TREATMENT_982,,DONOR_82,SYNTHETIC-3,Progression (liquid tumours),,N0a (biopsy)
"{'month_interval': 14, 'day_interval': 420}",Loco-regional progression,"{'month_interval': 27, 'day_interval': 810}",Laboratory data interpretation (procedure),AJCC 6th edition,T1,,Stage IVB,FOLLOW_UP_983,TREATMENT_983,,DONOR_83,SYNTHETIC-3,Local recurrence and distant metastasis,C13,N1a
"{'month_interval': 2, 'day_interval': 60}",Distant progression,"{'month_interval': 35, 'day_interval': 1050}",,St Jude staging system,T1a2,M0(i+),Stage B,FOLLOW_UP_984,TREATMENT_984,,DONOR_84,SYNTHETIC-3,Biochemical progression,C03|C01,
"{'month_interval': 5, 'day_interval': 150}",Stable,"{'month_interval': 15, 'day_interval': 450}",Physical examination procedure (procedure),AJCC 8th edition,T1a1,M1b,Stage IVS,FOLLOW_UP_985,TREATMENT_985,,DONOR_85,SYNTHETIC-3,Biochemical progression,C09,N3
,Distant progression,"{'month_interval': 31, 'day_interval': 930}",,FIGO staging system,,M1e,Stage IEB,FOLLOW_UP_986,,PRIMARY_DIAGNOSIS_286,DONOR_86,SYNTHETIC-3,Progression (liquid tumours),,
"{'month_interval': 33, 'day_interval': 990}",No evidence of disease,"{'month_interval': 19, 'day_interval': 570}",,AJCC 8th edition,,M1d(0),Stage IC,FOLLOW_UP_987,,PRIMARY_DIAGNOSIS_287,DONOR_87,SYNTHETIC-3,Local recurrence and distant metastasis,C14,N2c
"{'month_interval': 15, 'day_interval': 450}",Stable,"{'month_interval': 15, 'day_interval': 450}",,,T2b,M1d,Stage IIIB,FOLLOW_UP_988,,PRIMARY_DIAGNOSIS_288,DONOR_88,SYNTHETIC-3,Local recurrence and distant metastasis,C14,N2a
"{'month_interval': 6, 'day_interval': 180}",Loco-regional progression,"{'month_interval': 45, 'day_interval': 1350}",,AJCC 7th edition,Tis,,Stage IBE,FOLLOW_UP_989,,PRIMARY_DIAGNOSIS_289,DONOR_89,SYNTHETIC-3,Progression (liquid tumours),,N1mi
"{'month_interval': 12, 'day_interval': 360}",No evidence of disease,"{'month_interval': 46, 'day_interval': 1380}",Histopathology test (procedure),AJCC 6th edition,T4e,MX,Stage 0is,FOLLOW_UP_990,,PRIMARY_DIAGNOSIS_290,DONOR_90,SYNTHETIC-3,Distant recurrence/metastasis,,N3
"{'month_interval': 1, 'day_interval': 30}",Partial remission,,Assessment of symptom control (procedure)|Tumor marker measurement (procedure),AJCC 7th edition,Tis(DCIS),M1d,,FOLLOW_UP_991,,PRIMARY_DIAGNOSIS_291,DONOR_91,SYNTHETIC-4,Local recurrence,,
"{'month_interval': 12, 'day_interval': 360}",,"{'month_interval': 21, 'day_interval': 630}",Laboratory data interpretation (procedure),,T1a,M0(i+),Stage IC,FOLLOW_UP_992,,PRIMARY_DIAGNOSIS_292,DONOR_92,SYNTHETIC-4,Local recurrence,,N2mi
"{'month_interval': 9, 'day_interval': 270}",Partial remission,"{'month_interval': 24, 'day_interval': 720}",,FIGO staging system,T1,M1d(0),Stage IIIBE,FOLLOW_UP_993,,PRIMARY_DIAGNOSIS_293,DONOR_93,SYNTHETIC-4,Local recurrence,,N0
"{'month_interval': 2, 'day_interval': 60}",Partial remission,"{'month_interval': 47, 'day_interval': 1410}",,,,M1e,Stage IIBS,FOLLOW_UP_994,,PRIMARY_DIAGNOSIS_294,DONOR_94,SYNTHETIC-4,Local recurrence,C05|C13,NX
"{'month_interval': 43, 'day_interval': 1290}",Complete remission,"{'month_interval': 4, 'day_interval': 120}",,AJCC 7th edition,T4a(m),M0(i+),,FOLLOW_UP_995,,PRIMARY_DIAGNOSIS_295,DONOR_95,SYNTHETIC-4,Local recurrence and distant metastasis,,N2b
"{'month_interval': 49, 'day_interval': 1470}",Relapse or recurrence,"{'month_interval': 41, 'day_interval': 1230}",,AJCC 6th edition,T1b1,M1c(0),Stage M,FOLLOW_UP_996,,PRIMARY_DIAGNOSIS_296,DONOR_96,SYNTHETIC-4,Progression (liquid tumours),,
,Relapse or recurrence,"{'month_interval': 30, 'day_interval': 900}",,Binet staging system,T3(m),M1a(1),Stage Ms,FOLLOW_UP_997,,PRIMARY_DIAGNOSIS_297,DONOR_97,SYNTHETIC-4,,C15|C11,N2b
,Partial remission,"{'month_interval': 47, 'day_interval': 1410}",,,T4c,M1b(1),Stage IAE,FOLLOW_UP_998,,PRIMARY_DIAGNOSIS_298,DONOR_98,SYNTHETIC-4,Biochemical progression,C05,N1b
"{'month_interval': 46, 'day_interval': 1380}",Loco-regional progression,"{'month_interval': 7, 'day_interval': 210}",,AJCC 6th edition,T1a,M1a(1),Stage 1A,FOLLOW_UP_999,,PRIMARY_DIAGNOSIS_299,DONOR_99,SYNTHETIC-4,Progression (liquid tumours),C12,N1a(sn)
"{'month_interval': 47, 'day_interval': 1410}",Relapse or recurrence,,Physical examination procedure (procedure)|Histopathology test (procedure),Revised International staging system (RISS),,M1d(1),Stage I,FOLLOW_UP_1000,,PRIMARY_DIAGNOSIS_300,DONOR_100,SYNTHETIC-4,Local recurrence,,N3b
